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ABSTRACT

N-TERMINAL PROTEIN MODIFICATION BY AMINOACYL TRANSFERASE:
ENZYMOLOGY AND APPLICATIONS.
Anne M. Wagner
E. James Petersson

Protein modification is an important tool for understanding how a protein moves,
folds, and operates in its cellular environment. We aim for a minimalist approach to
protein modification in order to learn more about the protein while not perturbing its
native state. Our method for ligation of small molecules to proteins has high N-terminal
specificity and creates natural amide bond linkages under mild conditions. We utilized E.
coli aminoacyl L/F transferase (AaT) in our ligation reaction to recognize a small
synthetic substrate analog, which mimics aminoacylated tRNA, and can be chemically
synthesized in only three steps. We have studied the mechanism of AaT in order better
utilize unnatural substrates and expand the scope of aminoacyl donors and N-terminal
acceptors. Using AaT, we can enzymatically attach a wide range of synthetic moieties to
the N-termini of peptides and proteins, including natural and unnatural amino acids with
reactive azido groups, fluorescent labels, protected disulfides, and photoinducible
crosslinkers. This method introduces new opportunities for protein semi-synthesis, which
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we have applied in two model systems, α-synuclein and calmodulin, and contributes as an
effective method to label proteins for biophysical research.
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CHAPTER 1

INTRODUCTION TO LEUCYL/PHENYLALANYL AMINOACYL TRANSFERASE AND
CURRENT N-TERMINAL MODIFICATION METHODS

1

Section 1.1 – Introduction to Protein Engineering
If DNA is considered the “blueprint” of life, then an enzyme would aptly be
described as the machine of life. Enzymes access a countless number of reactions to
maintain cell function, and their biological activities have evolved to incredible levels of
complexity over 4 billion years.1

Natural products can be accessed through enzymatic

reactivity that is mostly unavailable to synthetic chemists on the timescale and yield of
the enzyme.2 Learning more about the structure and function of enzyme molecular
machines gives us insight into how enzymes can access their reactive abilities. One way
to learn more about enzymes is through the process of protein engineering (Figure 1-1).
By making primary sequence changes to an enzyme, you can change its original
function.3 However, haphazard mutational changes without thought of the molecular
effects of the change are unlikely to be beneficial to enzymatic catalysis; evolution is
successful because it is possible to select for very rare enhancements of function.4 There
are several methods that can be used to enhance the effectiveness of primary sequence
mutations: rational design, computer-aided design, directed evolution, and protein semisynthesis.5 All of the aforementioned techniques can attain the engineered product, a
new and improved protein, with a variety of possible alterations such as improved
enzyme activity, altered specificity for a substrate or product, or enzyme regulation; they
can also be used as a tool to understand inherent protein characteristics that remain
mysterious, such as protein folding mechanisms.6 The desired ultimate change in the
protein is directly linked to the first step in changing the protein sequence. You can take
protein engineering one step further by putting in an unnatural amino acid into the protein
2

in order to give it entirely new functionality that is unavailable with the 20 naturally
occurring amino acids. In this introduction, I will review current methods of protein
modification and delve into the heart of my thesis research with a background and history
of leucyl/phenylalanyl aminoacyl transferase, which the Petersson group has utilized as
an N-terminally modifying enzyme that can contribute to the field of protein engineering.

Figure 1-1. Protein Engineering Pathway
This flow chart describes modes of protein engineering and their respective outcomes adapted
7
from Foo et al.

Section 1.2 – Current Methods of Protein Modification
1.2.1 – Introduction to Amide Bond-Forming Ligation Techniques
Modifications of proteins in a site-selective manner can introduce a chemical
consequence from which one can infer information about protein structure and function.
Standard manipulations of protein structure include molecular biology techniques such
amino acid mutagenesis.8 However, these modifications are limited to natural amino
acids, ribosomal synthesis, and uncontrolled posttranslational modifications.9
3

One

current method for adding a synthetic group to a protein is solid-phase peptide synthesis
(SPPS), which generates peptides in vitro (Figure 1-2).

This method allows for

sequence-specific addition of natural and unnatural amino acids. However, there are
some limitations to this method; SPPS requires lengthy synthetic steps, the use of
protecting groups, and undesirable peptide byproducts due to incomplete reactions.10 The
accumulation of peptide byproducts limits the number of amino acids that can be
synthesized directly on solid phase with an upper limit at ~ 50 amino acids.9 Despite its
limitations, SPPS was and continues to be an advantageous method, and proteins, such
as, RNAseA, have been fully synthesized by this method.11 Through the use of SPPS,
unnatural amino acids and backbone alterations, such as a thioamide, can be incorporated
easily into peptides.12
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Figure 1-2. Mechanism of SPPS Amino Acid Activation and Amide Bond Formation
(1) DCC deprotonates (often with added base) the unprotected carboxylic acid of an N-terminal
Fmoc-protected amino acid. (2) Negatively charged oxygen from the carboxylic acid attacks the
central carbon of DCC, forming an activated amino acid. (3) The activated amino acid can now
be attacked by an N-terminal amino acid that is resin bound. (4) The tetrahedral intermediate
collapses to form a peptide bond. Steps 1-4 are repeated until desired length of peptide is
reached. Peptide synthesis is completed with deprotection of all the amino acid protecting groups
13-14
and cleavage from the solid-phase resin. R1 and R2 are protected amino acid sidechains.

1.2.2 – Native Chemical Ligation
One technique that has expanded upon SPPS and can circumvent the limitation of
peptide length is native chemical ligation (NCL). (Figure 1-3) NCL utilizes the reaction
of a cysteine and thioester to generate an amide bond in aqueous conditions with nearphysiological pH. Kent et al. used NCL between two large SPPS fragments, 51 and 48
amino acids in length, to create the create the monomer of the HIV-1 protease, one
peptide containing a C-terminal thioester and the other fragment with an N-terminal
5

cysteine.15 This ligation strategy was a breakthrough into studying larger proteins and
without the need of amino acid protecting groups.16 Two key aspects of NCL are its
regioselectivity and chemoselectivity. In the presence of an exogenous thiol catalyst,
NCL is regioselective because the thiol(ate)-thioester exchange is reversible.9,

17

The

NCL reaction demonstrates chemoselectivity because the reaction will only occur at a
peptide or protein terminus and not at internal residues.18

Thioesters have unique

chemical properties in comparison to oxoesters, which contribute to their efficacy in
NCL. Thioesters are more stable than oxoesters to hydroxide-catalyzed hydrolysis, but
conversely, are also more reactive than oxoesters to thiolysis and aminolysis.9 Thus, the
thioester yields itself well to working with proteins and peptides in the NCL reaction
because under physiological pH, the thioester will react readily with cysteine but not
hydrolyze under these conditions.9 In addition to its mild conditions, racemization does
not occur at either the N or C-terminal residues of the connecting peptides.

The

aforementioned attributes of the NCL reaction make it a very powerful tool for protein
engineering.
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Figure 1-3. NCL Mechanism
(1) In the first step, the cysteine thiol attacks the c-terminal thioester carbonyl group. (2 and 3) A
transthioesterification reaction occurs, forming a tetrahedral intermediate that collapses with
expulsion of the SR leaving group. (4) An S to N acyl shift occurs, which is an irreversible
reaction, forming the final product, peptide 1 and 2 ligated together via a peptide bond,
highlighted in yellow.

1.2.3 – Expressed Protein Ligation
The NCL reaction has opened up the ability to synthetically create proteins that
are not limited by the 50 amino acid restriction of length and can produce protein in near
quantitative yield.9 Additionally, Muir and coworkers have improved upon the NCL
reaction through the use of inteins to make recombinant proteins that are functionalized
with a C-terminal thioester with a method termed expressed protein ligation (EPL). EPL
is a semi-synthetic technique that utilizes a recombinant protein with a fused intein,
which can be thiolysed to form a C-terminal thioester in situ and then ligated with the Nterminal cysteine of a synthetic peptide or recombinant protein.19 An intein is a protein
7

sequence within a precursor protein that is self-excised during the maturation process of a
protein; the protein segments that are rejoined after intein excision are called exteins
(Figure 1-4).20-22 To make inteins a more useful tool for semi-synthesis, Muir and
coworkers have made several modifications to native intein splicing. As seen in Figure
1-5, the EPL reaction and intein excision mechanism begin the same way, with an S-to-N
acyl shift. However, for EPL, the intein has been mutated, preventing the continuation of
the

splicing

mechanism,

and

the

exogenous

thiol,

such

as

sodium

2-

mercaptoethanesulfonate (MESNA), attacks the carbonyl of the transient thioester formed
from the acyl shift in excision of the intein. An additional mutation at N454A prevents the
intein from excising itself from its C-terminus. The C-terminus is fused to a chitin
binding domain (CBD) or a His tag, which is used to purify out the thiolysed intein from
the reaction.

Then, with the addition of a C-terminal cysteine-bearing peptide or

recombinant protein, the NCL reaction can proceed.

EPL’s exploitation of intein

thiolysis allowed for the formation of C-terminal thioesters in situ on a recombinant
protein. This procedure was a significant advancement in protein semi-synthesis because
the protein fragments did not need to be synthesized using SPPS, and thus much larger
fragments could be generated.
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ends with a final X-to-N acyl shift, forming an amide bond.
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1.2.4 – Traceless Staudinger Ligation
While NCL and EPL have helped to advance protein semi-synthesis, both
reactions require a cysteine residue at the ligation site. This amino acid requirement can
be a hindrance because the natural occurrence of cysteine in proteins is very low at less
than 2 % with tryptophan being the least abundant.9, 24 The low abundance of natural
cysteine limits the opportunities for ligation sites that maintain original primary sequence.
Additionally, cysteine mutagenesis can be detrimental to protein structure and function
due to its nucleophilic and oxidative reactivities.24 One strategy that circumvents the
need for a cysteine residue is the traceless Staudinger ligation (TSL); this ligation
reaction does not have any inherent residue restrictions at the ligation site (Figure 1-6).
The TSL reaction scheme begins with transthioesterification between a phosphinothiol
and a thioester-bearing peptide.25 Now the first peptide is ready for reaction with the
second peptide, which bears an N-terminal α-azido acid. The phosphorous and azide
react to form an iminophosphorane, which can undergo subsequent rearrangements.24
The negatively-charged nitrogen of the iminophosphorane will attack the carbonyl carbon
of the thioester and form an amidophosphonium salt, which upon hydrolysis, yields the
ligated peptide product and phosphine oxide byproduct.16, 24-25 The original ligation was
done in the presence of DMF, and since then a variety of phosphinothiol coupling
reagents have been synthesized that have a range of ligation efficiencies and water
solubilities.26 The TSL reaction using water soluble phosphinothiols has been shown to
be compatible with EPL so that C-terminal fragments can be prepared from expressed
proteins.26 Additionally, the TSL reaction has been modified by Bertozzi et al. through
metabolic labeling using biotinylated water soluble phosphinothiol and metabolically10

incorporated azido-bearing sugars.27-28 The TSL reaction has some limitations; in protein
semi-synthesis the incorporation of the azido group still must be synthetically
incorporated, and in addition, the phosphine can oxidize in the presence of air. Steric
bulk at the ligating residues can also slow the reaction. The TSL reaction, even with
these limitations, offers an alternate route for protein semi-synthesis at amino acids other
than cysteine.27
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amidophosphonium salt. (4) Hydrolysis of amidophosphonium salt forms amide bond.
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1.2.5 – KAHA Ligation: α-Ketoacid–hydroxylamine amide-forming ligation reaction
Another ligating reaction, recently developed by Bode et al., is a chemoselective
amide

ligation

occurring

via

decarboxylative

condensation

between

an

N-

alkylhydroxylamine and α-ketoacid named the KAHA ligation. KAHA ligations are
successful under two conditions, Type I and Type II, which differ by hydroxylamine
substitution and solvent conditions (Figure 1-7). Type II O-substituted hydroxylamines
have faster reaction kinetics in aqueous conditions, and Type I unsubstituted
hydroxylamines are much slower and are superior in organic solvents.29 Additionally,
11

Type II ligations require a lower hydroxylamine concentration for a successful ligation.
The Bode group has investigated the KAHA ligation over several years and have
proposed several mechanisms.29-30 Most recently in 2011, Pusterla et al. elucidated the
mechanism for Type I KAHA ligations by using

18

O labeling to determine which

intermediates were involved in producing the final amide product (Figure 1-8). In this
mechanism, formation of a nitrone is required, as opposed to being a non-productive
byproduct as they initially proposed in their 2006 mechanism. They also speculated that
the Type II ligation could follow direct oxidative decarboxylation as described in their
initial 2006 mechanism or through an oxaziridine intermediate.29-30 These ligations can
be performed in conditions that maintain protein folding and stability; however,
currently, successful ligations have only been performed on the peptide scale.
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Type I ligations use unsubstituted hydroxylamines and Type II ligations use substituted
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hydroxylamines.
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1.2.6 – Reverse Proteolysis - Subtiligase
Reverse proteolysis is another option for protein ligation. Proteases have two
possible reaction outcomes of the acyl intermediate, amide bond formation and
proteolytic cleavage, which is the primary reaction.31

One protease in particular,

subtilisin, has been mutated to favor amide bond formation. In its wild type form,
subtilisin has a kcat that is approximately 109 greater than spontaneous amide cleavage.
However, upon mutation of two residues, S221C and P225A, a high efficiency protein
ligase was created, called subtiligase (Figure 1-9). The S221C residue mutation is one of
the catalytic triad amino acids and the cysteine mutation creates steric crowding during
the formation of the oxyanion transition state required for cleavage, therefore, pushing
the reaction towards ligation. Additionally, it is suspected that the S221C mutation slows
hydrolysis and aids in bond formation. The P225A mutation aids in opening the active site
to fit the S221C mutation. This double mutant has a greater than 107 reduction in amidase
activity and a 500 fold increase in peptide bond formation preference over hydrolysis.
Subtiligase is useful because it can catalyze peptide bond formation under proteinfriendly conditions, but this reaction requires high concentrations of protein to reverse the
reaction equilibrium.32
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1.2.7 – Non-amide Bond Forming Ligations and N-Terminal Modifications
Forming unnatural linkages provides options at the ligation site other than amide
bonds (Figure 1-10). One ligation reaction that has been used in vitro and in vivo is click
chemistry. Click reactions have a broad definition of being high yielding, selective, and
kinetically favorable.34 The standard click reaction developed by Sharpless and Meldal is
a CuI-catalyzed reaction between an azido group and an alkyne, which forms a triazole
ring.35-36 The triazole is very stable and only 1.5 angstroms longer than an amide.16
Click reactions can also be accelerated without the use of copper by using strained
cyclooctynes developed by Carolyn Bertozzi (SPAAC reaction), which are more
biocompatible reagents and have been used in live cell imaging.37 Another option for
peptide modification is the PLP-mediated biomimetic transamination, which is special for
its chemoselectivity toward the N-terminus.38

This reaction introduces a ketone or

aldehyde at the α-amine of the N-terminus, and upon reacting with a substituted (R'-)
hydroxylamine, forms an N-terminal oxime or hydrazine.

The R' group of the

hydroxylamine can effectively label the N-terminus with new functionality. This reaction
can be done under reasonably mild aqueous conditions at pH 6.5. However, the reaction
is incompatible with N-terminal serine, threonine, cysteine and tryptophan residues due
to additional side reactions.38
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Figure 1-10. Alternate Non-Amide Bond Forming Reactions: Click Reaction, SPAAC, and
Biomimetic Transamination

All of the aforementioned ligation and protein modification techniques have their
respective strengths and weaknesses. There is a need for amide bond-forming reactions
that allow for more flexibility at the ligation site, yet can still be easily performed at pH 7
in aqueous solution. To develop such an ideal reaction, we have investigated enzymatic
catalysis by E. coli aminoacyl transferase (AaT). AaT catalyzes the formation of amide
bonds using aminoacyl-tRNA as its substrate and transfers the amino acid onto
positively-charged N-termini, i.e. Lys or Arg, of proteins independently of the
ribosome.39

In the following sections, I will discuss the biological basis for L/F

transferase function and current research on the AaT active site.
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Section 1.3 – AaT and the N-end Protein Degradation Pathway
1.3.1 – Prokaryotic N-End Pathway
AaT is the primary initiating enzyme in the N-end protein degradation pathway in
E. coli.40 The N-end pathway regulates protein half-life through the use of destabilizing
amino acids, called degrons, to signal proteolytic machinery to degrade the “destabilized”
protein.40 This protein degradation pathway exists in both prokaryotes and eukaryotes. I
will first discuss the role of AaT in the prokaryotic N-end pathway and then briefly
discuss the similar pathway that exists in eukaryotes.
The purpose of protein degradation pathways in living organism is multifold: the
regulation of short-lived signaling proteins and elimination of abnormal proteins that
could be cell toxic.41 The first degron (secondary destabilizing residue) in the N-end
pathway in E. coli is lysine or arginine exposure of the N-terminus of a protein; these
residues indicate metabolic instability.42 An N-terminal lysine or arginine makes the
protein a substrate for AaT, which is involved in the first step of the N-end pathway
(Figure 1-11 and 1-12).39 AaT specifically recognizes the positively charged N-terminal
Lys or Arg with a negatively charged pocket within its active site.43 AaT transfers
leucine or phenylalanine (primary destabilizing residue) via a leucyl- or phenyalanyltRNA substrate to the protein N-terminus, making the second degron signal, N-terminal
(L/F)(K/R).42-43 An “adapter protein,” ClpS, recognizes the second degron signal and
brings the protein to the proteolysis machinery complex, ClpAP.40, 44 According to Erbse
et al., ClpS has some affinity for the individual destabilizing residues, but ClpS has a
higher affinity for the N-terminal sequence (L/F)(K/R), which correlated well with their
in vivo degradation studies. Using a β-galatosidase-based assay, they found that F/L-R18

β-galatosidase was degraded faster than L-β-galatosidase.44 The ClpS protein brings the
two degron-tagged protein to the protease machine, ClpAP, a complex of two proteins
ClpA and ClpP. ClpA is an AAA+ protein (ATPases associated with various cellular
activities).45 AAA+ proteins include a large group of proteins that have wide-ranging
function, but have a connective structural element: an ATP-binding domain that is 200 to
250 amino acids in length.45 AAA+ proteins couple the energy provided by their ATPase
to an additional protein or macromolecule; in context of the ClpAP complex, ClpA is the
“gate keeper” for proteins to access ClpP.45-46 ClpS has an additional function in the E.
coli N-end pathway; ClpS inhibits degradation of non-N-end rule proteins.39

Upon

binding of the degron-tagged protein, ClpA unfolds the protein via ATP hydrolysis, and
passes it through a pore to ClpP, which processively degrades the protein into 7 to 10
residue peptide fragments without a significant degree of sequence specificity.39,

47-49

Upon degradation, the peptide fragments can now be used in an amino acid “pool” for
reuse in new protein synthesis.41

19

Step 1: Peptidase
exposes an N-terminal
secondary destabilizing
residue (K/R).

Step 2: L/F Transferase
ligates a primary
destabilizing residue
K/R onto L/F.

Step 3: ClpS recognizes
and binds with high
affinity to the K/R L/F
residue sequence.

AaT

K/R

K/R
L/F

ClpS

K/R
L/F
ClpS

ATP

Step 4: ClpS delivers
the protein to the
proteolytic complex
ClpAP.

ADP + PPi

X
Z
ClpS
ClpA

Step 5: The protein is
transferred to ClpA where
it is unfolded, aided by
ATP hydrolysis, and then
degraded by ClpP peptidase.

ClpP
ClpA

Figure 1-11. N-End pathway in E. coli
39
Adapted from Mogk et al.

An additional transferase called Bpt that transfers only leucine has been identified
in the N-end pathway of Vibrio vulnificus. V. vulnificus is prokaryotic pathogen found in
marine environments, particularly shellfish.50 Bpt has no sequence similarity to AaT but
is a sequelog of Ate1, an arginyl transferase involved in the N-end protein degradation
pathway in eukaryotes.47 Bpt ligates leucine to the N-terminus of proteins bearing an Nterminal aspartate or glutamate (Figure 1-12). Additionally, V. vulnificus also has an AaT
gene that is encoded in the genome directly adjacent to Bpt under the control of the same
operon. Graciet et al. tested whether deletion of one of the transferase genes affected the
20

other gene’s expression, and determined that each transferase could work
independently.50 According to coimmunoprecipitation tests and E. coli cAMP two hybrid
analysis, Graciet et al. determined that it was unlikely that the two transferases interacted;
however, the tandem gene of AaT-Bpt was found to be conserved within
proteobacteria.50-51

While key active site residues have been identified, the crystal

structure has yet to be determined and more information is needed to understand the
reason for transferase duplicity in V. vulnificus.
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Figure 1-12. N-End Pathway N-degrons in Prokaryotes
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Adapted from Varshavsky et al.

1.3.2 – Eukaryotic N-End Pathway
Eukaryotes have a similar N-end protein degradation pathway but have additional
N-degron signals (Figure 1-13).52 In eukaryotes, N-terminal destabilizing residues are
recognized by E3 ligases.39 E3 ligases, with the help of E2 ligases and E1 ligases, allow
for the polyubiquitilation of an internal lysine residue of the protein designated to be
degraded by its N-terminal residue.40 The multi-ubiquitilation acts as the adapter protein
for eukaryotes and brings the protein to be degraded to the 26S proteasome (Figure 114).39 The 26S proteasome acts similarly to the ClpAP machinery and is composed of
21

two complexes, 19S and 20S.47 The 19S complex has 6 AAA+ proteins that are involved
in the process of unfolding and passing the protein substrate to the 20S complex, which is
the proteolytic core.39 The origins of the ubiquitilation systems in the N-end pathway are
still unclear, but the processive proteolysis found both in prokaryotes and eukaryotes
likely links them by a common ancestor.50
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Section 1.4 – History of AaT and Its Active Site Chemistry
1.4.1 – History of AaT
The natural formation of amino acid peptide bonds can occur through a variety of
mechanisms in both eukaryotes and prokaryotes with two well-studied processes being
ribosomal protein synthesis and protein modification via aminoacyl-tRNA transferases.
The first observation of transferase activity, discovered by Kaji et al. in 1965, was found
thorough incorporation of radiolabeled leucine and phenylalanine in cell extracts of E.
coli.53 Five years later, the enzyme responsible for the amino acid transfer, AaT, was
first extracted from E. coli and purified by Leibowitz and Soffer.54

The unique

characteristic of E. coli AaT was its ability to transfer amino acids onto proteins with
equal preference for both leucine and phenylalanine.54 They also determined several
requirements of AaT function: optimal activity at pH 8, requirement of a monovalent
cation source, 0.15 M KCl to achieve maximal kinetic function, enzymatic inhibition by
divalent cations and the antibiotic puromycin, and complete independence of the
ribosome, magnesium ions, and GTP.54 In 1973, Soffer et al. found the protein acceptors
of the AaT reaction to be N-terminal lysine or arginine, with stereoselectivity for the Lisomer and some loss of peptide substrate binding according to the penultimate Nterminal residue, in particular, glutamate.55 In 1991, Tobias et al. determined that the
physiological role of AaT was its involvement in the N-end rule in bacteria, but a crystal
structure was yet to be determined until 2006 by Suto et al.42, 56 According to the crystal
structure at 2.4 angstrom resolution, AaT forms two distinct domains, an N-terminal
domain and a C-terminal domain (Figure 1-15).56 The crystal structure was solved with
puromycin, a known inhibitor of AaT, bound in its active site, which is a cleft formed
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between the N- and C-terminal domains.56 The structural fold of the C-terminal domain
is similar to enzymes in the FemABX family. The FemABX family of enzymes contain a
GNAT fold and their active sites catalyze the binding of an amino acid, using aminoacyl
tRNA, to a peptidoglycan precursor, which is involved in cell wall development.56-57
Despite the similarity in aminoacylation reactions, the FemABX enzymes hold no
significant primary sequence similarities to AaT.56

Figure 1-15. Crystal Structure of AaT at 2.4 Å
The N-terminal domain consists of amino acids 3-62 (four β-strands, β1–4, and one α-helix, α1)
and the C-terminal domain consists of amino acids 63-232 eight β-strands, β5–12, and six αhelices, α2–7). The chains that make up the active site of AaT are from both the N and C
terminal domains (β9, α5, and β10 of the C-terminal domain and β3 from the N-terminal domain).
56
PDB ID – 2DPT.

1.4.2 – AaT Active Site Chemistry
AaT naturally transfers three amino acids, leucine and phenylalanine, which are
involved in the N-end pathway, and methionine at a lower efficiency.58 Using the crystal
structure and amino acid mutagenesis, amino acid residues in the binding cleft, M144,
F153, L170, F173, and I185, were found to interact with the hydrophobic portion of
24

puromycin, which could indicate the leucyl/phenylalanyl binding site of the aminoacyl
tRNA.56

Suto et al. proposed that the active site discriminates against β-branched

residues such as isoleucine due to the close proximity (≤ 4 Å) of Met158 and the amide
bond of Gly155 and Glu156 (Figure 1-16). Additionally, they proposed a tRNA docking
model with AaT proposing that the tRNA 3' end likely adopts a bent conformation that
mediates amino acid binding in the hydrophobic pocket of AaT.56

Figure 1-16. Amino Acids Involved in Puromycin Binding in AaT
The aminoacyl moiety (Cα, Cβ, Cγ) is stacked between residues Met158 and the peptide bond
linking Gly155 and Glu156. The Hydrophobic pocket: Met144, Phe153, Leu170, Phe173, Ile185. Pm =
puromycin. Reprinted with permission from (Kyoko Suto, Yoshihiro Shimizu, Kazunori Watanabe,
Takuya Ueda, Shuya Fukai, Osamu Nureki, Kozo Tomita. The EMBO Journal. 2006, Vol. 25, No.
24, 15139–15147.). Copyright (2006) Nature Publishing Group.

More information about the reaction mechanism was elucidated in 2007 by the
same group using crystal structures bound separately to minimized AaT substrates,
phenylalanyl adenosine and peptide product, FRYLG. Watanabe et al. determined that
Q188, acting as a general base, follows a mechanism similar to the reverse reaction of a
serine protease (Figure 1-17).43 However, the mechanism was challenged by Fung et al.
25

in 2011, and through the use of highly sensitive MALDI analysis, it was determined that
none of the active site residues are actually catalytic; instead, the active site simply
allows for “substrate-assisted catalysis” of the substrates, in which the α-amine of the
protein substrate undergoes nucleophilic attack on the ester carbonyl bond of the
aminoacyl L-tRNALeu or Phe-tRNAPhe. Currently, the proposed mechanism by Fung et
al. seems more likely to be correct because the supposed catalytic residue of the
Watanabe et al. proposed mechanism, Q188, can be mutated to an alanine and still retain
enzymatic activity; however, neither mechanism has been fully confirmed or disproved.43,
59

Q188

Figure 1-17. Phe-A Bound to the Active Site of AaT
43
Q188 is labeled to show its close proximity to the Phe-A substrate, 2.9 Å. PDB – 2Z3K
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Section 1.5 – Minimization of AaT Substrates
The selection of the correct amino acids in ribosomal protein synthesis is
complex, with a variety of checks and balances throughout the process.60 Gromadski et
al. determined that the ribosome exhibited a greater than 450 fold selectivity for cognate
aminoacyl tRNA anticodons versus a single mismatch at the anticodon.60 Effraim et al.
tested the ribosomal acceptance of combinations of Ala, Phe, and Lys tRNAs and found
that misacylation does not effect the yield of dipeptide formation when only misacylated
tRNA is supplied; however, when in competition with correctly acylated tRNA, the
ribosome shows a clear discrimination against misacylation.61 Similarly, AaT has been
shown to use misacylated tRNA as well as minimized tRNA mimics (Figure 1-18).62-63
The ability of AaT to use misacylated non-cognate tRNA indicated that amino acid
identity was less selective than previously expected.64 Abramochkin et al. determined
that the aminoacyl-tRNA anticodon is not a transferase recognition determinant.64 Also,
mutations in the anticodon and extra arm of the tRNALeu substrate did not substantially
alter transfer.64 They did not find stringent conservation of nucleotide sequences between
L/F transferase tRNAs, but charged tRNA with a GC stem was a poor substrate.64
Connor et al. used mutant aminoacyl tRNA synthetases to transfer unnatural amino acids
to the N-termini of peptides using AaT.65 Taki et al. also minimized the aminoacyl tRNA
substrate and demonstrated that truncated aminoacyl tRNAs from 20 bases down to
dinucleotides could be utilized as an AaT substrates.63 The greatest minimization of the
AaT aminoacyl tRNA substrate was reduction to phenylalanyl adenosine (Phe-A), which
was used as a substrate analog for analysis of substrate binding in crystal structures.43
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Watanabe et al. found that in the presence of an accepter peptide AaT could use Phe-A as
a substrate, forming approximately 1 % N-terminally phenylalanine-ligated product.43
These findings have shown that AaT can have amino acid promiscuity in its active site
while maintaining ligation efficiency for a variety of tRNA lengths.
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Figure 1-18. Minimized Substrates
Aminoacyl tRNA, specifically L/F, is the natural substrate for AaT. Dinucleotides (Xaa = amino
acid) and phenylalanyl adenosine have also been shown to be AaT substrates.

Section 1.6 – Summary
Protein modification is an important tool for understanding how a protein moves,
folds, and operates in its cellular environment.

However, many current N-terminal

modifications and ligation techniques can perturb protein structure from its natural state
through cysteine mutagenesis and unnatural amide backbone linkages. In our work, we
aim to learn more about the protein structure and function with minimal perturbation
from its natural state. Our new method of protein modification ligates small molecules
onto proteins with N-terminal specificity and creates natural amide bonds at ligation sites.
AaT-mediated ligations recognize a small synthetic aminoacyl-tRNA analog, aminoacyl
adenosine, which can be chemically synthesized in only three steps.66 Using AaT, we
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can enzymatically attach a wide range of synthetic moieties to the N-termini of peptides
and proteins, including natural and unnatural amino acids with reactive azido groups,
fluorescent labels, protected disulfides, and photoinducible crosslinkers. This method
introduces new opportunities for protein semi-synthesis and contributes an effective
method to label proteins for biophysical research, which we have demonstrated in two
model proteins, α-synuclein and calmodulin. We have also explored other aminoacyl
transferase options, Bpt from V. vulnificus and Ate1, a mammalian arginyl transferase.
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CHAPTER 2

N-TERMINAL PROTEIN MODIFICATION USING SIMPLE AMINOACYL
TRANSFERASE SUBSTRATES

30

Reprinted (adapted) with permission from (Anne M. Wagner, Mark W. Fegley, John B.
Warner, Christina L. J. Grindley, Nicholas P. Marotta, and E. James Petersson. J. Am.
Chem. Soc. 2011, 133, 15139–15147.). Copyright (2011) American Chemical Society.

Section 2.1 - Introduction
The conjugation of synthetic molecules to proteins contributes to biomedical
research by enabling the immobilization of proteins on surfaces, modifications with
chromophores to make in vitro sensors, or tagging with in vivo imaging agents.67-71 In
most cases, the formation of well-defined conjugates is valuable, if not essential. The
protein termini are attractive targets for conjugation, because in many cases appending
synthetic molecules at the termini will have minimal undesired effects on protein folding
and function.72-92 This is particularly applicable in cases where the terminus is relatively
unstructured. As part of our research on minimalist labeling strategies for biophysical
studies, we sought a method for N-terminal modification that could be carried out easily
under conditions that maintain folding without substantial prior protein manipulation.12
Selective N-terminal modification has been achieved by a variety of chemical and
enzymatic methods, each with benefits and drawbacks. Small molecule strategies permit
the attachment of a variety of molecules, but they are subject to side reactions and
incomplete specificity for the N-terminus and may need to be carried out in organic
solvent mixtures.38, 82, 93-101 Reverse proteolysis methods can be used to modify the Nterminus under conditions that do not require protein unfolding, but the reaction can be
difficult to drive to completion without high protein concentrations.23, 32, 102-113 Several
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other chemoenzymatic methods are valuable in functioning under benign conditions but
have moderate-sized target sequences that must be appended to the protein.114-121 Here,
we describe a minimal system for N-terminal protein labeling that utilizes only adenosine
esters of natural or unnatural amino acids and a single, readily available enzyme. This
process gives high yields of modified proteins under nondenaturing conditions and
requires only a single basic amino acid for specific recognition.
Aminoacyl tRNA transferases (AaTs) are members of a growing class of enzymes
that use aminoacyl tRNAs in secondary metabolism.122 The E. coli AaT catalyzes the
transfer of Leu, Phe, or Met from an aminoacyl tRNA to a protein bearing an N-terminal
Arg or Lys.43, 56, 123 The addition of Leu or Phe targets that protein for degradation by
ClpA as part of the N-end rule pathway.39-40,

42, 124

Kaji et al. first observed AaT

aminoacylation activity in crude E. coli preparations.53,

123, 125

Soffer and Leibowitz

subsequently reconstituted the purified enzyme and characterized its specificity or both
the RNA and amino acid components of the donor molecule, demonstrating its first use in
transferring an unnatural amino acid, p-fluorophenylalanine (Figure 2-1, Top).126-127
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Figure 2-1. Transferase-Mediated N-terminal Protein Modification
(Top) Fully enzymatic methods use aminoacyl tRNA synthetase (aaRS), tRNA, aminoacyl
transferase (AaT), amino acid, and ATP. (Bottom) Chemoenzymatic methods use only a
synthetic nucleic acid donor and transferase. In this work, an aminoacyl mononucleoside (Rn =H)
was used.

Recently, purified AaT has been used to modify proteins in vitro with a variety of
unnatural amino acids charged onto tRNAs, either by chemical semi-synthesis or the use
of a mutant aminoacyl tRNA synthetase (aaRS).62-63, 85, 128-129 Abramochkin and Shrader
discovered that AaT was tolerant of variation in the acceptor stem (aminoacylation site)
of the tRNA, and Sisido and coworkers have shown that much shorter oligonucleotides
(Figure 2-1, bottom, Rn = 1 - 21 nucleotides) can act as donors.63-64, 130 As part of their
structural characterization of AaT, Tomita and co-workers found that AaT could bind
phenylalanyl adenosine and transfer Phe to peptides in trace amounts.43 However, the
use of adenosine mononucleoside as a donor substrate for AaT has not, to our knowledge,
been further explored.
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We have found that a variety of hydrophobic amino acids can be transferred from
adenosine donors with high yields at relatively low protein concentrations (Figure 2-1,
bottom, Rn = H). These donors can be synthesized from commercially available active
esters of the amino acids. Reduction of the two step synthetase/AaT reaction sequence to
the one step AaT-only sequence allows us to explore the substrate specificity of AaT
without limitation by the specificity of the synthetase in the first step. While this is also
possible with Sisido’s pdCpA dinucleotide donors, the shorter synthesis of the simple
adenosine donors (1 - 2 steps vs. 7 steps) makes this exploration easier. We have
characterized the substrate scope of the wild type AaT enzyme using a reporter peptide,
determined the kinetic parameters for the adenosyl substrates, and demonstrated the
efficient modification of a full-sized protein, 23 kDa α-casein.

Section 2.2 - Results and Discussion
The synthesis of adenosyl donor compounds, shown in Scheme 2-1, can be
carried out on any amino acid with appropriate acid-labile protecting groups (e.g., NBoc). This synthesis is not limited to α-amino acids, and our donor synthesis has also
enabled us to test the transfer of analogs such as α-azidophenylalanine (N3f, 4g).
Conversion to the cyanomethyl ester (1a - h) is typically high-yielding, although yields
for the subsequent acylation of 5′-O-dimethoxytrityl-adenosine ((DMT)-A) varied
between 60 and 90 %.

Acylation yields generally decreased with side chain bulk;

derivatives such as N-1,8-naphthyldiaminopropionic acid coupled poorly (data not
shown).

Uncatalyzed reactions took 1 - 5 days, but in all cases, addition of
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tetrabutylammonium acetate increased reaction rates.
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Scheme 2-1.
Synthesis of Adenosyl Donors and Use in AaT-Catalyzed Protein
Modifications
Donor synthetic intermediates: 1a, 2a, 3a X = NHBoc, Z = Ph; 1b, 3b X = NHBoc, Z = i-Pr; 1c, 3c
X = NHBoc, Z = p-azidophenyl; 1d, 3d X = NHBoc, Z = 2-naphthyl; 1e, 3e X = NHMeBoc, Z = Ph;
1f, 3f X = NHAc, Z = Ph; 1 g, 3 g X=N3, Z = Ph; 1 h, 3 h X = NHBoc, Z = 7-Methoxycoumarinyl; 1i,
3i X = NHMeBoc, Z = p-benzoylphenyl

The Phe donor 4a was synthesized from both the cyanomethyl ester (1a) and Nhydroxysuccinimidyl (OSu) ester (2a). All other adenosyl donors were synthesized from
the cyanomethyl ester (1b - h). After trifluoroacetic acid (TFA) deprotection and CH2Cl2
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washing (or Et2O precipitation) to remove DMT byproducts, the compounds could be
taken on directly to AaT enzymatic reactions (contaminants were limited to incompletely
deprotected compounds which are not transferred by AaT). However, in most cases the
deprotected adenosyl donor was purified by HPLC, and higher transfer yields were
generally observed with these purified donors.
Transfer extent was evaluated by HPLC analysis of reactions with adenosyl
donor, AaT, and an aminocoumarin-labeled reporter peptide used previously by Tirrell
and co-workers (LysAlaAcm, Scheme 2-1).65 Monitoring LysAlaAcm acylation in crude
reaction mixtures using absorbance at 325 nm conveniently eliminates background due to
other proteins and nucleic acids, although some unnatural amino acids such as
napthylalanine (Nap) and methoxycoumarinylalanine (Mcm) also absorb in this range.
Example HPLC chromatograms from Phe ligations are shown in Figure 2-2. LysAlaAcm
starting material eluted at 11.8 min (Figure 2-2A); hydrophobic products eluted at 12 to
15 min (PheLysAlaAcm 5a elutes at 13.0 min in Figure 2-2B, NapLysAlaAcm 5d elutes
at 14.1 min in Figure 2-2D).
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Figure 2-2. Reversed-Phase HPLC Analysis of Transferase Reactions
Top: AaT-mediated transfer of Phe from adenosyl donor 4a to LysAlaAcm reporter peptide.
HPLC chromatograms obtained after (A) 0 h or (B) 4 h show conversion of LysAlaAcm (11.8 min
retention time) to PheLysAlaAcm (13.0 min retention time). Conversion after one addition of
donor 4a is 92 % (B). A second addition of 1 mM 4a drives the reaction to completion with a
small amount of double Phe addition (C). Bottom: HPLC analysis of transfer of Nap from
adenosyl donor 4d to LysAlaAcm after (D) 4 h shows conversion to NapLysAlaAcm (14.1 min
retention time). Product identities confirmed by observation of indicated masses by MALDI MS.

To evaluate substrate scope, reactions were analyzed after 4 h, when transfer
should be complete for the fully enzymatic reaction with Phe tRNA synthetase.65 Phe
(4a) and Leu (4b) were transferred efficiently (Table 2-1). Our PheLysAlaAcm yields
from donor 4a were comparable to yields from Phe-pdCpA, the dinucleotide used by
Sisido. Transfer yields for other substrates varied with side chain size, where Mcm (4h)
is too large and benzoylphenylalanine (Bzf, 4i) is a poor substrate (see Table 2-1). Sisido
has shown that AaT mutants can use substrates with larger side chains; we are currently
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exploring some of these mutations.63

While transfer yields after 4 h varied, most

reactions could be driven to completion by a bolus of donor molecule (Figure 2-2C).

Table 2-1. N-Terminal Modification of Reporter Peptide After Single Addition of Adenosyl
Donor
Donor

a

Yield (%)

b

4a (Phe)

92.7 ± 5.2

Phe-pdCpA

95.2 ± 4.3

4a (Phe)

1 mM ATP

86.1 ± 0.8

4a (Phe)

5 mM ATP

79.1 ± 0.4

4a (Phe)

5 mM AMP

88.2 ± 0.8

4a (Phe)

5 mM A

93.1 ± 1.1

4a (Phe)

1 mM pdCpA

90.4 ± 0.9

4b (Leu)

80.4 ± 0.9

4c (Azf)

78.5 ± 5.2

4d (Nap)

95.4 ± 0.4

4d (Nap)

a

Additives

100 µM PheLysAlaAcm

93.8 ± 0.3

4e (Mef)

0.6 ± 0.1

4f (Acf)

5f not observed

4g (N3f)

5g not observed

4h (Mcm)

5h not observed

4i (Bzf)

9.2 ± 0.3

c

b

Standard AaT-catalyzed transfer conditions with or without potential inhibitor added. Yield
determined by integration of HPLC chromatogram peak areas at 325 nm, described in Materials
and Methods. Standard deviations are reported for an average of at least 6 experiments with at
c
least 2 different AaT preparations.
HPLC and MALDI MS analysis indicate that the observed
product is 5a not 5g.

One of the advantages of adenosyl donors over in situ tRNA aminoacylation with
a tRNA synthetase is that we are not limited by the substrate specificity of the synthetase.
In particular, nonamino acid substrates can be attached to adenosyl donors to assess their
transferability by AaT. N-Methyl phenylalanine (Mef, 4e) can be transferred, albeit with
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low yield.

We have also tested N-acetyl phenylalanine (Acf, 4f) and α-

azidophenylalanine (4g) and found them to be poor substrates. In some experiments,
substantial conversion of LysAlaAcm was found when incubated with 4g, but MALDI
MS analysis has shown the product to be 5a, presumably obtained by transfer of Phe after
prior reduction (i.e., Phe donor 4a is formed from 4g under the reaction conditions).
Steps taken to alter the concentration of β-mercaptoethanol reductant did not improve the
yield of 5g (data not shown).

We believe that disproportionation of the azide is

incomplete, but that AaT is selective for the α-amine substrate (Phe-A, 4a), so far more
5a than 5g is formed. This may be due to an important interaction of the α-amine with
Q188, which also acts as a catalytic base to deprotonate the peptide substrate for amide
bond formation.

The Q188/α-amine interaction was defined by the structural and

enzymological work of Watanabe and co-workers.43 We note that the preference of AaT
for unmodified N-termini was previously documented with full-length tRNA by Soffer
and Leibowitz.127
To better understand limitations on the yield from AaT reactions, we assessed the
possibilities of inhibition by hydrolyzed substrate or aminoacylated product. Since the
acyl adenosine donor substrate is not regenerated during the reaction (unlike the
aaRS/tRNA/AaT reaction), we hypothesized that the adenosine byproduct might inhibit
further acylation by binding to AaT. To investigate this possibility, we added adenosine
to the reaction at varying concentrations and monitored the reaction timecourse by
fluorescence spectroscopy and by HPLC. Addition from the Phe donor 4a was not
inhibited by the addition of 5 mM concentrations of adenosine (Table 2-1).
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A

comparison of adenosine compounds, including pdCpA, the dinucleotide donor used by
Sisido, showed that only adenosine triphosphate (ATP) inhibited the reaction.
We were also able to monitor product formation in real time based on partial
quenching of coumarin fluorescence upon addition of Nap to the LysAlaAcm peptide to
form 5d. The fluorescence intensity at 390 nm of NapLysAlaAcm is 28 % of the
fluorescence of LysAlaAcm, and the overall fluorescence of mixtures of the two peptides
can be used to determine the proportions of each peptide if the total concentration is
known. Intensity was used to monitor NapLysAlaAcm formation in real time, and HPLC
injection of the reaction end points were used to confirm the final product distribution.
We found that exogenous adenosine did not significantly inhibit the reaction, even at
concentrations up to 1 mM (Figure 2-3A).

Figure 2-3. Kinetic Analysis of AaT Reactions
(A) Real time monitoring of Nap transfer to LysAlaAcm from 4d by quenching of Acm
fluorescence. No significant inhibition is observed in the presence of 1 mM adenosine. (B)
Saturation curve used to determine Michaelis-Menten kinetic parameters for LysAlaAcm
modification by Phe donor 4a.

We also assessed the possibility of product inhibition by the aminoacylated
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LysAlaAcm product. In our standard 4 h transfer assay, addition of 100 µM (1 equiv.)
PheLysAlaAcm did not significantly inhibit production of NapLysAlaAcm (5d) when
Nap-A (4d) was used as a donor (Table 2-1). MALDI MS analysis and differences in
HPLC retention time allowed us to easily distinguish LysAlaAcm and PheLysAlaAcm
from NapLysAlaAcm (Figure 2-2). Finally, we investigated the question of whether
donor hydrolysis slowed reaction rates after 30 - 60 min. Analysis of mock reactions
lacking transferase or LysAlaAcm indicates that donor hydrolysis may contribute
significantly to slowing reactions, which is why a donor bolus can be used to drive the
reaction to completion (see Materials and Methods section).
To characterize the enzymatic activity of AaT toward our acyl adenosyl
substrates, we used our HPLC assay to determine initial reaction rates to be fit to a
standard Michaelis-Menten kinetic model. Equations describing this kinetic analysis are
included in the Supporting Information. Since adenosine does not inhibit the enzyme, by
keeping LysAlaAcm concentrations high (100 µM), we measured the rate of transfer as a
function of the concentration of Phe donor 4a and fit this to a single-substrate kinetic
model to determine a kcat of 1.68 ± 0.09 × 10–1 s–1 and a KM of 1.24 ± 0.23 × 10–4 M. The
enzyme efficiency (kcat/KM = 1.35 ± 103 M–1 s–1) is relatively low.131 While KM is higher
for Phe-A than what Shrader reported for aminoacyl tRNALeu-4 (0.3 µM), the kcat is
comparable (0.13 × 10–1 s–1).64

Since it is trivial to run our reactions at donor

concentrations well above KM, the lower apparent affinity for our substrates should not
affect the utility of the reaction. We note that the binding affinity, which gives a KM of
124 µM for 4a must arise primarily from Phe binding interactions since the KI for
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adenosine inhibition is greater than 5 mM.
It is possible that larger protein substrates are modified with different efficiencies
than peptide substrates.63-64, 127 To address this question and to demonstrate the utility of
our method in tagging full-sized proteins with useful fluorophores or affinity purification
tags, we modified the milk protein α-casein (bearing a native N-terminal Arg after
proteolysis of a leader sequence).132 First, modification using Phe donor 4a was assessed
by Edman degradation, where successful, quantitative addition of Phe was observed.
In a more complex set of experiments, we first modified α-casein with Azf using
donor 4c and then used a Cu-catalyzed Huisgen cycloaddition (“click” reaction) to
append a fluorescein label (Figure 2-4A).133-136 Prior to fluorescent-labeling, the initial
transfer of Azf was analyzed by trypsin digest and MALDI MS of α-casein (Figure 24C). The N-terminal peptide ArgProLys disappeared from the mass spectrum following
modification and a peptide corresponding to AzfArgProLys was observed (also a mass
corresponding to AzfArgProLys after loss of N2 during ionization; N2 loss was also
observed for AzfLysAlaAcm).

Complete conversion of α-casein was observed in

MALDI MS due to double addition of 4c to drive the reaction.
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Figure 2-4. AaT-Catalyzed Modification and “Click” Reaction of α-Casein N-terminus
(A) α-Casein modification scheme. (B) PAGE gel analysis of α-casein modification. Lanes (left to
right): (1) molecular weight (MW) markers (Masses in kDa: 17, 25, 30, 46, 58, 80, 175); (2) αcasein; (3) α-casein mixed with fluorescein alkyne (FlAlk); (4) α-casein mixed with FlAlk, CuSO4,
THPTA, and sodium ascorbate; (5) α- casein mixed with Azf-A (4c) and AaT; (6) α-casein mixed
with 4c and AaT, then FlAlk; (7) α-casein mixed with 4c and AaT, then propargylamine (Alk),
CuSO4, Tris-(3-hydroxypropyltriazolylmethyl) amine (THPTA), and sodium ascorbate; (8) αcasein mixed with 4c and AaT, then FlAlk, CuSO4, THPTA, and sodium ascorbate;( 9) MW
markers; and (10) cell lysate labeling, α-casein reaction carried out using conditions of lane 8 with
unpurifed AaT in cleared E. coli lysate. (C) MALDI MS analysis of trypsinized N-terminal
fragment of α-casein with or without modification by Azf using AaT and 4c (double addition).
	
  

After AaT-catalyzed modification of α-casein with Azf, residual 4c was removed
by dialysis, AaT (His10-tagged) was removed by treatment with Ni beads, and the azide43

bearing protein was reacted with fluoroescein alkyne (FlAlk) in the presence of Cu(I).
The results of this labeling experiment, as well as appropriate control reactions, are
shown in Figure 2-4B. One can see that fluorescent α-casein is only observed under the
proper conditions (Lane 8), where both the chemoenzymatic labeling by AaT with 4c and
the subsequent click reaction are successful. Finally, we carried out a similar labeling
experiment in crude E. coli lysate with unpurified AaT. Azf transfer was successful, as
shown by the observation of fluorescence after labeling with FlAlk. Control reactions
(shown in Supporting Information) show no observable labeling of any protein, implying
that endogenous levels of proteins terminating in Arg or Lys are too low to be observed
here.
Substantial recent effort has been devoted to developing methods for labeling
proteins under conditions that maintain protein folding and activity.16,

137-138

E. coli

aminoacyl tRNA transferase can work under these conditions and specifically modifies
the N-terminus, a useful point for conjugation. However, certain aspects of its native
mechanism are nonideal for its use as a preparative tool (i.e., a multistep, multienzyme
reaction sequence). The work of Leibowitz, Shrader, and Sisido showed that E. coli
aminoacyl tRNA transferase can modify the N-terminus of a protein ending in Arg or Lys
with amino acids from an aminoacyl oligonucleotide donor.63-64,

127

Watanabe et al.

crystallized AaT with Phe-A bound and showed that Phe could be transferred from Phe-A
to the N-terminus of the peptide RYLGYL in trace amounts. These two results provide
crucial precedent for our own work, in which we show that AaT can efficiently use a
variety of easily synthesized acyl adenosine substrates.
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Enzymological analysis

demonstrates that AaT is able to use the Xaa-A substrates with turnover numbers
comparable to full-length aminoacyl tRNAs. Furthermore, we have shown that neither
the adenosine reaction byproduct nor aminoacylated protein product (at least in the case
of our reporter peptide) appreciably inhibit the reaction. In fact, the major obstacle to
efficient transfer is donor hydrolysis, but this can be overcome by a second addition of
donor molecule since the KI for inhibition by adenosine is greater than 5 mM.
Our AaT-only reaction sequence allows us to explore the compatibility of Phe
analogs lacking a primary α-amine with transfer by AaT. The wild type transferase
seems to have a strong preference for the α-amine, as only N-methylphenylalanine was
transferred. In contrast, the side chain pocket is quite permissive: we have observed the
transfer of bicyclic amino acid side chains and Sisido has reported mutants capable of
transferring tricyclic amino acids.63 We are currently investigating the transfer of larger
side chains such as benzophenone, biotin, and fluorescein derivatives.
Our reaction conditions and yields compare favorably to two well-established
methods in the field. Subtiligase (reverse proteolysis) reactions can be carried out in a
few hours, but rarely go to completion.108-109,

113

The pryidoxyl-5-phosphate (PLP)

transamination reactions of Francis and co-workers can require elevated temperatures to
achieve high yields and are subject to a number of side reactions.100-101 AaT transfer
reactions are highly specific (no Lys side chain modifications were observed in our work
or the work of others) and can be driven to completion by subsequent repeated additions
of donor. Our discovery of efficient transfer from simple adenosyl donors removes the
limitations imposed by the selectivity of synthetases on the range of molecules that can
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be AaT substrates without restricting reaction scale by necessitating the synthesis of
oligonucleotide donors. Our yields are comparable to those obtained with pdCpA donors,
but pdCpA synthesis requires 6 steps, and overall yields are typically 25 %. We see our
methods as complementary to the fully enzymatic synthetase-based methods (Figure 2-1,
Top). Fully enzymatic methods do not require prior synthesis and aminoacyl tRNAs are
efficient substrates for AaT. On the other hand, our methods can be easily scaled up to
modify larger quantities of protein since they do not require the use of purified tRNA.
We have shown that our method can be used to transfer reactive handles to the Nterminus under “protein friendly” (pH ∼7, high salt, 37 °C) conditions and that the
labeled protein product can be easily purified afterward. Given the previous success of
Sisido and co-workers, we expect that further mutation of AaT will allow us to transfer
larger side chains that may permit direct transfer of fluorescent probes or affinity tags.
We also hope to use the available crystal structures to redesign AaT to act on other Nterminal sequences through a combination of rational design and selection. Finally, our
demonstration that AaT can modify α-casein in crude lysates, coupled with the cellpermeability of our moderately polar donors raises the exciting possibility of using AaT
as part of an in vivo labeling strategy.
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Section 2.3 – Materials and Methods
2.3.1 – Materials
General Information.
5′-O-(4,4′-Dimethoxytrityl)

Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA),
adenosine

((DMT)-A),

tetrabutylammonium

acetate

(TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane (TIPSH) were purchased
from Sigma-Aldrich (St. Louis, MO). Note: (DMT)-A production was discontinued by
Sigma-Aldrich, after which it was purchased as a custom order from ChemGenes
Corporation (Wilmington, MA) and was additionally synthesized in-house following the
protocol outlined by Ogilvie et al.139 N-Boc-L-phenylalanine-O-succinimide (Boc-PheOSu) and Lysylalanylaminomethylcoumarin (LysAlaAcm) were purchased from Bachem
(Torrence, CA). N-Boc-L-phenylalanine (Boc-Phe-OH) and all solvents were purchased
from Fisher Scientific (Pittsburgh, PA). All deuterated solvents were purchased from
Cambridge Isotopes Laboratories, Inc. (Andover, MA). E. coli BL21(DE3) cells were
purchased from Stratagene (La Jolla, CA). The pEG6 plasmid, containing His10-tagged
E. coli AaT, was a gift from Alexander Varshavsky (California Institute of Technology).
Sequencing-grade trypsin was purchased from Promega (Madison, WI).

All other

reagents were purchased from Fisher Scientific (Pittsburgh, PA). N-Boc-L-leucine (BocLeu-OH),

N-Boc-L-p-azidophenylalanine

(Boc-Nap-OH),

N-Boc-,

(Boc-Azf-OH),

N-Me-L-phenylalanine

N-Boc-L-naphthylalanine

(Boc-Mef-OH),

N-Acetyl-L-

phenylalanine (Acf-OH), and N-Fmoc-methoxycoumarinylalanine (Fmoc-Mcm-OH)
were purchased from Bachem (Torrence, CA). All solvents were purchased from Fisher
Scientific (Pittsburgh, PA). QuikChange® site-directed mutagenesis kits were purchased
from Stratagene (La Jolla, CA). DNA oligomers were purchased from Integrated DNA
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Technologies, Inc (Coralville, IA). Bradford reagent assay kits were purchased from
BioRAD (Hercules, CA). Protease inhibitor cocktail was purchased from Sigma-Aldrich
(St. Louis, MO). All other reagents were purchased from Fisher Scientific (Pittsburgh,
PA). Infrared spectra were recorded on a Nicolet 6700 FT-IR instrument. Milli-Q
filtered (18 MΩ) water was used for all aqueous solutions (Millipore; Billerica, MA).
Matrix-assisted laser desorption ionization (MALDI) mass spectra were collected using a
Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA).

UV

absorbance spectra were obtained with a Hewlett-Packard 8452A diode array
spectrophotometer (currently Agilent Technologies; Santa Clara, CA). Donor molecule
purification was conducted on a BioCad Sprint FPLC (GMI Inc.; Ramsey, MN; originally
from Perseptive Biosystems) with a Waters Sunfire Prep C18-prep OBD column, 5 µm,
17 - 150 mm (Milford, MA). Analytical HPLC assays were performed on an Agilent
1100 HPLC using a Waters Symmetry Shield C18 column. NMR spectra, 1H and

13

C,

were collected with a Bruker DRX 500 MHz instrument. “Low resolution” electrospray
ionization (ESI) mass spectra (LRMS) were obtained on a Waters Acquity Ultra
Performance LC connected to a single quadrupole detector (SQD) mass spectrometer.
“High resolution” ESI mass spectra (HRMS) were obtained on a Waters LCT Premier
XE LC/MS. DNA sequencing was performed at the University of Pennsylvania DNA
sequencing facility. Fluorescence spectra were collected with a Varian Cary Eclipse
fluorescence spectrophotometer fitted with a Peltier multicell holder (currently Agilent
Technologies).
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2.3.2 – Donor (4a) Synthesis
The synthesis of Phe donor 4a is given as a general procedure, starting from
commercially available Boc-Phe-OH or Boc-Phe-OSu. The carboxy-terminus of the
amino acid was activated as a cyanomethyl ester using chloroacetonitrile to give 1a.
Next, the protected amino acid was attached to one of the available hydroxyls (2′ OH or
3′ OH) of (DMT)-A without preference. The resulting protected adenylate (3a) was
deprotected using a 50/50 mixture of TFA and THF with TIPSH present as a scavenger.
The final product, deprotected adenylate (4a), was purified on C18 reverse-phase HPLC
column.

(S)-Cyanomethyl

2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate

(Boc-Phe-

OCH2CN, 1a).
Boc-Phe-OH (2.01 g, 7.57 mmol) was dissolved in 10 mL tetrahydrofuran under
ambient conditions. Ten equivalents of chloroacetonitrile (4.78 mL, 75.4 mmol) and 1.1
equiv. of DIPEA (8.30 mmol, 1.45 mL) were added to the reaction mixture and allowed
to stir overnight. 1a was purified on silica gel (20 % EtOAc in hexanes) to give 2.474 g
(100 %) of a pale-yellow oil after evaporation. Rf 0.4 in 20 % EtOAc in hexanes; 1H
NMR (500 MHz, CDCl3) δ 7.26 (t, J = 7.0 Hz, 2H), 7.20 (t, J = 7.1 Hz, 1H), 7.11 (d, J =
7.3 Hz, 2H), 5.11 (d, J = 7.8 Hz, 1H), 4.69 - 4.57 (m, 3H), 3.09 - 2.98 (m, 2H), 1.36 (s,
9H);

13

C NMR (125 MHz, CDCl3) δ 170.8, 155.1, 135.4, 129.2, 128.7, 127.3, 114.0,

80.9, 80.2, 54.4, 48.8, 37.8, 28.2; HRMS (ESI) calcd m/z for C16H20N2O4Na [M + Na]+
327.132, found 327.133.
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(S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(
phenyl)methoxy)

methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-phenylpropanoate (Boc-Phe-(DMT)-A, 3a).
(DMT)-A (25 mg, 44 µmol) was dissolved in 5 mL of tetrahydrofuran (dried with
4 Å molecular sieves) in an oven-dried 4 dram reaction vessel. Twenty equivalents of 1a
(272 mg, 0.895 mmol) were added to the reaction mixture. TBAAc (4.9 mg, 16 µmol),
the reaction catalyst, was added last to the reaction mixture. In reproductions of this
reaction, TBAAc additions varied according to reaction progress. The reaction stirred
under argon overnight at room temperature for 1 - 4 days. After evaporation of solvent,
the product was purified on silica gel (gradient solvent system: 20 – 0 % petroleum ether
in EtOAc, 5 % methanol in EtOAc) to give 27 mg (75 %) of a pale-yellow foam after
evaporation. Rf 0.5 in 5 % methanol in EtOAc. 1H NMR (500 MHz, THF-d8) δ 8.08 (s,
1H), 8.00 (s, 1H), 7.44 (d, J = 3.68Hz, 2H), 7.32 (d, J = 8.85 Hz, 4H), 7.20 (dd, J =
8.33Hz, J = 6.66, 2H), 7.13 (t, J = 7.25Hz, 1H), 7.21 - 7.10 (m, 4H), 6.77 (d, J = 4.30 Hz,
2H), 6.75 (d, J = 4.29 Hz, 2H), 5.92 (d, J = 4.87 Hz, 1H), 5.49 (t, J = 4.34 Hz, 1H), 5.13
(t, J = 5.54 Hz, 1H), 4.51 - 4.47 (m, 1H), 4.14 (t, J = 4.07Hz, 1H), 3.71 (s, 6H) (S), 3.42 3.32 (m, 2H), 3.12 - 2.96 (m, 3H), 1.37 (s, 9H); 13C NMR (125 MHz, THF-d8) δ 172.2,
159.9, 157.6, 156.7, 153.8, 146.3, 138.3, 146.3, 138.3, 1367.0, 136.9, 131.2, 131.1, 130.3,
129.3, 129.2, 129.1, 128.6, 128.5, 127.5, 114.0, 113.9, 89.7, 87.5, 82.5, 79.7, 75.1, 73.5,
64.7, 56.4, 55.5, 38.9, 30.6, 28.8; LRMS (ESI) calcd m/z for C45H48N6O9H (M + H)+
816.9, C45H48N6O9Na (M + Na)+ 839.3, found 817.3, 839.3.
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(S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(
phenyl)methoxy)

methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-phenylpropanoate (3a) from 2a.
(DMT)-A (26 mg, 45 µmol) was dissolved in 5 mL of tetrahydrofuran (dried with
4 Å molecular sieves) in an oven-dried 4-dram reaction vessel. Twenty equivalents of 2a
(321 mg, 0.885 mmol) were added to the reaction mixture. TBAAc (19 mg, 64 µmol),
the reaction catalyst, was added last to the reaction mixture in two separate additions, 6
mg, at the beginning of the reaction, and 13 mg after the first 24 h of reaction. The
reaction stirred under argon overnight at room temperature for 2 days. After evaporation
of solvent, the product was purified on silica gel (gradient solvent system: 20 – 0 %
petroleum ether in EtOAc, 5 % methanol in EtOAc) to give 19.1 mg (52.1 %) of a paleyellow foam after evaporation. LRMS (ESI) calcd m/z for C45H48N6O9H(M+H)+ 816.9,
C45H48N6O9Na (M + Na)+ 839.3, found 817.4, 839.4.

(S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-phenylpropanoate (Phe-A, 4a).
3a (50 mg) was dissolved in 1 mL of THF and 1 mL trifluoroacetic acid (TFA)
and reacted overnight with four equiv. of TIPSH. Upon addition of TFA, the reaction
turned a bright-orange color and at the completion of the reaction, the color had become a
dark brown. The reaction mixture was reduced to dryness by rotary evaporation and
extracted using 1 mL dichloromethane and 1 mL water twice with a 1 mL water final
back-extraction against the dichloromethane layer. The water-soluble layer containing 4a
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was then HPLC-purified on a C18-prep column using an increasing acetonitrile gradient
(Gradient 2: 1 – 100 % acetonitrile with water and 0.1 % TFA, 1 % per min) to remove
any protected material. Prep. HPLC purified to give 13.6 mg (53.5 %) of a white solid
after evaporation.

MALDI MS calcd m/z for C19H22N6O5H (M + H)+ 415.4,

C19H22N6O5Na (M + Na)+ 437.4, found 415.0, 437.0.

2.3.3 – Donor (4b-i) Synthesis
As described above, the carboxy-terminus of the amino acid (or analog) was
activated as a cyanomethyl ester using chloroacetonitrile to give 1b-i. Next, the protected
amino acid was attached to one of the available hydroxyls (2′ OH or 3′ OH) of DMT-A
without preference. The resulting protected adenylate (3b-i) was deprotected using a
50/50 solvent mixture of trifluoroacetic acid and THF (1 mL) or neat TFA (1 mL) with
TIPSH present as a scavenger, stirred for 24 h, concentrated under reduced pressure,
extracted using DCM and water as mentioned in the main text, and HPLC purified. The
final product, deprotected adenylate (4b-i), was purified via C18 column purification
using an HPLC.

(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-methylpentanoate (Boc-LeuOCH2CN, 1b).
Chloroacetonitrile (5 mL) and DIPEA (160 mg, 0.21 mL, 1.2 mmol) were added
to Boc-Leu-OH (252 mg, 1.09 mmol) and stirred for 12 h. The solvent was removed
under reduced pressure and SiO2 flash chromatography (20 % ethyl acetate in hexanes)
afforded 284 mg of a pale yellow oil in 96 % yield. Rf 0.5 in 20 % ethyl acetate in
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hexanes; 1H NMR (500 MHz, CDCl3): δ 5.00 (d, J = 7.7 Hz, 1H), 4.80 – 4.65 (m, 2H),
4.30 – 4.29 (m, 1H), 1.70 – 1.65 (m, 1H), 1.60 – 1.47 (m, 2H), 1.39 (s, 9H), 0.91 – 0.89
(m, 6H);

13

C NMR (125 MHz, CDCl3): δ172.2, 155.5, 114.21, 80.3, 53.2, 52.0, 41.0,

28.3, 24.8, 22.8, 21.7; HRMS (ESI) m/z calcd for C13H22N2O4Na [M + Na]+ 293.147,
found 293.151.

(S)-cyanomethyl 3-(4-azidophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (BocAzf-OCH2CN, 1c).
Chloroacetonitrile (5 mL) and DIPEA (99 mg, 0.13 mL, 0.76 mmol) were added
to Boc-Azf-OH (212 mg, 0.691 mmol) and stirred for 12 h. The solvent was removed
under reduced pressure and SiO2 flash chromatography (30 % ethyl acetate in hexanes)
afforded 230 mg of a pale yellow oil in 96 % yield. Rf 0.5 in 30 % ethyl acetate in
hexanes; 1H NMR (500 MHz, CDCl3): δ 7.13 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.4 Hz,
2H), 5.00 (d, J = 7.7 Hz, 1H), 4.80 – 4.65 (m, 2H), 4.62 – 4.58 (m, 1H), 3.12 – 3.01 (m,
2H), 1.40 (s, 9H);

13

C NMR (125 MHz, CDCl3): δ 170.7, 155.1, 139.4, 132.0, 130.7,

119.5, 114.0, 80.7, 54.4, 49.0, 37.5, 28.3; HRMS (ESI) m/z calcd for C16H19N5O4Na [M
+ Na]+ 368.133, found 368.135.

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)propanoate

(Boc-Nap-OCH2CN, 1d).
Chloroacetonitrile (2.5 mL) and DIPEA (25 mg, 33 µL, 0.19 mmol) were added
to Boc-NapAla-OH (54.8 mg, 0.174 mmol) and stirred for 12 h. The solvent was
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removed under reduced pressure and SiO2 flash chromatography (30 % ethyl acetate in
hexanes) afforded 61 mg of a pale yellow solid in 99 % yield. Rf 0.5 in 30 % ethyl
acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.83-7.81 (m, 3H), 7.62 (s, 1H), 7.51
– 7.46 (m, 2H), 7.29 (dd, J = 8.4, 1.5 Hz, 1H), 5.00 (d, J = 7.4 Hz, 1H), 4.79 – 4.64 (m,
3H), 3.31 (dd, J = 14.1, 5.9 Hz), 3.25 (dd, J = 14.0, 6.5 Hz, 1H), 1.41 (s, 9H); 13C NMR
(125 MHz, CDCl3): δ 170.9, 155.2, 133.6, 132.8, 132.8, 128.8, 128.3, 127.8, 127.2,
126.5, 126.2, 114.0, 80.7, 54.5, 49.0, 38.2, 28.4; HRMS (ESI) m/z calcd for
C20H22N2O4Na [M + Na]+ 377.147, found 377.149.

(S)-cyanomethyl 2-((tert-butoxycarbonyl)(methyl)amino)-3-phenylpropanoate (BocMef-OCH2CN, 1e).
Chloroacetonitrile (1.1 mL) and DIPEA (258 mg, 0.341 mL, 1.99 mmol) were
added to Boc-MePhe-OH (497 mg, 1.78 mmol) in tetrahydrofuran (5 mL) and stirred for
12 h. The solvent was removed under reduced pressure and SiO2 flash chromatography
(20 – 35 % ethyl acetate in hexanes) afforded 505 mg of a pale yellow oil in 89 % yield.
Rf 0.3 in 20 % ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.28 – 7.25 (m,
2H), 7.20 – 7.16 (m, 3H), 4.72 – 4.68 (m, 2H), 4.53 – 4.52 (m, 1H), 3.27 (m, 1H), 3.11 –
3.02 (m, 1H), 2.67 (d, J = 17 Hz, 3H), 1.36 (d, J = 12 Hz, 9H);

13

C NMR (125 MHz,

CDCl3): δ 169.9, 155.5, 136.8, 128.9, 128.6, 128.4, 126.8, 126.7, 114.2, 80.8, 61.5, 48.7,
35.4, 33.0, 28.1; HRMS (ESI) m/z calcd for C17H22N2O4Na [M + Na]+ 341.147, found
341.149.
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(S)-cyanomethyl 2-acetamido-3-phenylpropanoate (Acf-OCH2CN, 1f).
Chloroacetonitrile (2 mL) and DIPEA (630 mg, 0.841 mL, 4.87 mmol) were
added to N-Ac-Phe-OH (501 mg, 2.42 mmol) and stirred for 12 h. The solvent was
removed under reduced pressure and SiO2 flash chromatography (50 % ethyl acetate in
hexanes) afforded (535 mg) of a pale yellow oil in 90 % yield. Rf 0.2 in 50 % ethyl
acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.26 (t, J = 7 Hz, 2H), 7.22 (t, J = 2.3
Hz, 1H), 7.07 (d, J = 7.1 Hz, 2H), 6.02 (d, J = 7.4 Hz, 1H), 4.83 (dd, J = 14.0, 6.5 Hz,
1H), 4.66 (dd, J = 15.7, 4.7 Hz, 2H), 3.10 – 3.01 (m, 2H), 1.91 (s, 3H); 13C NMR (125
MHz, CDCl3): δ 170.6, 170.1, 135.2, 129.3, 139.0, 127.7, 114.0, 53.6, 53.2, 49.0, 37.7,
23.0; HRMS (ESI) m/z calcd for C13H14N2O3Na [M + Na]+ 269.090, found 269.091.

(S)-cyanomethyl 2-azido-3-phenylpropanoate (Boc-N3f-OCH2CN, 1g).
Chloroacetonitrile (1 mL) and DIPEA (310 mg, 0.411 mL, 2.41 mmol) were
added to 2-azido-3-phenylpropanoate and stirred for 12 h. The solvent was removed
under reduced pressure and SiO2 flash chromatography (40 – 50 % ethyl acetate in
hexanes) afforded (250 mg) of a white solid in 50 % yield. Rf 0.5 in 50 % ethyl acetate in
hexanes; 1H NMR (500 MHz, CDCl3) δ 7.37 (t, J = 7.6 Hz, 2H), 7.32-7.29 (m, 1H), 7.25
(t, J = 7.6 Hz, 2H), 4.77 (t, J = 1.0 Hz, 1H), 4.18 (dd, J = 6.2, 1.8 Hz, 1H), 3.21 (dd, J =
14.0, 5.8 Hz, 1H), 3.08 (dd, J = 13.9, 8.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 168.8,
135.1, 129.3, 129.1, 127.8, 113.7, 62.9, 49.3, 37.7; HRMS (ESI) m/z calcd for
C11H10N4O2Na [M + Na]+ 253.070, found 253.071.
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(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-3-(7-methoxy-2-oxo-2H-chromen-

4-yl) propanoate (Boc-Mcm-OCH2CN, 1h).
A solution of 20 % piperidine in tetrahydrofuran (4 mL) was added to FmocMcm-OH (200 mg, 0.439 mmol) and was stirred for 15 minutes. The solvent was
removed under reduced pressure and ethyl acetate (10 mL) and 2M sodium hydroxide
was added until pH > 8 followed by addition of Boc anhydride (110 mg, 0.526 mmol) to
the white residue and stirred overnight. The organic layer was extracted and washed with
saturated sodium bicarbonate (2 x 10 mL) and all aqueous fractions were combined and
acidified with 1 M sodium bisulfate until pH < 2. The aqueous layer was then extracted
with ethyl acetate (3 x 10 mL), dried with magnesium sulfate, and concentrated under
reduced pressure. Chloroacetonitrile (1 mL) and DIPEA (62 mg, 82 µL, 0.48 mmol)
were added to the white residue and stirred for 12 h. The solvent was removed under
reduced pressure and SiO2 flash chromatography (50 % - 65 % ethyl acetate in hexanes)
afforded 56 mg of a pale yellow oil in 35 % yield. Rf 0.4 in 50 % ethyl acetate in
hexanes; 1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 8.7 Hz, 1H), 6.90 (dd, J = 8.9, 2.4
Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 6.12 (s, 1H), 5.16 (d, J = 7.7 Hz, 1H), 4.79 (d, J = 4.2
Hz, 2H), 4.69-4.68 (m, 1H), 3.88 (s, 3H), 3.32 (dd, J = 14.1, 5.2 Hz, 1H), 3.12 (dd, J =
13.9, 8.4 Hz, 1H), 1.41 (s, 9H);

13

C NMR (125 MHz, CDCl3) δ 170.0, 163.2, 160.8,

155.9, 155.1, 150.5, 125.3, 113.7, 113.3, 113.0, 112.3, 101.6, 81.3, 56.0, 52.8, 49.5, 34.6,
28.4; HRMS (ESI) m/z calcd for C20H22N2O7Na [M + Na]+ 425.133, found 425.133.
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(S)-cyanomethyl

3-(4-benzoylphenyl)-2-((tert-butoxycarbonyl)amino)propanoate

(Boc-Bzf-OCH2CN, 1h).
Chloroacetonitrile (1 mL) and DIPEA (20 mg, 34 µL, 0.21 mmol) were added to
Boc-p-benzoylphenylalanine (61 mg, 0.19 mmol). The reaction was stirred for 18 h, then
concentrated under reduced pressure. SiO2 flash chromatography (40 % ethyl acetate in
hexanes) afforded 70 mg of a pale yellow oil in 93 % yield. Rf 0.5 in 50 % ethyl acetate
in hexanes. 1H NMR (500 MHz, CDCl3) δ 7.79 (dd, J = 7.1, 4.9 Hz, 4H), 7.59 (t, J = 7.6
Hz, 1H), 7.48 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.00 (d, J = 7.4 Hz, 1H), 4.83
(d, J = 15.7 Hz, 1H), 4.72 – 4.69 (m, 2H), 3.25 (dd, J = 13.7, 5.8 Hz, 1H), 3.16 (dd, J =
13.1, 6.5 Hz, 1H), 1.43 (s, 9H);

13

C NMR (125 MHz, CDCl3) δ 196.4, 170.6, 155.1,

140.3, 137.6, 136.9, 132.7, 130.8, 130.2, 129.4, 128.5, 113.9; HRMS (ESI) m/z calcd for
C23H24N2NaO5 [M + Na]+ 431.158, found 431.158.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-4methylpentanoate (Boc-Leu-(DMT)-A, 3b).
Tetrahydrofuran (5 mL) was added to Boc-Leu-OCH2CN 1b (226 mg, 0.837
mmol), (DMT)-A (120 mg, 0.211 mmol), and TBAAc (15 mg, catalyst) and stirred for 24
h. The solvent was removed under reduced pressure and chromatography (80 – 100 %
ethyl acetate in petroleum ether, 5 % methanol in ethyl acetate), afforded 122 mg of a
white solid in 74 % yield. Rf 0.5 in 5 % methanol in ethyl acetate; 1H and 13C NMR for
3b shown below; LRMS (ESI) m/z calcd for C42H50N6O9Na (M + Na)+ 805.4, found
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805.3.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

3-(4-

azidophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-Azf-(DMT)-A, 3c).
Tetrahydrofuran (5 mL) was added to Boc-Azf-OCH2CN 1c (101 mg, 0.290
mmol), (DMT)-A (43 mg, 75 µmol), and TBAAc (2 mg, catalyst) and stirred for 24 h.
Solvent was removed under vacuum and preparative TLC (100 % ethyl acetate), afforded
44 mg of white solid in 69 % yield. Rf 0.3 - 0.5 in ethyl acetate; 1H and 13C NMR for 3c
shown below; LRMS (ESI) m/z calcd for C42H47N9O9Na (M + Na)+ 880.3, found 880.4.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3(naphthalen-2-yl)propanoate (Boc-Nap-(DMT)-A, 3d).
Tetrahydrofuran (5 mL) was added to Boc-Nap-OCH2CN 1d (58 mg, 0.16 mmol),
(DMT)-A (26 mg, 46 µmol), and TBAAc (6.4 mg, catalyst) and stirred for 24 h. The
solvent was removed under reduced pressure and preparative TLC (5 % methanol in ethyl
acetate), afforded 36 mg of a white solid in 91 % yield. Rf 0.3 - 0.5 in 5 % methanol in
ethyl acetate; 1H and

13

C NMR for 3d shown below; LRMS (ESI) m/z calcd for

C49H50N6O9Na (M + Na)+ 889.9, found 889.4.
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy)

methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)(methyl)amino)-3-phenylpropanoate (Boc-Mef-(DMT)-A, 3e).
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to
Boc-Mef-OCH2CN 1e (110 mg, 0.347 mmol), (DMT)-A (50 mg, 89 µmol), and TBAAc
(3 mg, catalyst) and stirred for 12 h. The solvent was removed under reduced pressure
and SiO2 flash chromatography (50 – 100 % ethyl acetate in hexanes), afforded 10 mg of
a white solid in 14 % yield. Rf 0.4 - 0.5 in ethyl acetate; 1H and 13C NMR for 3e shown
below; LRMS (ESI) m/z calcd for C46H50N6NaO9 (M + Na)+ 853.4, found 853.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-acetamido-3-phenylpropanoate
(Acf-(DMT)-A, 3f).
Tetrahydrofuran (5 mL) and DIPEA (250 mg, 0.30 mL, 1.9 mmol) were added to
Boc-Acf-OCH2CN 1f (400 mg, 1.93 mmol), (DMT)-A (73 mg, 0.13 mmol) and TBAAc
(5 mg, catalyst) and stirred for 12 h. The solvent was removed under reduced pressure
and SiO2 flash chromatography (5 % methanol in ethyl acetate), afforded 75 mg of a clear
solid that was mix of DMTA and product.

Subsequent HPLC analysis suggests

approximately 38 % of this mixture was product. Rf 0.1 - 0.25 % methanol in ethyl
acetate; 1H and 13C NMR for 3f shown below; LRMS (ESI) m/z calcd for C42H43N6O8 (M
+ H)+ 759.3 C42H42N6NaO8 (M + Na)+ 781.3, found 759.3, 781.4.
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-azido-3phenylpropanoate (Boc-N3f-(DMT)-A, 3g).
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to
Boc-N3f-OCH2CN 1g (80 mg, 0.35 mmol), (DMT)-A (50 mg, 89 µmol), and TBAC (3
mg, catalyst) and stirred for 12 h. The solvent was removed under reduced pressure and
purification by silica flash chromatography (75 – 100 % ethyl acetate in hexanes),
afforded 53 mg of a white solid in 80 % yield. Rf 0.3 - 0.5 in ethyl acetate; 1H and 13C
NMR for 3g shown below; LRMS (ESI) m/z calcd for C40H39N8O7 (M + H)+ 743.3,
C40H39N8O7Na (M + Na)+ 765.3, found 743.4, 765.4; FTIR (Film) vmax 3334, 3179,
3063, 3032, 2953, 2934, 2837, 2112 (-N3), 1757, 1644, 1606, 1508, 1252, 1177 cm-1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate (Boc-Mcm-(DMT)-A, 3h).
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µl, 0.35 mmol) were added to
Boc-Mcm-OCH2CN 1h (56 mg, 0.15 mmol), (DMT)-A (50 mg, 89 µmol), and TBAAc (3
mg, catalyst) and stirred for 12 h. The solvent was removed under reduced pressure and
SiO2 flash chromatography (50 – 100 % ethyl acetate in hexanes), afforded 35 mg of a
white solid in 43 % yield. Rf 0.3 – 0.4 in ethyl acetate; 1H and 13C NMR for 3h shown
below; LRMS (ESI) m/z calcd for C49H50N6NaO12 (M + Na)+ 937.3, found 937.4.

60

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

3-(4-

benzoylphenyl)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-Bzf-(DMT)-A, 3i).
THF (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to Boc-BzfOCH2CN (70 mg, 0.17 mmol), (DMT)-A (50 mg, 89 µmol) and TBAAc (5 mg, catalyst)
and stirred for 16 h. The solvent was removed under reduced pressure and SiO2 flash
chromatography (75 % – 100 % ethyl acetate in hexanes) afforded 66 mg of a white solid
in 81 % yield. Rf 0.3 in 100 % ethyl acetate. LRMS (ESI) m/z calcd for C52H52N6NaO10
(M+ Na)+ 943.4, found 943.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-4-methylpentanoate (Leu-A, 4b).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (99 mg, 0.13 mL,
0.63 mmol) were added to 3b (123 mg, 0.157 mmol) following the general deprotection
procedure. HPLC/MALDI analysis m/z calcd C16H25N6O5 (M + H)+ 381.2; Gradient 2;
retention time 14.9 min, found 381.1; retention time 16.6 min, found 381.1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-3-(4-azidophenyl)propanoate (Azf-A, 4c).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (33 mg, 42 µL,
0.21 mmol) were added to 3c (44 mg, 52 µmol) following the general deprotection
procedure. HPLC/MALDI analysis m/z calcd C19H22N9O5 (M + H)+ 456.2; Gradient 2;
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retention time 19.6 min, found 456.1; retention time 21.1 min, found 456.1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-3-(naphthalen-2-yl)propanoate (Nap-A, 4d).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (26 mg, 0.34 mL,
0.17 mmol) were added to 3d (36 mg, 41 µmol) following the general deprotection
procedure. HPLC/MALDI analysis m/z calcd C23H25N6O5 (M + H)+ 465.2,
C23H24N6O5Na (M + Na)+ 487.2; Gradient 2; retention time 21.9 min, found 464.6, 486.6;
retention time 23.4 min, found 464.6, 486.6.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-(methylamino)-3-phenylpropanoate (Mef-A, 4e).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and oxalic acid (2.9 mg) were
added to 3e (31 mg, 37 µmol) following the general deprotection procedure. No TIPSH
was used in this reaction. HPLC/MALDI analysis m/z calcd C20H25N6O5 (M + H)+
429.2, C20H24N6O5Na (M + Na)+ 451.2; Gradient 2; retention time 16.3 min, found 429.1;
retention time 18.6 min, found 429.1, 451.1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-acetamido-3-phenylpropanoate (Acf-A, 4f).
During HPLC analysis, 3f was directly deprotected to 4f by exposure to the 0.1 %
TFA in the HPLC solvent and confirmed via MALDI. HPLC/MALDI analysis m/z calcd
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C21H25N6O6 (M + H)+ 457.2, (M + Na)+ C21H24N6NaO6 479.2; Gradient 2; retention time
18.2 min, found 457.3, 479.3; retention time 19.5 min, found 457.3, 479.3.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-azido-3-phenylpropanoate (N3f-A, 4g).
Trifluoroacetic acid (1 mL) and TIPSH (21 mg, 30 µl, 0.13 mmol) were added to
3g (25 mg, 33 µmol) following the general deprotection procedure. HPLC/MALDI
analysis m/z calcd C19H21N8O5 (M + H)+ 441.2, C19H20N8NaO8 (M + Na)+ 463.1;
Gradient 2; retention time 24.5 min, found 440.9, 462.9; retention time 24.7 min, found
440.9, 462.9.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl

2-amino-3-(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate

(Mcm-A, 4h).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and oxalic acid (3.9 mg) were
added to 3e (31 mg, 37 µmol) following the general deprotection procedure, except was
worked up in water only and water-soluble portion was HPLC purified. No TIPSH was
used in this reaction. HPLC/MALDI analysis m/z calcd C23H25N6O8 (M + H)+ 513.2,
C23H24N6O8Na (M + Na)+ 535.2; Gradient 2; retention time 19.9 min, found 513.1, 535.1;
retention time 20.9 min, found 513.1, 535.1.
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-3-(4-benzoylphenyl)propanoate (Bzf-A, 4i).
TFA (1 mL) and TIPSH (40 mg, 50 µL, 0.26 mmol) were added to DMT-A
benzoylphenylalanine (59 mg, 64 µmol) according the general deprotection procedure.
HPLC/MALDI analysis m/z calcd C26H27N6O6 (M + H)+ 419.2, C26H26N6NaO6 (M +
Na)+ 441.2; Gradient 2, retention time 19.7 min found 519.1, 541.1.
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Figure 2-5. H and

13

C NMR Characterization of Boc-Leu-(DMT)-A (3b)
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1

Figure 2-6. H and

13

C NMR Characterization of Boc-Azf-(DMT)-A (3c)
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1

Figure 2-7. H and

13

C NMR Characterization of Boc-Nap-(DMT)-A (3d)
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1

Figure 2-8. H and

13

C NMR Characterization of Boc-Mef-(DMT)-A (3e)
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Figure 2-9. H and

13

C NMR Characterization of Boc-Acf-(DMT)-A (3f)
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1

Figure 2-10. H and

13

C NMR Characterization of Boc-N3f-(DMT)-A (3g)
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1

Figure 2-11. H and

13

C NMR Characterization of Boc-Mcm-(DMT)-A (3h)
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1

Figure 2-12. H and

13

C NMR Characterization of Boc-Bzf-(DMT)-A (3i)
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2.3.4 – HPLC Analysis of Donor Deprotection
Trifluoroacetic acid (1 mL) and TIPSH (10 mg, 13 µl, 65 µmol) were added to 3a
(10 mg, 13 µmol) and stirred for 12 h. Solvent was removed under reduced pressure
followed by precipitation with diethyl ether. HPLC analysis of the deprotection reaction
is shown in Figure 2-13. The assignment of the 2' and 3' acetylated forms of Phe-A is
based on the known thermodynamic preference for 3' acylation of adenosine.140 The
HPLC method (Solvents A and B defined in main text) had the following solvent gradient
(Gradient 3): 0 min 2 % B, 60 min 100 % B, 65 min 1 % B. Monitored at 215 nm and
260 nm.

Figure 2-13. HPLC Analysis of Donor 4a Purity After TFA Deprotection

2.3.5 – HPLC Analysis of Donor Hydrolysis
The amino acid analog donor (4a–h) was suspected to be hydrolytically unstable
and was tested in mock LysAlaAcm reactions without enzyme present and then analyzed
by HPLC. The mock LysAlaAcm reactions were performed as described in section 2.3.7;
however, the AaT solution was replaced with water. Phe-A solutions were analyzed at 30
min, 1 h, and 4 h. Immediately following the reaction, the sample was diluted to 1200 µL
and injected onto the C18 HPLC column using Gradient 1. As seen in Figure 2-14, PheA is completely hydrolyzed after 4 h. Additionally, 1 mM A and 1 mM Phe were
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injected on the HPLC to serve as standards to verify retention times. Note: The relative
concentrations of 2' and 3' Phe-A would be different in an actual reaction where the 3'
Phe-A is preferentially consumed by AaT in the transfer reaction.43 The change in 2':3'
ratio between 0 h and 30 min probably reflects the higher pH of the 30 min data.140

Figure 2-14. HPLC Analysis of Donor 4a Hydrolysis in Mock Transferase Reactions
Slight differences in retention time were observed, compound identities confirmed by MALDI MS.
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2.3.6 – Aminoacyl Transferase Expression and Purification
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3)
cells using a procedure adapted from Graciet et al (Figure 2-15).50 E. coli were grown in
a primary culture of 5 mL LB at 37 °C to OD600 of 0.5 and then were rediluted into a
secondary culture of 500 mL LB and grown to OD600 of 0.6. AaT expression was
induced using 0.1 mM isopropyl β-D-thiogalactoside and cells were grown at 25 °C for
~16 h. Cells were pelleted at 6,000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge.
Cell pellets were resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 mM
imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0) and included protease
inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II.

Following

resuspension, the cells were lysed using sonication. Soluble proteins were collected via
centrifugation at 13, 200 RPM for 15 min. Collected soluble protein was gently shaken
for 1 h at ambient temperature with Ni-NTA resin. The resin was prepared by rinsing
with Ni-NTA binding buffer and then washed with four volumes of Ni-NTA wash buffer
(50 mM Tris, 50 mM imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0).
The proteins were eluted with elution buffer (50 mM Tris, 250 mM imidazole, 300 mM
KCl, and 5 mM β-mercaptoethanol, pH 8.0). Pure elution fractions of E. coli AaT were
dialyzed overnight in transferase buffer (50 mM Tris, 30 % glycerol, 120 mM
(NH4)2SO4, 5 mM β-mercaptoethanol, pH 8.0) at 4 °C. The dialyzed enzymes were
stored at – 80°C. Protein concentrations were determined using the Bradford assay and a
bovine serum albumin standard curve according to the manufacturer’s instructions.141
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Figure 2-15. SDS PAGE Gel Analysis of AaT Expression and Purification
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2)
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) NiNTA column flow-through; 7) Column wash 1; 8) Column wash 3; 9) Elution fraction 1; 10)
Combined elution fractions 3-5 after overnight dialysis.

2.3.7 – LysAlaAcm Ligation Assay
Each ligation reaction, 125 µL total volume, contained the following reagents:
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2). The reaction mixtures were incubated at
37 °C for four hours and quenched with 1 % acetic acid. The proteins were extracted
from the reactions via acetone precipitation. The reactions were precipitated using 4X
reaction volume of acetone and cooled at -20 °C for 1 h. Next, the reactions were
centrifuged at 13, 200 rpm at 4 °C for 20 min to separate the reaction from precipitated
protein. The supernatant was transferred to fresh 1.5 mL centrifuge tubes and allowed for
acetone evaporation overnight at room temperature.
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After acetone evaporation, the

supernatant was dried in a Speedvac (Savant, Thermo Scientific, Fisher Inc.) for 30 min
to remove residual acetone. The resulting reaction volume was dissolved up to 1.2 mL
using Milli-Q water and analyzed by HPLC (gradient below) to determine ligation yield
by integration of separated peak intensities monitored at 325 nm. Collected HPLC
fractions were characterized through MALDI MS analysis. Reactions were performed
with 6 trials on at least two protein preparations for all successful reactions, 3 trials for
failed reactions. Reactions using Phe-pdCpA as donor were carried out in an identical
fashion.142

2.3.8 – AaT Ligation Reaction Analysis by HPLC
All HPLC analyses of LysAlaAcm ligations were monitored as described in the
main text (Gradient 1). Peptide retention times monitored at 325 nm (Acm absorption)
and MALDI MS analyses confirming peptide identity are in Table 2-2.

Table 2-2. HPLC Analysis of LysAlaAcm Transfer Reactions
M+H

+

Product Peptide

Retention
Time (min)

Calc’d

Obs.

LysAlaAcm

11.8

375.2

374.9

PheLysAlaAcm

13.0

522.3

522.1

LeuLysAlaAcm

12.7

488.3

487.3

AzfLysAlaAcm

13.6

563.3 (- N2 537.3)

563.3 (- N2 537.3)

NapLysAlaAcm

14.1

572.3

572.1

MefLysAlaAcm

13.1

536.3

536.3

AcfLysAlaAcm

NA

NA

NA

N3fLysAlaAcm

NA

NA

NA

McmLysAlaAcm

NA

NA

NA

BzfLysAlaAcm

14.6

626.3

626.1
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2.3.9 – A/AMP/ATP/pdCpA Inhibition Studies
Each ligation reaction was performed as described above. The addition of four
types of adenosyl compounds (adenosine, AMP, ATP, or pdCpA) were monitored
individually in ligation reactions with Phe donor 4a. Adenosyl compound concentrations
tested were 1 mM, 2.5 mM, and 5 mM HPLC analysis was used to determine inhibition
of ligation by integration of HPLC reagent and product peaks. The LysAlaAcm ligation
assay was used to analyze the kinetics of AaT with substrate 4a. The ligation assay was
modified for ease of analysis as follows: the total reaction volume was scaled up to 590
µL and all reagents were maintained at the same concentrations as mentioned above.
Five concentrations of 4a were monitored for a total reaction time of 30 min, with
concentrations ranging from 0.05 to 1 mM. Each 30 min kinetic experiment was done in
triplicate with a total of fourteen 40 µL aliquots for all substrate concentrations. The
synthesis of pdCpA was carried out essentially as previously described.

2.3.10 – AaT Ligation Reaction Analysis by HPLC
All HPLC analyses of LysAlaAcm ligations were monitored on an Agilent HPLC
using a Waters C18 column (Milford, MA). The solvents used for peptide purification
were the following: 0.1 % trifluoroacetic acid in water (Solvent A) and 0.1 %
trifluoroacetic acid in acetonitrile (Solvent B). The HPLC method had the following
solvent gradient (Gradient 1): 0 min 1 % B, 5 min 1 % B, 10 min 30 % B, 15 min 40 %
B, 20 min 100 % B, 25 min 100 % B, 27 min 1 % B, 30 min 1 % B. Peptides were
monitored at two absorption wavelengths during HPLC analysis, 215 nm for peptide
absorption, and 325 nm for Acm absorption. MALDI MS analyses confirmed identity of
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peptide, Xaa-A donor, and ligated products.

2.3.11 – Fluorometric Analysis of Transferase Experiments
Real time fluorescent monitoring of Nap addition to LysAlaAcm was carried out
using reaction solutions prepared on the 500 µL scale in stirred quartz cuvettes with 1.00
cm path lengths. Reagent concentrations were as described above, except that donor 4d
was withheld until the cuvette was placed in the fluorometer and temperature
equilibrated. Reactions were then initiated by addition of 20 µL of 25 mM Nap-A (4d)
stock or water (for negative controls). Fluorescence emission at 390 nm was monitored
after excitation at 325 nm.

Prior calibration had shown that NapLysAlaAcm (5d)

concentrations could be estimated from fluorescence intensity readings (F5d) using the
equation [5d] = (1 – (F5d/ FControl))1.39[LysAlaAcm], where FControl is the fluorescence
reading of the reaction with water added instead of 4d. Measurements were taken on the
Cary Eclipse fluorometer in the “Kinetics” mode at 37 °C, acquiring data every 15 s. The
excitation and emission slit widths were 5 nm and the averaging time was 1 s.

2.3.12 – Calibration of NapLysAlaAcm Fluorometric Transfer Analysis
In order to monitor conversion of LysAlaAcm to NapLysAlaAcm (5d) in real
time, we designed a fluorometric assay based on intramolecular quenching of
aminocoumarin fluorescence by the naphthyl ring. Equimolar solutions of LysAlaAcm
and NapLysAlaAcm, as well as mixtures of the two solutions, were prepared and their
fluorescence compared (Figure 2-16A). The fluorescence emission of NapLysAlaAcm at
390 nm (λex = 325 nm) was 72 % lower than LysAlaAcm, and no non-linear effects were
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exhibited in the mixtures (Figure 2-16B).

Therefore, the mole fraction of

NapLysAlaAcm could be linearly related to the measured fluorescence of a reaction
solution

(F5d),

and

the

concentration

of

5d

determined

as

(1

-

(F5d/FControl))•1.39•[LysAlaAcm], where FControl is the fluorescence reading of the reaction
with water added instead of donor 4d. This calibration was used to determine the timedependent concentration of the NapLysAlaAcm product as described in the main text.

Figure 2-16. Fluorescence Emission of NapLysAlaAcm Solutions
(A) Fluorescence emission of mixtures of LysAlaAcm and NapLysAlaAcm (5d); χ5d = 0.00 (red),
0.10 (orange), 0.20 (light green), 0.25 (green), 0.33 (light blue), 0.50 (blue), 1.00 (purple)(B)
Linear fit of normalized fluorescence vs. mole fraction NapLysAlaAcm (y = 1 – 0.72x, R = 0.999)

2.3.13 – Michaelis-Menten Kinetic Analysis of Phe Transfer
The reaction scheme for the catalysis of N-terminal aminoacylation by AaT is
shown in Equation S1. Previously, it has been shown that the sequential bisubstrate AaT
reaction can be treated as pseudo-first order when carried out with saturating
concentrations of one substrate (acceptor peptide).64 Therefore, we characterized the
reaction in terms of the Michaelis-Menten kinetic scheme in Equation S2.
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To determine initial velocities, we fit the primary kinetic data to the hyperbolic Equation
S3, which, though phenomenological, produces a high quality fit (R > 0.99 for all 5 data
sets). Data from the first two minutes were fit to a linear expression (Eqn. S4). We
employ a non-zero intercept for improved quality of fit; this can be justified in terms of a
rapid burst phase not captured in the 1 min resolution of this assay. Note that this burst
phase seems to be extremely rapid, even the 15 s intervals of our direct fluorometric
assay are not sufficient to capture this phase (See Figure 3-3A). The results of these
linear fits are shown in Figure 2-17.

The initial velocities were then plotted as a function of Phe-A donor concentration and fit
to Equation S5 to obtain kcat and KM values, where KM = (k-1 + kcat)/k1 (See Figure 3-3B).
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Figure 2-17. Phe Transfer Reaction Kinetics
Product concentration as a function of time determined by integration of HPLC traces. Data are
an average of 3 trials. Bars indicate standard error. Black lines indicate best fit to early
timepoints using Eqn. S4. Bottom Right: Fits to kinetic data according to Eqn. S4.
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2.3.14 – α-Casein N-Terminal Modification
α-Casein (4.8 mg) was modified with Azf-A (4c) in a reaction volume of 1 mL in
modified AaT buffer (50 mM HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2) and AaT
(0.05 mg). The reaction mixture was incubated at 37 °C for 12 h, AaT was removed
using Ni2+ resin (Ni-NTA Superflow, Qiagen), and then buffer exchanged four times into
phosphate buffered saline (PBS, 12 mM NaH2PO4, 50 mM NaCl, 4.7 mM KCl, pH 8.0)
by Spectra/Por 1 dialysis tubing (Spectrum Laboratories; Rancho Dominguez, CA). Azfmodified α-casein was used directly after buffer exchange into PBS. Aliquots (1 nmol)
of α-casein were diluted into PBS (22 µL) containing either fluorescein-alkyne (FlAlk, 91
µM) or propargylamine (Alk, 227 µM) for copper-catalyzed azide-alkyne cycloaddition
(CuAAC). The CuAAC reaction was initiated by addition of CuSO4 (100 µM), tris-(3hydroxypropyltriazolylmethyl) amine (THPTA, 500 µM), and sodium ascorbate (5 mM).
For control reactions, equivalent volumes were replaced with either PBS or water. The
reaction mixtures were incubated at 4 °C for 2 h. Reactions were boiled with gel loading
dye LDS (Pierce; Rockford, IL) for 10 min at 95 °C and analyzed by SDS-PAGE.
Fluorescence images were obtained with a Geldoc (BioRAD; Hercules, CA) using an
excitation wavelength of 302 nm for detection of fluorescein. α-Casein was also directly
visualized by Coomassie Brilliant Blue staining. Section 2.3.14 was performed by John
Warner.

2.3.15 - Edman Degradation Analysis of α-Casein Modification
Phe was ligated to α-casein using 4a as described in the main text with the
following modifications. The substrate (1 mM) was 10 times more concentrated, and the
83

total volume was 4 times greater. This reaction was run overnight; at the 4 h timepoint,
an additional 50 µL dose of 25 mM 4a donor was added to the reaction. The His10tagged AaT was separated from the reaction via nickel bead purification: 100 µL Ni-NTA
resin was added at a ratio of 25 µL per 12.5 µM AaT, the beads were shaken with the
reaction for 2 hours, then separated via centrifugation at 13, 200 RPM for 2 min. The
supernatant was removed, diluted to 1 mL with Milli-Q water, and dialyzed against 1X
PBS (Hyclone, Fisher) overnight at 4 °C to remove any residual 4a. The protein was
electroblotted onto PVDF membrane and sent to Johns Hopkins University Synthesis and
Sequencing Facility (Baltimore, MD) for Edman Degradation analysis (Figure 2-18).

Figure 2-18. Edman Degradation Analysis of α-Casein Modification
Top: Unmodified α-casein. R peak area is 196 counts of total, F peak area is 44 counts. Bottom:
Phe-modified α-casein. F peak area is 97 counts. R peak area is 53 counts.
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2.3.16 – Tryptic Digest Analysis of α-Casein Modification
α-Casein-Azf (33 µg), or α-casein (33 µg), was digested with sequencing grade
modified Trypsin (0.6 µg) in 27 µL of 25 mM ammonium bicarbonate pH 7.5 (freshly
prepared). Digestions were carried out at 37 °C for 14 h. Trypsin digest aliquots (1 µL)
were combined with α-cyano-4-hydroxycinnamic acid (1 µL of a saturated solution in 1:1
H2O/CH3CN with 1 % TFA) and analyzed by MALDI MS.

Section 2.3.16 was

performed by John Warner.

2.3.17 – α-Casein Labeling in Cleared Cell Lysate
AaT was expressed in E. coli BL21-Gold (DE3) cells as previously described. A
cleared cell lysate was obtained by centrifugation following cell lysis using sonication.
Proteins were modified in a final reaction volume of 110 µL with Azf-A (4c, 3 mM)
using AaT (25 µL) from cleared lysate in AaT buffer (50mM HEPES pH 8.0, 150mM
KCl, 10mM MgCl2). α-Casein (0.012 mg or 0.12 mg) was added to the reaction and
incubated at 37 °C for 2 h, after 1 h, an additional 0.3 µmole of 4c was added. For
control reactions, equivalent volumes were replaced with water. Excess 4c was removed
by buffer exchange four times against phosphate buffered saline (PBS, 12mM NaH2PO4,
50mM NaCl, 4.7mM KCl, pH 8.0) by Spectra/Por 1 dialysis tubing. Aliquots (18 µL) of
4c modified lysates were diluted to a final volume of 22 µL using PBS containing FlAlk
(182 µM) for copper catalyzed “click” reactions. The “click” reaction was initiated by
addition of CuSO4 (100 µM), THPTA (500 µM), and sodium ascorbate (5 mM). The
reaction mixtures analyzed by PAGE gel using Coomassie staining and fluorescence as
above (Figure 2-19). Section 2.3.17 was performed by John Warner.
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Figure 2-19. SDS PAGE Gel Analysis of α-Casein Modification in Cleared E. coli lysate
Left: Coomassie stained gel. Right: Fluorescence image from 302 nm excitation. Lanes (left to
right): 1) Molecular weight markers (Masses in kDa: 17, 25, 30, 46, 58, 80, 175); 2) Cleared
lysate reacted with FlAlk; 3) Cleared lysate modified with 4c then reacted with FlAlk; 4) Cleared
lysate with α-casein (0.012 mg) modified with 4c then reacted with FlAlk; 5) Cleared lysate with αcasein (0.12 mg) modified with 4c then reacted with FlAlk; 6) Molecular weight markers.

2.3.18 – “Click” Reagent Synthesis
Fluorescein 5- and 6-proparglyamide (Fluorescein-alkyne, FlAlk) was synthesized
as previously described (Figure 2-20).134 Briefly, propargylamine (8.7 µL, 136 µmol)
was added to a solution of 5- and 6-Carboxyfluorescein N-hydroxysuccinimide ester (32
mg, 68 µmol) in tetrahydrofuran (5 mL). The reaction was stirred continuously and
monitored by TLC. Solvent was removed by under reduced pressure. Purification by
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silica chromatography (Rf = 0.3, 20 % MeOH in CH2Cl2) afforded fluorescein-alkyne as
a red-orange solid.

Tris-(3-hydroxypropyltriazolylmethyl)amine (THPTA) was also

synthesized as previously described (Figure 2-20).143 Briefly, to a solution of 3-bromopropanol (2 g, 14.4 mmol) in dichloromethane (10 mL) was added Ac2O (2.94 g, 28.8
mmol) and NEt3 (2.91 g, 28.8 mmol).

The reaction was stirred continuously and

monitored by TLC. An aqueous solution of NaHCO3 was added and the phases were
separated. The organic layer was washed once more with NaHCO3 and twice with brine.
Solvent was removed under reduced pressure and 3-bromopropyl acetate was afforded as
a colorless oil. To a solution of 3-bromopropyl acetate (1.0 g, 6.0 mmol) in water (10
mL) was added sodium azide (780 mg, 12.1 mmol). The solution was stirred at 90 °C
overnight. The solution was extracted three times with 15 mL CH2Cl2 and dried with
MgSO4. Solvent was removed under reduced pressure to afford 3-azidopropyl acetate as
a pale yellow oil.

To a solution of tripropargylamine (12.3 mg, 0.941 mmol) in

tetrahydrofuran (6.5 mL) was added 3-azidopropyl acetate (0.672 g, 4.71 mmol) and
Cu(I) acetate (5.8 mg, 5 mol %). The solution was refluxed overnight under inert
atmosphere.

Solvent was removed under reduced pressure.

Silica chromatography

purification (Rf = 0.5, 5-10 % MeOH in CH2Cl2) afforded acetyl-protected THPTA as a
yellow oil. A solution of acetyl-protected THPTA (397 mg, 0.711 mmol) in 2.0 M
ammonia in MeOH (10 mL) was continuously stirred overnight at 40 °C. Solvent was
removed under reduced pressure. The solid was washed and filtered four times with
acetonitrile and dried under reduced pressure to afford THPTA as a white solid. For both
FlAlk (25 % overall yield) and THPTA (98 % overall yield), intermediate and product
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identities were confirmed by comparison of 1H NMR and LRMS (ESI) MS data to
previous reports.134, 143 Section 2.3.18 was performed by John Warner.

Figure 2-20. Click Chemistry Reagents

88

CHAPTER 3

NATIVE CHEMICAL LIGATIONS IN PEPTIDES AND PROTEINS USING
PROTECTED DISULFIDE AMINOACYL TRANSFERASE ANALOGS

89

Reprinted (adapted) with permission from (Tomohiro Tanaka, Anne M. Wagner, John B.
Warner, Yanxin J. Wang, E. James Petersson. Angew. Chem. Int. Ed. 2013, 125, 6330–
6333.). Copyright (2013). John Wiley and Sons.

Section 3.1 - Introduction
Protein engineering is an expansive field that has a wide-ranging definition from
designing and creating new proteins to altering proteins to have a desired function.16
Despite the breadth of the field, there is an overarching goal to analyze and understand
protein structure and function. One recent method has revolutionized the field of protein
synthesis, native chemical ligation (NCL). NCL component groups include a C-terminal
peptidyl thioester and a N-terminal cysteine peptide that react to form an amide bond
while retaining the cysteine residue at the ligation site.9 In order to minimize the need for
peptide synthesis, the NCL reaction can be used with expressed protein fragments and is
termed expressed protein ligation (EPL).144 The EPL reaction can be implemented in two
methods that vary in the degree of chemical synthesis required. One method expresses an
N-terminal cysteine protein fragment in E. coli cells and utilizes chemical synthesis to
create a small thioester-bearing peptide for the ligation reaction.

Another method,

pioneered by Muir, expresses both protein fragment domains: an N-terminal cysteinebearing protein fragment and a fused intein at the C-terminus.

Under reducing

conditions, the intein can be self-excised and form a C-terminal thioester in situ. Both
methods, NCL and EPL, have helped to make protein synthesis an efficient process.
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The major limitation to NCL and EPL is the need of a cysteine at the ligation site.
Since cysteine is coded by only two codons, it will be theoretically underrepresented in
proteins at a random occurrence of 3.3 % composition in proteins.145

The percent

composition of cysteine in proteins is actually lower than the random value, depending on
species, 2.3 % in mammals and 0.5 % in some archeabacteria.145 One way to bypass the
constraint of low cysteine abundance in proteins is amino acid mutagenesis. However,
mutagenesis to a cysteine can be disruptive to protein structure and activity. Therefore,
several groups have developed methods to erase or mask the ligation site to a different
residue. Several methods include alkylation of cysteine to form an amino acid analog or
desulfurization of cysteine to form alanine.146-148 Other strategies, such as one developed
by Danishefsky, desulfurize synthetic cysteine analogs to a variety of other amino acids
such as valine and lysine.149-155 Post-ligation reactions, demonstrated by Dawson and
Muir, utilize nitrobenzyl cysteine surrogates at ligations, which can be removed via
photolysis.156-157 Other ligations methods create cysteine-less sites such as “traceless”
Staudinger ligations and Bode’s ketoacid/alkoxyamine ligation.30,

158-159

Additionally,

homocysteine (Hcs) can be used as a cysteine surrogate for ligation and then converted to
methionine by selective methylation.160-163 All of the aforementioned strategies to mask
the ligation site have one common link, the requirement of at least one synthetically
incorporated reactive ligation group.
We have developed and demonstrated a method that utilizes an enzyme,
aminoacyl transferase (AaT) from E. coli, to specifically functionalize the N-termini of
peptides and proteins with a wide variety of natural and unnatural residues. Recently we
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have developed aminoacyl donors that can transfer ligation handles such as Hcs, which
were not previously accessible in expressed proteins. The natural function of AaT is to
transfer phenylalanine, leucine, and at a lesser efficiency, methionine from an aminoacyl
tRNA (Xaa-tRNA) to the N-terminus of a protein.40,

123

In previous work, we have

successfully demonstrated that AaT can transfer amino acids with large phenylalaninelike side chains such as benzoylphenylalanine and naphthylalanine.66 We applied a
similar strategy to a variety of methionine-like analogs and determined their efficiency as
AaT substrates to be used to functionalize proteins with erasable Cys analogs for ligation.
The applicability of AaT transfer is far reaching since it recognizes N-terminal Arg and
Lys residues without influence by adjacent amino acids; both arginine and lysine are
significantly more abundant than cysteine at 5.5 % and 6.4 %, respectively.40, 127, 145 We
have demonstrated that AaT can transfer disulfide-protected Hcs and Cys to the Nterminus of a protein via amide bond formation and in conditions that maintain protein
stability and functionality. Additionally, following reduction and ligation, Hcs can be
effectively and selectively masked to become Met by alkylation (Figure 3-1). We have
validated the utility of this approach in two ways: by synthesizing α-synuclein (αS), a
protein whose aggregation contributes to Parkinson’s disease pathology, and through a
multi-step semi-synthesis of the well-characterized calcium-binding protein calmodulin
(CaM), to demonstrate the ability to selectively incorporate an unnatural site in the
middle of a protein while retaining the original primary sequence in the rest of a Cys-less
protein.164-165 This N-terminal modification technique will expand the utility of current
NCL methods.
92

Figure 3-1. Expressed Protein Ligation at Methionine
An expressed protein bearing an N-terminal Arg or Lys (green) is functionalized with a protected
Hcs analog from an aminoacyl adenosine donor, under catalysis by AaT transferase. A synthetic
peptide thioester (red) is ligated to the modified protein under reducing conditions that allow
deprotection of Hcs. After ligation, Hcs is converted to Met via methylation.

Section 3.2 - Results and Discussion
Methionine is the only sulfur-containing amino acid that is naturally transferred
by AaT in E. coli. Although methionine is not a substrate for NCL, Hcs and other thiolor selenol-containing Cys analogs can be used in ligation . Therefore, we investigated the
possibilities of AaT ligation of Hcs and Cys (as a test for various Cys analogs such as
selenocysteine) in the form of adenosyl analogs, which bypass the restrictive selectivity
of an aminoacyl synthetase. Previous studies had shown that Cys-tRNA is not a substrate
for AaT and our own preliminary experiments showed that Hcs was not transferred (data
not shown).58,

127

Therefore, we prepared Hcs analogs masked as aliphatic or aromatic

disulfides in order to mimic the endogenous AaT substrates: Met, Leu, and Phe.
Disulfide protecting groups (MeS, i-PrS, t-BuS, PhS, and CF3CH2S) were used so that
they could be removed in situ under the reducing conditions of the subsequent NCL
reaction.
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3.2.1 - Disulfide Aminoacyl Adenosyl Donor Synthesis.
All of the aminoacyl donors for AaT were created using a similar synthetic
protocol.

For the synthesis of S-protected 3'-adenosyl homocysteine, the reaction

sequence began with Boc-protection of the exposed amino groups of homocystine to
form homodisulfide 1.

The second step involved disulfide exchange with a thiol

containing the desired aliphatic or aromatic protecting group to form heterodisulfides 2ae. Next, the carboxylic acid group was activated in the form of a cyanomethyl ester (3ae). In the following step, the activated carbonyl will allow for nucelophilic attack of the
2' or 3' hydroxyls of 5'-O-dimethoxytrityladenosine (DMT-A) to form protected
aminoacyl adenosines 4a-e. The last step of the synthetic route was deprotection of all
protecting groups (Boc and DMT) with 50 % trifluoroacetic acid and 50 %
tetrahydrofuran yielding the aminoacyl adenosyl analogs 5a-e, denoted Xaa-A (Scheme
3-1). Overall yields of products 4a-e from homocystine were ~ 40 %. To ensure high
purity of final product and removal of deprotection side products, the final step was
purified by HPLC. The syntheses of Cys analogs were carried out in a similar fashion
(Scheme 3-2).
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Scheme 3-1. Synthesis of Homocysteine (Hcs) Analogs
All homocysteine (Hcs) analogs began with the starting material homocystine, (Hcs)2. The Rgroups for each letter is as follows: 2a-5a R = methyl, 2b-5b R = isopropyl, 2c-5c R = tertbutyl,
2d-5d R = phenyl, and 2e-5e R = trifluoroethyl. Reactions and conditions for step (A) 2.5
equivalents of (Boc)2O, 4 equivalents of NaOH, 50/50 dioxane/water, (B) excess RSH (R =
protecting group), I2, 50/50 THF/water, (C) 1.1 equivalents of DIPEA, ClCH2CN, (D) 2 – 4
equivalents of cyanomethylester, 1 equivalent of DMT-A, catalytic equivalent of TBAC, THF, (E) 4
equivalents TIPSH, 50/50 TFA/THF. Yields can be found in section 3.3 Supplementary Materials
and Methods.
Boc = tert-butyloxycarbonyl, DIPEA = N-diisopropylethylamine, THF =
tetrahydrofuran, (DMT)-A = 5′-O-dimethoxytrityl adenosine, NBu4Ac = N,N,N,Ntetrabutylammonium acetate, TFA = trifluoroacetic acid, TIPSH = triisopropylsilane.
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Scheme 3-2. Synthesis of Cysteine (Cys) Analogs
All Reagents and conditions: a) NaSMe, I2, 1:1 H2O/THF, 0 °C; b) ClCH2CN, DIPEA, THF; c)
(DMT)-A, NBu4Ac, THF; d) TFA, TIPSH, THF. The R-groups for each letter is as follows: 7a-10a
R = methyl, 7b-10b R = isopropyl, 7c-10c R = tertbutyl, 7d-10d R = phenyl, and 7e-10e R =
trifluoroethyl. Reactions and conditions for step (A) excess RSH (R = protecting group), I2, 50/50
THF/water, (B) 1.1 equivalents of DIPEA, ClCH2CN, (C) 2 – 4 equivalents of cyanomethylester, 1
equivalent of DMT-A, catalytic equivalent of TBAC, THF, (D) 4 equivalents TIPSH, 50/50
TFA/THF. Yields can be found in section 3.3 Supplementary Materials and Methods. Some
analogs were commercially-bought as the Boc-protected amino acid, including Cys-S-t-butyl
(Csb) and Cys-benzyl (Cbz). All cysteine disulfide cyanomethylesters were synthesized by Dr.
Tomohiro Tanaka except for Csb and Cbz, which were synthesized by Anne Wagner and Jose
Villegas. The rest of the synthetic pathway was completed by Anne Wagner.

3.2.2 - LysAlaAcm Model Ligations with Disulfide Analogs
As in Chapter 2, we used LysAlaAcm as a model peptide to test the feasibility of
disulfide analogs as aminoacyl-tRNA substrate mimics for AaT. All reactions were kept
standardized, as discussed in Chapter 2, with one additional change: all reactions had a
total of 4 doses of 1 mM Xaa-A added at t = 0 h, 1h, 2h, and 3 h time-points of the 4 h
reaction. This change significantly enhanced ligation efficiency by making more analog
available throughout the 4 h reaction to compete against analog hydrolysis.
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We

compared yields of XaaLysAlaAcm by HPLC analysis after four hour reactions at pH 8.0
at 37 °C (Figure 3-2). Under these conditions, transfer of Phe is quantitative and Met
proceeds in 75 % yield. Once we determined that AaT could transfer sulfur-containing
amino acids, we tested a methionine isostere, Cys-S-methyl (Csm), and it produced a
ligation efficiency of 21 %. While this was lower than Met, it established that we could
transfer disulfide-protected analogs without substantial sidereactions. Hcs donors (5a-e)
and Cys donors (10a-10e) were tested in a similar fashion (Schemes 3-1 and 3-2). For
homocysteine analogs, the bulk of the protecting group was a significant factor in transfer
efficiency: Hcm was transferred most efficiently from 5a, with somewhat lower yields
for Hcp and Hcb.

Of the cysteine disulfide analogs, Csp had the highest transfer

efficiency: Csp (10b) > Csb (10c) > Csm (10a). All of the aromatic protecting groups
(5d and 10d) prevented the ligation of their respective amino acid to LysAlaAcm,
including Cbz, which was not a disulfide, indicating that issues with residue steric bulk,
not reactivity of the aryl-S bond. In order to probe active site pocket polarity, ligation
with a trifluoroethyl protecting group (5e and 10e) was attempted without success for
either homocysteine or cysteine disulfide analogs.
To ensure maintenance of the disulfide-protected analogs during the transfer
reaction, we eliminated β-mercaptoethanol (BME) from the AaT purification process and
reaction buffer (Figure 3-3). This small change increased the yields of HcmLysAlaAcm
from 21 % to 37 % and CspLysAlaAcm from 64 % to 68 %. Once Hcm was identified as
the optimal homocysteine substrate, we assessed the possibility of generating Hcm-tRNA
in situ using a synthetase. Free Hcm was synthesized by TFA deprotection of Boc-Hcm.
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Wild type E. coli MetRS and an L13G mutant (Met*RS) previously used by the Tirrell
group were tested with Hcm, ATP, and E. coli total tRNA.166 Met*RS was more active
than MetRS, giving full transfer at ≤ 0.1 mg/mL loading. This is consistent with Met*RS
structural analysis, where longer sidechains are accommodated by the expanded active
site.166
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Figure 3-2. (A) Schematic Representation of Model LysAlaAcm Peptide N-Terminal
Ligation Reaction Using AaT. (B) Molecular Structures of All Sulfur-Based Analogs Tested
with AaT
Listed below each amino acid is its percent ligation efficiency, (a) reaction in the presence of 5
mM beta-mercaptoethanol, (b) reaction with no beta-mercaptoethanol, and (c) reaction using
methionine L13G synthetase, free-amino acid, tRNA, and AaT. NR = no reaction.
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Figure 3-3. Hcm Ligation Increased Efficiency
(A) LysAlaAcm starting material, (B) Hcm ligation in presence of 5 mM BME using Hcm-A and
AaT, (C) Hcm transfer using MetRS L13G mutant synthetase (Met*RS), tRNA ATP and AaT

3.2.3 – Hcm/Csp and Native Chemical Ligation
Our next step in analyzing our analogs’ applicability to semi-synthetic techniques
was to test their efficiency in NCL reactions (Figures 3-4a, 3-4b). First, we analyzed the
Csp analog, which was most efficiently transferred onto our model peptide, LysAlaAcm.
We ligated CspLysAlaAcm (12) with Ac-MetAspValPhe-SR (11), which is the four
amino acid starting sequence of αS, and formed the NCL product (13) over a 24 h
reaction in 100 % yield (Figure 3-5a). We then took HcmLysAlaAcm (14) on to a model
ligation reaction with Ac-MetAspValPhe-SR (11). HPLC and MALDI MS analyses
showed that disulfide cleavage was completed almost immediately and that the
subsequent ligation reached 100 % completion after 24 h (Figure 3-5b). After ligation,
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the product peptide (15) was treated with 1000 equiv. MeI at pH 8.6 to form 16. After 5
min, 89 % conversion of Hcs5 to Met5 was observed by HPLC and MALDI MS analyses
(See Materials and Methods). Unreacted 15 (11 %) could be removed after disulfide
formation. Oxidation of Met1, was observed (4 %), but no undesired alkylation of Met or
Lys was seen. This is consistent with previous uses of Hcs as a ligation handle, where
subsequent alkylation is surprisingly selective, given that the pKa of Hcs (8.9) is close to
the pKa of Lys (9.5).167
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Figure 3-4a. Peptide Native Chemical Ligation and Masking Proof-of-Principle for Csp
Compound 11 is the C-terminal thioesterified first four amino acid sequence of α-synuclein.
Compound 12 is Csp ligated to LysAlaAcm via AaT. Compound 13 is the NCL product. Reaction
Conditions: (A) 1.0 mM (12), 3.3 mM (11), 100 mM sodium phosphate dibasic, 20 mM TCEP, 0.5
% thiophenol, 0.5 % benzylmercaptan, pH 7.2 at room temperature for 24 h, 100 % yield for 13.
The formed amide bond is highlighted in a yellow box. The resulting deprotected disulfide is
highlighted in pink (Cys).
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Figure 3-4b. Peptide Native Chemical Ligation and Masking Proof of Principle for Hcm
Compound 11 is the C-terminal thioesterified first four amino acid sequence of α-synuclein.
Compound 14 is Hcm ligated to LysAlaAcm via AaT. Compound 15 is the native chemical
ligation product with Hcm deprotected to Hcs. Compound 16 is the methylated masked final
product, creating a traceless ligation site at the second methionine. Reaction Conditions: (A) 1.0
mM 13, 3.3 mM 11, 100 mM sodium phosphate dibasic, 20 mM TCEP, 0.5 % thiophenol, 0.5 %
benzylmercaptan, pH 7.2 at room temperature for 24 h, 100 % yield for 15; (B) 50 mM MeI, 100
mM sodium bicarbonate, pH 8.6 at room temperature for 5 min, 89 % yield for 16. The formed
amide bond is highlighted in a yellow box. The resulting deprotected disulfide is highlighted in
blue (Hcs). The Hcs is selectively methylated, highlighted in the green box.
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Figure 3-5a. HPLC Analysis of Peptide Ligation Reactions with Csp
(A) N-terminal Csp peptide 12 formation reaction; (B) C-terminal thioester peptide (11) NCL
reaction with 12 after 24 h, forming product 13.

Figure 3-5b. HPLC Analysis of Peptide Ligation Reactions with Hcm
(A) N-terminal Hcm peptide 14; (B) C-terminal thioester peptide 11; (C) Ligation reaction after 1 h;
(D) Purified ligation product 15; (E) Methylation of 15 to form methionine in peptide 16. (15)2 is a
disulfide between the Hcs thiol of two 15 product peptides. Peak areas indicated by red, green,
and blue shading were integrated in Kaleidagraph to obtain methylation yields.
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After successful completion of the model peptide ligation, we wished to test the
Hcm transfer/ligation strategy with a full-sized protein.

One protein that we have

previously studied, which has the requisite MetLys motif, is αS. Several recent studies
have shown that the N-terminal sequence of αS can have important consequences for its
folding and self-association.168-172 However, these studies profoundly disagree on what
those consequences are. Therefore, the preparation of N-terminally-modified αS could be
useful to addressing these questions and serve as a valuable demonstration of our method.
We chose Met5Lys6 as the point of disconnection and prepared an αS6-140 plasmid
with an N-terminal His10 tag and a Factor Xa proteolysis site. The precursor protein,
HisTag-αS6-140 (17), was isolated by Ni-affinity chromatography and cleaved with Factor
Xa to yield αS6-140 (18). We incubated 18 with AaT, Met*RS, tRNA, Hcm, and ATP.
Transfer of Hcm was complete after 1 h, within the limits of quantitation by MALDI MS
(Figure 3-6). Complete transfer is extremely valuable for large proteins, since separation
of an Hcm-modified protein such as 19 from unmodified 18 is not generally feasible.
Modified αS 19 was isolated from AaT, Met*RS, and tRNA by boiling and FPLC
purification. Then 19 was incubated with thioester Ac-McmMetAspValPhe-SR (S13),
which corresponds to αS1-4 labeled at the N-terminus with 7-methoxycoumarinylalanine
(Mcm). Overnight incubation at 37 °C gave 20a in high yield from 19. No unligated
starting materials were observed, though some oxidized 20a was observed. Purified 20a
was quantitatively converted to 21a by treatment with aqueous MeI, as determined by
analyses by John Warner using Ellman’s reagent and MALDI MS (Figure 3-7). In
general, we expect that the NCL reaction will not be 100 % efficient, but we do not view
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this as a severe limitation, provided that the NCL product can be purified away from the
starting materials and methylation is quantitative and selective.
A similar ligation was carried out with Ac-MetAspValPhe-SR (11), yielding NAc-αS after methylation (21b) (Figure 3-8). The ligation product 21b was subjected to
trypsin digest and MALDI MS analysis to confirm that methylation occurred with high
yield and few side reactions. Observation of the Ac-MetAspValPheMetLys fragment
(Ac-αS1-6) with only trace Ac-MetAspValPheHcsLys contamination confirmed that
methylation proceeded in > 95 % yield within the limitations of quantitation by MS
(Figure 3-6). Furthermore, MALDI MS analysis of the rest of the tryptic fragments
demonstrated that there were no substantial alkylation side reactions, even on His50 in the
αS46-58 fragment (See Materials and Methods).
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Figure 3-6. α-Synuclein Model Ligation
Functionalization of αS6-140 by a) cleavage of His tag at Factor Xa site, b) attachment of Hcm by
AaT-catalyzed modification, c) ligation of an N-terminal thioester peptide (11 or S10), and d)
conversion of Hcs to Met by methylation. 20a, 21a Xxx = AcMcm; 20b, 21b Xxx = Ac. Top Right:
Gel image showing product of each step, WT indicates full-length αS. Middle Right: MALDI MS
analysis of full length Ac-αS before (12b) and after (13b) methylation. Bottom Right: Trypsinized
fragment corresponding to Ac-αS1-6 (812.4 m/z) confirms successful methylation. Asterisk
indicates the expected mass of unmethylated Ac-αS1-6Hcs5.

Figure 3-7. Edman Degradation Analysis
Left: UV/Vis analysis of Hcs methylation using Ellman’s reagent. Right: Fluorescence emission
spectra of Ac-Mcm-αS6-140 (20a) and WT αS.
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Figure 3-8. HPLC and MALDI MS Analysis of Ligation and Methylation

3.2.4 – Three-Part Native Chemical Ligation with Hcs Masking
With αS, we have shown that we can semi-synthetically create a protein with a
new type of ligation site, methionine. To further demonstrate the power of our semisynthetic techniques, we will perform a three-part native chemical ligation. Our goal is to
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introduce one non-native protein element while maintaining native amide bonds at the
connection points and retaining the correct primary sequence in the final protein product.
As shown in Scheme 3-3, we will recombinantly express the N- and C- terminal domains
of calmodulin and only chemically synthesize a small four amino acid middle segment,
which contains the non-native element, either a fluorescent label, 7-methoxycoumarinyl
alanine, or a thioamide analog of alanine, which can be used as a quencher of Tyr
fluorescence in calmodulin. Currently we have reached step 3A, a three-part native
chemical ligation with homocysteine at the ligation sites, and have obtained MALDI
confirmation of all steps prior.
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Scheme 3-3. Three-Part Native Chemical Ligation of Calmodulin
Reaction steps: (1A) AaT N-terminal ligation of Hcm, (1B) Native chemical ligation of middle
peptide to C-terminus CaM domain, (1C) Deprotection of thiazolidine to expose N-terminal
homocysteine, (2) Cleavage of intein from N-terminus CaM domain to form a thioester, (3A)
Native chemical ligation of N-terminus and C-terminus CaM domains, (3B) Methylation of
homocysteine residues using methyl iodide.
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3.2.5 – Method Applications
Application of our system to targets other than αS may require mild denaturation
of the protein in order to access the N-terminal amino acids. Therefore, we have tested
AaT activity in the presence of low concentrations of denaturants and detergents. We
find that AaT activity has a Gdn•HCl IC50 of 0.4 M and that full activity could be
maintained in 5 % v/v Triton X-100. While the N-termini of some proteins may be
buried in important structural interactions, these concentrations should allow one to
partially unfold many proteins to access the terminus for Hcm transfer and ligation.
While our experiments begin to remove the sequence limitations for EPL, they
certainly do not eliminate them entirely. Essentially, one can now use XxxMetArg or
XxxMetLys as a disconnection point in a retrosynthetic analysis of a potential protein
target. The utility of our approach depends on how frequently this motif occurs. To
address this, Jerri Wang analyzed the protein sequences in the PDB and found that out of
the 60,325 proteins surveyed, 5,405 possible N-terminal ligation sites (< 40 amino acids
from the N-terminus) were identified in 5,156 unique proteins. These numbers increased
to 31,259 ligation sites and 20,701 proteins when we considered proteins with the ligation
motif in the center of the protein where one might use multiple ligations to synthesize the
full-length protein. We chose to restrict our search to the PDB since these sequences
represent proteins with some degree of prior characterization typical of a protein target
chosen for synthesis via NCL.
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3.2.6 – Future Directions
While it is clear that many proteins could be potential synthesis targets using AaT,
we wish to eventually make our methods as broadly useful as possible. Therefore, it is
worth noting that there exist other transferases with different N-terminal specificity, such
as the Bpt transferase from V. vulnificus, which transfers Leu to an N-terminal Asp or
Glu.50

Our preliminary experiments indicate that Bpt can transfer Leu from small

molecule donors in vitro, but our current yields are too low (< 10 % after 4 h) to be
useful. In situ aminoacylations using Hcp, Hcb, or Hcm with Bpt and either Met*RS or
E. coli LeuRS have not produced significant transfer yields. Efforts are underway to
improve transfer of Hcs analogs. We are also working to mutate AaT to alter the
substrate specificity for both Xaa and the N-terminal residue. (See Chapter 4.)
Prior to our work, the only way to avoid Cys at a ligation site in the expressed
protein fragment during EPL was to desulfurize to form Ala or mask Cys by forming a
non-native amino acid.

Here, we have shown that a protein N-terminus can be

functionalized with Hcs under mild conditions. After ligation, Hcs can be efficiently and
selectively converted to Met, erasing the ligation site. Our work begins to remove the Nterminal Cys requirement for ligation by allowing one to use the MetArg or MetLys motif
as a point of disconnection in protein semi-synthesis.
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Section 3.3 – Materials and Methods
3.3.1 – Materials
Homocystine ((Hcs)2) was purchased from Toronto research chemical (Toronto,
Canada).

Benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium

hexafluorophosphate

(PyBOP), Fmoc-Met-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmocβ-(7-methoxy-coumarin-4-yl)-Ala-OH, and 2-chlorotrityl chloride resin were purchased
from Bachem (Torrance, CA) or EMD Chemicals (Philadelphia, PA). Piperidine and 2(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were
purchased

from

American

Bioanalytical

(Natick,

MA).

Sigmacote,

N,N-

diisopropylethylamine (DIPEA), thiophenol, methyl mercaptopropionate, sodium
thiomethoxide, 2-propanthiol, 2-methyl-2-propane thiol, mercaptophenylacetic acid
(MPAA), trifluoroacetic acid (TFA), tris(2-carboxyethyl) phosphine hydrochloride
(TCEP), and 5,5'-dithiobis-(2-nitrobenzoic acid (DTNB) were purchased from SigmaAldrich (St. Louis, MO). Iodine was purchased from JT Baker (Phillipsburg, NJ). All
deuterated solvents were purchased from Cambridge Isotopes Laboratories, Inc.
(Andover, MA). Ni-NTA resin was from Qiagen (Valencia, CA). E. coli BL21(DE3)
cells were purchased from Stratagene (La Jolla, CA). Sequencing-grade trypsin was
purchased from Promega (Madison, WI). Restriction-grade Factor Xa protease was
purchased from Novagen (San Diego, CA). QuikChange® site-directed mutagenesis kits
were purchased from Stratagene. DNA oligomers were purchased from Integrated DNA
Technologies, Inc (Coralville, IA).

Protease inhibitor cocktail was purchased from

Sigma-Aldrich. All other reagents were purchased from Fisher Scientific (Pittsburgh,
PA). Milli-Q filtered (18 MΩ) water was used for all solutions (Millipore, Billerica,
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MA). Matrix-assisted laser desorption/ionization (MALDI) mass spectra were collected
with a Bruker Ultraflex III MALDI-TOFTOF mass spectrometer (Billerica, MA).
Electrospray ionization (ESI) mass spectra were collected with a Waters LCT Premier
XE liquid chromatograph/mass spectrometer (Milford, MA). UV/vis absorbance spectra
were obtained with a Hewlett-Packard 8452A diode array spectrophotometer (Agilent
Technologies, Santa Clara, CA). Intein plasmid pTXB1 and all restriction enzymes were
purchased from New England Biolabs (Ipswich, MA).

3.3.2 – Adenosyl Donor Synthesis
The synthesis of (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl) tetrahydrofuran-3-yl 2-amino-3-phenylpropanoate (Phe-A, Figure 3-9)
has been reported previously.66 The other Xaa-A donors were synthesized in a similar
fashion (Scheme 3-4).
NH2
Phe-A

N
N

HO
O

N
N

O
O

OH

H2N

Figure 3-9. Structure of Phenylalanyl Adenosine (Phe-A)
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Scheme 3-4. Synthesis of Met-A and Cbz-A Donor
S2-S4a – R = methionine. S2-S4b – R = Cys(Bz). Reagents and conditions: a) ClCH2CN,
DIPEA, THF; b) (DMT)-A, THF, RT; c) TFA, TIPSH, THF. Cbz-A was synthesized in the same
fashion but starting with Boc-Cys(Bz)-OH

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-4-(methylthio)butanoate

(Boc-

Met-OCH2CN, S2a).
Chloroacetonitrile (5 mL) and DIPEA (471 mg, 0.64 mL, 3.6 mmol) were added
to Boc-Met-OH (826 mg, 3.3 mmol) and stirred for 14 h. The solvent was removed
under reduced pressure and SiO2 flash chromatography (gradient from 10 - 50 % ethyl
acetate in hexanes) afforded 799 mg of a pale yellow oil in 83 % yield. Rf 0.45 in 30 %
ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ = 5.19 (d, J = 8.0 Hz, 1H), 4.83
– 4.69 (m, 2H), 4.47 – 4.46 (m, 1H), 2.59 – 2.49 (m, 2H), 2.14 – 1.96 (m, 2H), 2.08 (s,
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3H), 1.42 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 171.3, 155.4, 114.1, 80.6, 52.5, 49.1,
31.3, 30.0, 28.4, 15.6,14.3; HRMS (ESI) m/z calculated for C12H20N2NaO4S [M + Na]+
311.104, found 311.104.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-4-(methylthio) butanoate (Boc-Met-(DMT)-A, S3a).
Tetrahydrofuran (5 mL) was added to Boc-Met-OCH2CN S2 (219.4 mg, 0.702
mmol), (DMT)-A (179.2 mg, 0.1792 mmol), and NBu4Ac (7.4 mg) and stirred for 24 h.
The solvent was removed under reduced pressure and chromatography (100 % Hexanes,
50 – 100 % ethyl acetate in hexanes, 5 - 10 % methanol in ethyl acetate), afforded 92.9
mg of an off-white solid in 64.7 % yield. Rf 0.5 in 5 % methanol in ethyl acetate; 1H and
13

C NMR for S3a shown in Figure 3-10; LRMS (ESI) m/z calculated for C41H49N6O9S

(M + H)+ 801.3, found 801.6.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-4-(methylthio)butanoate (Met-A, S4a).
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (73.5 mg, 0.095
mL, 0.46 mmol) were added to S3a (92.9 mg, 0.116 mmol). Upon addition of TFA, the
reaction turned a bright orange color and at the completion of the reaction, the color had
become a pale yellow - orange. The reaction mixture was reduced to dryness by rotary
evaporation and extracted using 1 mL dichloromethane and 1 mL water twice with a final
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1 mL water back-extraction against the dichloromethane layer. The water-soluble layer
containing S4a was then HPLC-purified on a C18-prep column using Gradient 1 at 11
mL/min (Table 3-1). HPLC/MALDI analysis m/z calculated C15H23N6O5S (M + H)+
399.1; retention time 21.0 min, found 399.3 retention time 22.44 min, found 399.3.

(R)-cyanomethyl

3-(benzylthio)-2-((tert-butoxycarbonyl)amino)propanoate

(Boc-

Cbz-OCH2CN, S2b).
Boc-Cys(benzyl)-OH (500.0 mg, 1.681 mmol) was dissolved in 5 mL
chloroacetonitrile (solvent) and DIPEA (0.322 mL, 1.849 mmol) were added to the
reaction mixture and allowed to stir overnight. The reaction mixture was concentrated
under reduced pressure, then purified on silica gel (30 % EtOAc in hexanes) to give
588.7 mg (~ 100 %) of the titled compound S2b. Rf 0.4 in 30 % EtOAc in hexanes; 1H
NMR (500 MHz, CDCl3): δ = 7.30 – 7.20 (m, 5H), 4.68 (s, 2H), 4.51 – 4.5 (d, 1H), 3.67
(s, 2H), 2.85 – 2.75 (m, 2H). 1.40 (s, 9H);

13

C NMR (125 MHz, CDCl3): δ = 170.1,

155.2, 137.5, 129.1, 128.9, 127.7, 113.9, 80.9, 53.2, 49.3, 36.9, 33.3, 28.5. LRMS (ESI)
m/z calculated for C17H22N2O4SNa [M + Na]+ 373.1, found 373.2.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

3-

(benzylthio)-2-((tert-butoxycarbonyl)amino)propanoate
(Boc-Cbz-(DMT)-A, S3b).
Tetrahydrofuran (5 mL) was added to Boc-Cys(Bz)-OCH2CN S2b (279.4 mg,
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0.797 mmol), (DMT)-A (113 mg, 0.199 mmol), and NBu4Ac (6.3 mg,) and stirred for 24
h.

The solvent was removed under reduced pressure and preparative thin-layer

chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform),
afforded 42.3 mg of a white solid in 24.6 % yield.

1

H and

13

C NMR for (Figure 3-11)

shown below; LRMS (ESI) m/z calculated for C46H51N6O9S (M + H)+ 863.3, found
863.5.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(benzylthio)propanoate
(Cbz-A, S4b).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (7.8 mg, 0.01 mL,
0.05 mmol) were added to S3b (28.5 mg, 0.0331 mmol) following the deprotection
procedure given for S4a. The water-soluble layer containing S3b was then HPLCpurified on a C18-prep column using Gradient 1 at 15 mL/min (Table 3-1).
HPLC/MALDI analysis m/z calculated C20H25N6O5S (M + H)+ 461.2; retention time 17.5
min, found 460.5.

(R)-2-((tert-butoxycarbonyl)amino)-3-(methyldisulfanyl)propanoic acid (Boc-CsmOH, 7a).
Boc-L-Cys-OH (110 mg, 0.50 mmol) was dissolved in 20 mL of 1:1 H2O/THF.
Sodium thiomethoxide (350 mg, 5.0 mmol) was added to the solution after cooling to 0
°C in an ice bath. Then, a solution of iodine in 95 % EtOH was added dropwise until the
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color of the reaction changed from colorless to brown. The mixture was stirred for 5.5 h
with warming to room temperature.

After removing tetrahydrofuran under reduced

pressure, the reaction mixture was acidified by addition of 1 N HCl aq. until the pH was 2
- 3. The solution was extracted with EtOAc. The organic phase was washed with
saturated NaS2O4 aq. and brine, and dried over MgSO4. The solvent was removed under
reduced pressure, and then the reaction was purified on silica gel (25 % EtOAc in
hexanes containing 1 % AcOH) to give 90.8 mg (68 %) of the titled compound 7a. Rf
0.37 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR (360 MHz,
CDCl3): δ = 5.34 (s, 1H), 4.63 (s, 1H), 3.26 - 3.16 (m, 2H), 2.43 (m, 3H), 1.47 (s, 9H);
13

C NMR (90 MHz, CDCl3): δ = 175.2, 155.7, 80.9, 53.2, 39.9, 28.5, 23.3. NMRs, 1H

and 13C, can be found in Figure 3-12. HRMS (ESI) m/z calculated for C9H17NNaO4S2
[M + Na]+ 290.049, found 290.050.

(R)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-3-(methyldisulfanyl)propanoate

(Boc-Csm-OCH2CN, 8a).
Compound 7a (106 mg, 0.397 mmol) was dissolved in 3 mL tetrahydrofuran. 50
equiv. chloroacetonitrile (1.26 mL, 19.85 mmol) and DIPEA (67 µL, 796 µmol) were
added to the reaction mixture and allowed to stir overnight. The reaction mixture was
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes)
to give 47 mg of compound 8a (44 %). Rf 0.33 in 25 % EtOAc in hexanes; 1H NMR (360
MHz, CDCl3): δ = 5.34 (s, 1H), 4.87 – 4.74 (dd, J = 33.1 Hz, 2H), 4.71 (s, 1H), 3.18 3.11 (m, 2H), 2.43 (m, 3H), 1.46 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 170.0, 155.2,
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113.9, 81.0, 52.8, 49.3, 39.2, 28.5, 23.1; HRMS (ESI) m/z calculated for
C11H18N2NaO4S2 [M + Na]+ 392.061, found 392.061.

(R)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tertbutoxycarbonyl)amino)-3-(methyldisulfanyl) propanoate (Boc-Csm-(DMT)-A, 9a).
Tetrahydrofuran (5 mL) was added to Boc-Csm-OCH2CN 8a (123.6 mg, 0.403
mmol), (DMT)-A (115.7 mg, 0.2031 mmol), and NBu4Ac (7.4 mg,) and stirred for 48 h.
The solvent was removed under reduced pressure and preparative thin-layer
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 %
methanol in chloroform), afforded 80.8 mg of a white solid in 48.6 % yield. Rf 0.7 in 5 %
methanol in ethyl acetate; 1H and

13

C NMR shown below in Figure 3-13; LRMS (ESI)

m/z calculated for C40H47N6O9S2 (M + H)+ 819.3, found 819.4.

(R)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-(methyldisulfanyl)propanoate

(Csm-A, 10a).
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (62.6 mg, 0.081
mL, 0.40 mmol) were added to 9a (80.8 mg, 0.0987 mmol) following the deprotection
procedure given for S4a. The water-soluble layer containing 10a was then HPLCpurified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).
HPLC/MALDI analysis m/z calculated C14H21N6O5S2 (M + H)+ 417.1; retention time
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21.3 min, found 416.8; retention time 23.4 min, found 416.8.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)
(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-(isopropyldisulfanyl)propanoate (Boc-Csp-(DMT)-A, 9b).
Tetrahydrofuran (5 mL) was added to Boc-Csp-OCH2CN 8b (332.5 mg, 0.994
mmol), (DMT)-A (141.5 mg, 0.249 mmol), and NBu4Ac (12.5 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and flash chromatography over silica
gel (Gradient 20 % -100 % ethyl acetate in hexanes, 5 % - 10 % methanol in ethyl
acetate) afforded 159.3 mg of a white solid in 75.7 % yield. Rf 0.75 in 5 % methanol in
ethyl acetate; 1H and

13

C NMR for (Figure 3-14) shown below; LRMS (ESI) m/z

calculated for C42H51N6O9S2 (M + Na)+ 869.3, found 869.6.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-(isopropyldisulfanyl)propanoate

(Csp-A, 10b).
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (11.9 mg, 0.154
mL, 0.752 mmol) were added to 9b (159.3 mg, 0.188 mmol) following the deprotection
procedure given for S4a. The water-soluble layer containing 10b was then HPLCpurified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).
HPLC/MALDI analysis m/z calculated C16H25N6O5S2 (M + H)+ 445.1; retention time
26.1 min, found 445.2; retention time 28.1 min, found 445.2.
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(R)-2-((tert-butoxycarbonyl)amino)-3-(tert-butyldisulfanyl)propanoic

acid

(Boc-

Csb-OH, 7c).
Cys(S-tBu)-OH (250 mg, 1.2 mmol) was dissolved in 12 mL of 1:1 H2O/dioxane.
Sodium hydroxide (71.6 mg, 1.8 mmol) and di-tert-butyl carbonyl anhydride (391 mg,
1.8 mmol) were added to the solution and the mixture was stirred overnight at room
temperature. 20 mL of MilliQ water was added to the reaction, and then the reaction
mixture was extracted twice with ethyl acetate. The organic layer was back extracted
twice with saturated sodium bicarbonate solution. The combined aqueous layers were
acidified to a pH of 1 using 6 M HCl aq. The solution was extracted with EtOAc three
times. The extract was washed with brine, and dried over MgSO4. After filtration,
solvent was removed to give 263.4 mg (70 %) of 7c, a white solid. Further purification
was not performed. Rf 0.5 in 60 % ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3):
4.59 - 4.47 (m, 1H), 3.23 – 3.13 (m, 2H), 1.45 (s, 9H), 1.32 (s, 9H); 13C NMR (125 MHz,
CDCl3): δ = 175.5, 155.6, 80.8, 53.4, 48.4, 42.3, 30.0, 28.5; LRMS (ESI) m/z calculated
for C12H23NO4S2Na (M + Na)+ 332.1, found 332.2.

(R)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(tert-butyldisulfanyl)propanoate
(Boc-Csb-OCH2CN, 8c).
Compound 7c (206.7 mg, 0.668 mmol) was dissolved in 5 mL chloroacetonitrile
(solvent) and DIPEA (0.128 mL, 0.735 mmol) were added to the reaction mixture and
allowed to stir overnight. The reaction mixture was concentrated under reduced pressure,
then purified on silica gel (30 % EtOAc in hexanes) to give 140.6 mg (60 %) of the titled
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compound 8c. Rf 0.6 in 30 % EtOAc in hexanes; 1H NMR (500 MHz, CDCl3): δ = 4.80
(dd, J = 12.5 Hz, 2H), 2.66 - 2.64 (m, 1H), 3.15 – 3.14 (m, 2H), 1.44 (s, 9H), 1.33 (s,
9H); 13C NMR (125 MHz, CDCl3): δ = 169.9, 155.2, 114.0, 80.8, 53.1, 49.3, 48.8, 41.9,
29.9, 28.4; LRMS (ESI) m/z calculated for C14H24N2O4S2Na [M + Na]+ 371.1, found
371.2.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl)
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3(tert-butyldisulfanyl)propanoate (Boc-Csb-(DMT)-A, 9c).
Tetrahydrofuran (5 mL) was added to Boc-Csb-OCH2CN 8c (140.6 mg, 0.404
mmol), (DMT)-A (57.5 mg, 0.101 mmol), and NBu4Ac (7.7 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin-layer
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform),
afforded 28.5 mg of a white solid in 30.4 % yield. Rf 0.5 in 5 % methanol in ethyl
acetate; 1H and 13C NMR for (Figure 3-15) shown below; LRMS (ESI) m/z calculated for
C43H52N6O9S2Na (M + Na)+ 883.3, found 883.6.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-(tert-butyldisulfanyl)propanoate

(Csb-A, 10c).
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (21 mg, 0.027 mL,
0.13 mmol) were added to 9c (28.5 mg, 0.0331 mmol) following the deprotection
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procedure given for S4a. The water-soluble layer containing 10c was then HPLCpurified on a C18-prep column using Gradient 1 with a flow rate of 15 mL/min (Table 31). HPLC/MALDI analysis m/z calculated C17H27N6O5S2 (M + H)+ 459.2; retention time
20.0 min, found 459.0; retention time 22.1 min, found 459.0.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((t-

butoxycarbonyl)amino)-3-(phenyldisulfanyl)propanoate
(Boc-Csf-(DMT)-A, 9d).
Tetrahydrofuran (5 mL) was added to Boc-Csf-OCH2CN 8d (110.0 mg, 0.303
mmol), (DMT)-A (85.0 mg, 0.152 mmol), and NBu4Ac (15 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin-layer
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform),
afforded 64.5 mg of a yellow solid in 48.3 % yield. Rf 0.75 in 5 % methanol in ethyl
acetate; 1H and 13C NMR for (Figure 3-16) shown below; LRMS (ESI) m/z calculated for
C45H49N6O9S2 (M + H)+ 881.3, found 881.4.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(phenyldisulfanyl)propanoate
(Csf-A, 10d).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (46.4 mg, 0.06
mL, 0.29 mmol) were added to 9d (64.5 mg, 0.073 mmol) following the deprotection
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procedure given for S4a. The water-soluble layer containing 10d was then HPLCpurified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).
HPLC/MALDI analysis m/z calculated C19H23N6O5S2 (M + H)+ 479.1; retention time
29.1 min, found 479.0; retention time 30.6 min, found 479.0.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-((2,2,2-trifluoroethyl)disulfanyl)propanoate
(Boc-CsTf-(DMT)-A, 9e).
Tetrahydrofuran (5 mL) was added to Boc-Csf-OCH2CN 8e (36.9 mg, 0.10
mmol), (DMT)-A (40.7 mg, 0.07 mmol), and NBu4Ac (2.7 mg,) and stirred for 24 h. The
solvent was removed under reduced pressure and preparative thin-layer chromatography
(5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), afforded 18.8 mg
of a white solid in 29.7 % yield. Rf 0.8 in 5 % methanol in ethyl acetate; 1H and

13

C

NMR for (Figure 3-17) shown below; LRMS (ESI) m/z calculated for C41H46F3N6O9S2
(M + H)+ 887.3, found 887.5.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-((2,2,2-

trifluoroethyl)disulfanyl)propanoate (CsTf-A, 10d)
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (13.4 mg, 0.02
mL, 0.085 mmol) were added to 9e (18.8 mg, 0.021 mmol) following the deprotection
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procedure given for S4a. The water-soluble layer containing 10d was then HPLCpurified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).
HPLC/MALDI analysis m/z calculated C15H20F3N6O5S2 (M + H)+ 485.1; retention time
25.4 min, found 485.0; retention time 27.5 min, found 485.0.

(2S,2’S)-4,4’-disulfanediylbis(2-((tert-butoxycarbonyl)amino)butanoic acid ((BocHcs)2, 1).
L-Homocystine ((Hcs)2, 402.5 mg, 1.5 mmol) was dissolved in 15 mL of 1:1
H2O/dioxane.

600 mL of 10 N Sodium hydroxide aq. (6 mmol) and di-tert-butyl

carbonyl anhydride (618 mg, 3.75 mmol) were added to the solution after cooling to 0 ºC
in the ice bath. The mixture was stirred overnight with warming to room temperature.
The reaction mixture was acidified by 1 N HCl aq. until reached 2 - 3. The solution was
extracted with EtOAc. The extract was washed with brine, and dried over MgSO4. After
filtration, solvent was removed to give 572.8 mg (81 %) of 1. Further purification was
not performed.

(S)-2-((tert-butoxycarbonyl)amino)-4-(methyldisulfanyl)butanoic

acid

(Boc-Hcm-

OH, 2a).
Boc-L-Homocystine (1), 188 mg, 0.4 mmol) was dissolved in 16 mL of 1:1
H2O/THF. Sodium thiomethoxide (560 mg, 8.0 mmol) was added to the solution after
cooling to 0 °C in an ice bath. Then, a saturated solution of iodine in 95 % EtOH was
added dropwise until the color of the reaction changed from colorless to brown. The
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mixture was stirred for 1.5 h with warming to room temperature.

After removing

tetrahydrofuran under reduced pressure, the reaction mixture was acidified by addition of
1 N HCl aq. until the pH reached 2 - 3. The solution was extracted with EtOAc. The
extract was washed with saturated NaS2O4 aq. and brine, dried over MgSO4, and purified
on silica gel (25 % EtOAc in hexanes containing 1 % AcOH) to give 179.3 mg (80 %) of
2a. Rf 0.4 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR (360 MHz,
CDCl3): δ = 5.34 (s, 1H), 4.63 (s, 1H), 2.80 - 2.76 (m, 2H), 2.42 (s, 2H), 2.35 (m, 1H),
2.09 (s, 1H), 1.46 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 176.5, 155.6, 80.6, 52.5, 33.8,
32.8, 28.3, 23.3 (Note: A second set of concentration-dependent peaks was also observed,
these peaks can be seen in the included

13

C spectrum. These could be reduced but not

eliminated by diluting the sample, no evidence of dimerization is seen in the more dilute
1

H spectrum sample, Figure 3-18); HRMS (ESI) m/z calculated for C10H19NNaO4S2 [M +

Na]+ 304.065, found 304.066.

(S)-2-amino-4-(methyldisulfanyl)butanoic acid (Hcm-OH, free amino acid)
Boc-Hcm-OH (2a), 150 mg, 0.53 mmol) was dissolved in 10 mL of 95:2.5:2.5
TFA/H2O/TIPS. Reaction was stirred for 2 hours. Solvent was removed under reduced
pressure. Crude Hcm was extracted using excess cold diethylether. Precipitate was
collected via centrifugation and pellet was resuspended in water.

Crude Hcm was

purified by HPLC (Gradient 2). Post purification, sample concentration was determined
by UV-Vis at 280 nm using the extinction coefficient of disulfide (ε280 = 125 M-1 cm-1).
1

H NMR (500 MHz, CDCl3): δ = 4.12 (t, J = 6.5 Hz, 1H), 2.95 (t, J = 7.5 Hz, 2H), 2.52
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(s, 1H), 2.50 – 2.39 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 173.0, 52.7, 32.0, 29.6,
22.1; HRMS (ESI) m/z calculated for C5H12NO2S2 [M + H]+ 182.030, found 182.031.
NMRs can be found in Figure 3-19.

(S)-2-((tert-butoxycarbonyl)amino)-4-(isopropyldisulfanyl)butanoic acid (Boc-HcpOH, 2b).
1 (234 mg, 0.5 mmol) was dissolved in 19 mL of 50 % aqueous tetrahydrofuran.
2-propanethiol (929 µL, 10.0 mmol) and 10 N sodium hydroxide aq. (1.1 mL, 11 mmol)
were added to the solution at 0 °C. Then, a solution of iodine in 95 % EtOH was added
dropwise until the color of the reaction system changed from colorless to brown. The
mixture was stirred for over-night with gradual warming room temperature.

After

removing THF under reduced pressure, reaction mixture was neutralized by 1 N HCl aq.
until pH 2 - 3. The solution was extracted with EtOAc. The extract was washed with
saturated NaS2O4 aq. and brine, and dried over MgSO4. Concentration under reduced
pressure followed by flash chromatography over silica gel with EtOAc/Hexane/AcOH
(75:25:1) gave 2b (170 mg, 55 % yield). Rf 0.47 in 33 % ethyl acetate in hexanes
containing 1 % AcOH; 1H NMR (360 MHz, CDCl3): δ = 5.05 (s, 1H), 4.40 (s, 1H), 3.07
– 2.95 (m, 1H), 2.75 (t, J = 7.6 Hz, 2H), 2.30 (s, 1H), 2.08 (s, 1H), 1.46 (s, 9H), 1.32 1.30 (dd, J = 6.8 Hz, 6H); 13C NMR (90 MHz, CDCl3): δ = 176.6, 155.8, 80.7, 52.8, 41.3,
35.6, 32.5, 28.5, 22.8 (Note: A second set of concentration-dependent peaks was also
observed, these peaks can be seen in the included 13C spectrum. These could be reduced,
but not eliminated by diluting the sample, no evidence of dimerization is seen in the more
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dilute

1

H spectrum sample, Figure 3-21); HRMS (ESI) m/z calculated for

C12H23NNaO4S2 [M + Na]+ 332.096, found 332.097.

(S)-2-((tert-butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoic acid (Boc-HcbOH, 2c).
1 (56.4 mg, 0.12 mmol) was dissolved in H2O/THF (50 % v/v, 19 mL). To the
solution was added 2-methyl-2-propanethiol (270 µL, 2.4 mmol) and 5 N sodium
hydroxide aq. (528 µL, 2.64 mmol) after cooling to 0 °C in an ice bath. Then, a solution
of iodine in 95 % EtOH was added dropwise until the color of the reaction changed from
colorless to brown.

The mixture was stirred overnight with warming to room

temperature. After removing THF under reduced pressure, the reaction mixture was
acidified by addition of 1 N HCl aq. until the pH reached 2 - 3. The solution was
extracted with EtOAc. The extract was washed with saturated NaS2O4 aq. and brine, and
dried over MgSO4.

Concentration under reduced pressure followed by flash

chromatography over silica gel with EtOAc/Hexane/AcOH (75:25:1) gave 2c (78.4 mg,
quant. yield). Rf 0.5 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR
(360 MHz, CDCl3): δ = 5.05 (s, 1H), 4.39 (s, 1H), 2.78 - 2.74 (m, 2H), 2.30 (s, 1H), 2.10
(s, 1H), 1.46 (s, 9H), 1.33 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 176.2, 155.7, 114.0,
80.4, 60.7, 52.8, 48.0, 33.6, 31.9, 28.5, 23.3 (Note: A second set of concentrationdependent peaks was also observed; these peaks can be seen in the included
spectrum.

13

C

These could be reduced, but not eliminated by diluting the sample, no

evidence of dimerization is seen in the more dilute 1H spectrum sample, Figure 3-23);
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HRMS (ESI) m/z calculated for C13H24NO4S2 [M + H]+ 322.115, found 322.115.

(S)-2-((tert-butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoic acid (Boc-Hcf-OH,
2d).
1 (234 mg, 0.5 mmol) was dissolved in H2O/THF (50 % v/v, 19 mL). To the
solution was added thiophenol (600 µL, 5.9 mmol) and 10 N sodium hydroxide aq. (700
µL, 7 mmol) after cooling to 0 °C in an ice bath. Then, a solution of iodine in 95 %
EtOH was added dropwise until the color of the reaction changed from colorless to
brown. The mixture was stirred overnight with warming to room temperature. After
removing THF under reduced pressure, the reaction mixture was acidified by addition of
1 N HCl aq. until the pH reached 2 - 3. The solution was extracted with EtOAc. The
extract was washed with saturated NaS2O4 aq. and brine, and dried over MgSO4.
Concentration under reduced pressure followed by flash chromatography over silica gel
with EtOAc/Hexane/AcOH (80:20:1) gave 2d (166 mg, 44 %). Rf 0.47 in 33 % ethyl
acetate in hexanes containing 1 % AcOH 1H NMR (360 MHz, CDCl3): δ = 7.52-7.50 (m,
2H), 7.32-7.28 (m, 2H), 7.23-7.21 (m, 1H), 4.98 (s, 1H), 4.36 (s, 1H), 2.80 - 2.76 (m,
2H), 2.35-2.29 (m, 1H), 2.08-2.00 (m, 1H), 1.42 (s, 9H); 13C NMR (90 MHz, CDCl3): δ =
176.5, 155.8, 137.2, 129.3,128.2, 127.3, 80.8, 52.7, 34.6, 32.1, 28.5 (Note: A second set
of concentration-dependent peaks was also observed, these peaks can be seen in the
included

13

C spectrum. These could be reduced, but not eliminated by diluting the

sample, no evidence of dimerization is seen in the more dilute 1H spectrum sample,
Figure 3-25); HRMS (ESI) m/z calculated for C15H21NNaO4S2 [M + Na]+ 366.080, found
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366.081.

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-4-(methyldisulfanyl)butanoate

(Boc-Hcm-OCH2CN, 3a).
Compound 2a (367 mg, 1.3 mmol) was dissolved in 4 mL tetrahydrofuran. 50
equiv. chloroacetonitrile (4.1 mL, 65.2 mmol) and DIPEA (453 mL, 2.6 mmol) were
added to the reaction mixture and allowed to stir overnight. The reaction mixture was
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes)
to give 307.5 mg (74 %) of the titled compound 3a. Rf 0.33 in 25 % EtOAc in hexanes;
1

H NMR (360 MHz, CDCl3): δ = 5.02 (s, 1H), 4.73 (dd, J = 31.3 Hz, 2H), 4.49 (s, 1H),

2.77 - 2.73 (m, 2H), 2.37 - 2.27 (m, 1H), 2.13 - 2.02 (m, 1H), 1.46 (s, 9H); 13C NMR (90
MHz, CDCl3): δ = 171.2, 155.4, 114.03, 80.9, 52.5, 49.2, 33.6, 31.9, 28.5, 23.3; HRMS
(ESI) m/z calculated for C12H20N2NaO4S2 [M + Na]+ 343.076, found 343.076.

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-4-(isopropyldisulfanyl)butanoate

(Boc-Hcp-OCH2CN, 3b).
Compound 2b (100 mg, 324 µmol) was dissolved in 1 mL tetrahydrofuran. 50
equiv. chloroacetonitrile (1.08 mL, 16.2 mmol) and DIPEA (113 uL, 647 µmol) were
added to the reaction mixture and allowed to stir overnight. The reaction mixture was
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes)
to give 95.1 mg (84 %) of 3b. Rf 0.43 in 25 % EtOAc in hexanes; 1H NMR (360 MHz,
CDCl3): δ = 5.01 (s, 1H), 4.85 - 4.73 (m, 2H), 4.46 (s, 1H), 3.03 - 2.99 (m, 1H), 2.72 (t,
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2H), 2.30 - 2.27 (m, 1H), 2.09 - 2.03 (m, 1H), 1.45 (s, 9H), 1.33 - 1.31 (m, 4H); 13C NMR
(90 MHz, CDCl3): δ = 171.2, 155.4, 114.0, 80.8, 52.5, 49.2, 41.3, 35.2, 31.9, 28.4, 22.8,
22.8; HRMS (ESI) m/z calculated for C14H24N2NaO4S2 [M +Na]+ 371.107, found
371.108.

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoate

Boc-Hcb-OCH2CN, 3c).
Compound 2c (100 mg, 309 µmol) was dissolved in 1 mL tetrahydrofuran. 50
equiv. chloroacetonitrile (977 µL, 15.5 mmol) and DIPEA (108 uL, 618 µmol) were
added to the reaction mixture and allowed to stir overnight. The reaction mixture was
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes)
to give 106.3 mg (95 %) of compound 3c. Rf 0.47 in 25 % EtOAc in hexanes; 1H NMR
(360 MHz, CDCl3): δ = 5.00 (s, 1H), 4.73 (dd, J = 25.2 Hz, 2H), 4.46 (s, 1H), 2.74 (t,
2H), 2.33 - 2.24 (m, 1H), 2.11 - 2.00 (m, 1H), 1.45 (s, 9H), 1.34 (s, 9H); 13C NMR (90
MHz, CDCl3): δ = 171.2, 155.4, 114.1, 80.8, 52.6, 49.2, 48.3, 35.9, 31.9, 30.1, 28.5;
HRMS (ESI) m/z calculated for C15H26N2NaO4S2 [M + Na]+ 385.123, found 385.124.

(S)-cyanomethyl

2-((tert-butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoate

(Boc-Hcf-OCH2CN, 3d).
Compound 2d (100 mg, 291 µmol) was dissolved in 1 mL tetrahydrofuran. 50
equiv. chloroacetonitrile (921 µL, 14.6 mmol) and DIPEA (101.5 uL, 583 µmol) were
added to the reaction mixture and allowed to stir overnight. The reaction mixture was
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concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes)
to give 103.8 mg (93 %) of compound 3d. Rf 0.37 in 25 % EtOAc in hexanes; 1H NMR
(360 MHz, CDCl3): δ = 7.53-7.50 (m, 2H), 7.34-7.30 (m, 2H), 7.25-7.21 (m, 1H), 4.91 (s,
1H), 4.73 (dd, J = 25.2 Hz, 2H), 4.41 (s, 1H), 2.79-2.74 (m, 2H), 2.30 - 2.22 (m, 1H),
2.07 - 2.01 (m, 1H), 1.42 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 171.1, 155.4, 137.0,
129.4, 128.3, 127.5, 114.0, 80.9, 52.4, 49.2, 34.5, 31.5, 28.5; HRMS (ESI) m/z calculated
for C17H21N2O4S2 [M + H]+ 381.094, found 381.094.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tertbutoxycarbonyl)amino)-4-(methyldisulfanyl) butanoate (Boc-Hcm-(DMT)-A, 4a).
Tetrahydrofuran (5 mL) was added to Boc-Hcm-OCH2CN 3a (80 mg, 0.250
mmol), (DMT)-A (71.3 mg, 0.125 mmol), and NBu4Ac (5 mg) and stirred for 24 h. The
solvent was removed under reduced pressure and preparative thin-layer chromatography
(5 % methanol in ethyl acetate and eluted from silica with 10 % methanol in chloroform),
afforded 67.4 mg of a white solid in 64.7 % yield. Rf 0.75 in 5 % methanol in ethyl
acetate; 1H and

13

C NMR for 4a shown below in Figure 3-20; LRMS (ESI) m/z

calculated for C41H49N6O9S2 (M + H)+ 833.3, found 833.4.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tertbutoxycarbonyl)amino)-4-(isopropyldisulfanyl) butanoate (Boc-Hcp-(DMT)-A, 4b).
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Tetrahydrofuran (5 mL) was added to Boc-Hcp-OCH2CN 3b (74.5 mg, 0.214
mmol), (DMT)-A (61.2 mg, 0.107 mmol), and NBu4Ac (4 mg) and stirred for 24 h. The
solvent was removed under reduced pressure and chromatography (100 % hexanes, 20 –
100 % ethyl acetate in hexanes, 2.5 - 10 % methanol in ethyl acetate), afforded 38.0 mg
of a white solid in 41.1 % yield. Rf 0.75 in 5 % methanol in ethyl acetate; 1H and

13

C

NMR for 4b shown below, Figure 3-22; LRMS (ESI) m/z calculated for C43H53N6O9S2
(M + H)+ 861.3, found 861.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoate (Boc-Hcb-(DMT)-A, 4c).
Tetrahydrofuran (5 mL) was added to Boc-Hcb-OCH2CN 3c (95.3 mg, 0.263
mmol), (DMT)-A (76.6 mg, 0.1316 mmol), and NBu4Ac (11.4 mg) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin layer
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 %
methanol in dichloromethane), afforded 94.6 mg of a white solid in 39.9 % yield. Rf 0.75
in 5 % methanol in ethyl acetate; 1H and

13

C NMR for 4c shown below, Figure 3-24;

LRMS (ESI) m/z calculated for C44H55N6O9S2 (M + H)+ 875.3, found 875.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoate (Boc-Hcf-(DMT)-A, 4d).
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Tetrahydrofuran (5 mL) was added to Boc-Hcf-OCH2CN 3d (103.8 mg, 0.272
mmol), (DMT)-A (78.3 mg, 0.137 mmol), and NBu4Ac (13.5 mg) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin layer
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 %
methanol in dichloromethane), afforded 91.5 mg of a white solid in 74.6 % yield. Rf 0.75
in 5 % methanol in ethyl acetate; 1H and

13

C NMR for 4d shown below, Figure 3-26;

LRMS (ESI) m/z calculated for C46H51N6O9S2 (M + H)+ 895.3, found 895.5.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl
butoxycarbonyl)amino)-4-((2,2,2-trifluoroethyl)disulfanyl)butanoate

2-((tert-

(Boc-HcTf-

(DMT)-A, 4e).
Tetrahydrofuran (5 mL) was added to Boc-HcTf-OCH2CN 3e (76.1 mg, 0.196
mmol), (DMT)-A (75.9 mg, 0.133 mmol), and NBu4Ac (4.7 mg) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin layer
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 %
methanol in chloroform), afforded 94.9 mg of a white solid in 79.1 % yield. Rf 0.75 in 5
% methanol in ethyl acetate; 1H and 13C NMR for 4e shown below, Figure 3-27; LRMS
(ESI) m/z calculated for C42H48F3N6O9S2 (M + H)+ 901.3, found 901.5.
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-4-(methyldisulfanyl)butanoate

(Hcm-A, 5a).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (51.3 mg, 0.066
mL, 0.32 mmol) were added to 4a (67.4 mg, 0.081 mmol) following the deprotection
procedure given for S4a. HPLC/MALDI analysis m/z calculated C15H23N6O5S2 (M +
H)+ 431.1; Gradient 1, 11 mL/min (Table 3-1); retention time 24.7 min, found 430.7;
retention time 26.3 min, found 430.7.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-4-(isopropyldisulfanyl)butanoate

(Hcp-A, 5b).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (29 mg, 0.036
mL, 0.18 mmol) were added to 4b (38 mg, 0.0441 mmol) following the deprotection
procedure given for S4a. HPLC/MALDI analysis m/z calculated C17H27N6O5S2 (M +
H)+ 459.1; Gradient 1, 11 mL/min (Table 3-1); retention time 29.3 min, found 458.9;
retention time 30.8 min, found 458.9.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-4-(tert-butyldisulfanyl)butanoate

(Hcb-A, 5c).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (68 mg, 0.089
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mL, 0.43 mmol) were added to 4c (94.6 mg, 0.108 mmol) following the deprotection
procedure given for S4a. HPLC/MALDI analysis m/z calculated C18H29N6O5S2 (M +
H)+ 473.2; Gradient 1, 11 mL/min (Table 3-1); retention time 31.3 min, found 472.8;
retention time 32.8 min, found 472.8.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-4-(phenyldisulfanyl)butanoate (Hcf-A, 5d).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (65 mg, 0.084
mL, 0.409 mmol) were added to 4d (91.5 mg, 0.1022 mmol) following the deprotection
procedure given for S4a. HPLC/MALDI analysis m/z calculated C20H25N6O5S2 (M +
H)+ 493.1; Gradient 3 (Table 3-1); retention time 32.1 min, found 493.1; retention time
33.2 min, found 493.1.

(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-3-yl 2-amino-4-((2,2,2-trifluoroethyl)disulfanyl)butanoate
(HcTf-A, 5e).
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (67.1 mg, 0.087
mL, 0.421 mmol) were added to 4e (94.9 mg, 0.105 mmol) following the deprotection
procedure given for S4a. HPLC/MALDI analysis m/z calculated C16H22F3N6O5S2 (M +
H)+ 499.1; Gradient 1 at 11 mL/min (Table 3-1); retention time 29.1 min, found 499.1;
retention time 30.6 min, found 499.1.

135

1

Figure 3-10. H and

13

C NMR Characterization of Boc-Met-(DMT)-A (S3a)
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1

Figure 3-11. H and

13

C NMR Characterization of Boc-Cys(Bz)-(DMT)-A (S3b)
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1

Figure 3-12. H and

13

C NMR Characterization of Boc-Csm-OH (7a)
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1

Figure 3-13. H and

13

C NMR Characterization of Boc-Csm-(DMT)-A (9a)
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1

Figure 3-14. H and
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C NMR Characterization of Boc-Csp-(DMT)-A (9b)
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1

Figure 3-15. H and
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C NMR Characterization of Boc-Csb-(DMT)-A (9c)
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1

Figure 3-16. H and
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C NMR Characterization of Boc-Csf-(DMT)-A (9d)
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1

Figure 3-17. H and
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C NMR Characterization of Boc-CsTf-(DMT)-A (9e)
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1

Figure 3-18. H and

13

C NMR Characterization of Boc-Hcm-OH (2a)
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1

Figure 3-19. H and

13

C NMR Characterization of Hcm-OH, Free Amino Acid
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1

Figure 3-20. H and
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C NMR Characterization of Boc-Hcm-(DMT)-A (4a)
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1

Figure 3-21. H and
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C NMR Characterization of Boc-Hcp-OH (2b)
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1

Figure 3-22. H and
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C NMR Characterization of Boc-Hcp-(DMT)-A (4b)
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1

Figure 3-23. H and

13

C NMR Characterization of Boc-Hcb-OH (2c)
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1

Figure 3-24. H and

13

C NMR Characterization of Boc-Hcb-(DMT)-A (4c)
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1

Figure 3-25. H and

13

C NMR Characterization of Boc-Hcf-OH (2d)
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1

Figure 3-26. H and

13

C NMR Characterization of Boc-Hcf-(DMT)-A (4d)
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1

Figure 3-27. H and

13

C NMR Characterization of Boc-HcTf-(DMT)-A (4e)
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3.3.3 – Peptide synthesis
All peptides were synthesized using a manual, Fmoc-solid phase procedure on 2chlorotrityl (ClTrt) resin as described previously.173

Protected αS1-4 peptides Ac-

MetAsp(t-Bu)ValPhe-OH (S6) and Ac-McmMetAsp(t-Bu)ValPhe-OH (S7), where Mcm
is β-(7-methoxy-coumarin-4-yl)-alanine, were cleaved by treatment with acetic acid
/trifluoroethanol/dichloromethane (1/1/3, v/v) for 1 h.
solvent

was

removed

in

vacuo.

After the resin was filtered,

Ac-MetAspValPheHcsLys

(S8)

and

Ac-

MetAspValPheMetLys (S9) were cleaved with TFA/triisopropylsilane/water (95/2.5/2.5,
v/v) for 1 h, and purified by C18 reverse phase HPLC using Gradient 4a (S8) and
Gradient 4b (S9).

3.3.4 – Thioesterification of Ac-MetAspValPhe-SR (11) and Ac-McmMetAspValPheSR (S10)
100 µmol of protected S6 or S7 was dissolved in 10 mL of DMF in an ice bath.
10 equiv. each of PyBOP and triethylamine were added to the peptide solution. Then, 20
equiv. of methyl mercaptopropionate were added and the solution was allowed to stir
overnight. Solvent was removed in vacuo. Pouring water onto the residue caused
immediate precipitation of a white solid. The precipitate was collected by centrifugation,
and washed again with water. The crude protected peptide thioester was dissolved in
TFA/triisopropylsilane/water (95/2.5/2.5, v/v) and allowed to stir for 1 h. After removal
of the solvent in vacuo, pouring Et2O onto the residue gave a precipitate that was
collected by centrifuge, and washed with Et2O (3 times). Deprotected thioesters 11 or
S10 (see structure below) were then purified by C18 reverse phase semi-prep HPLC
154

using Gradient 5.
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Table 3-1. Solvent Gradients Used for Peptide Purification and Analysis
Gradient #
1
(rate in text)

3
12 mL/min

4b
11 mL/min

6
1 mL/min

Time (min)
0:00
10:00
40:00
45:00
50:00
55:00
60:00
0:00
10:00
40:00
50:00
55:00
65:00
70:00
0:00
5:00
35:00
40:00
45:00
50:00

Buffer A (%)
99
99
65
0
0
99
99
99
99
65
0
0
99
99
71
71
65
0
0
71

Gradient #
2
15 mL/min

Time (min)
0:00
5:00
35:00
40:00
45:00
50:00

Buffer A (%)
0
0
15
100
100
0

4a
14 mL/min

0:00
5:00
35:00
40:00
45:00
50:00

71
71
65
0
0
71

5
4 mL/min

0:00
5:00
35:00
40:00
45:00
50:00

71
71
65
0
0
71

0:00
5:00
10:00
15:00
20:00
25:00
27:00
30:00

99
99
70
60
0
0
99
99

7
4 mL/min

0:00
5:00
10:00
42:00
46:00
49:00
52:00
55:00

99
99
85
55
0
0
99
99
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3.3.5 – MetRS and Met*RS Expression and Purification
E. coli MetRS and Met*RS were obtained from David Tirell. Plasmids were
transformed into E. coli BL21 (DE3) and grown to OD600 0.6 in LB media. Protein
expression was induced with 1.0 mM isopropyl β–D–thiogalactoside and grown for 18 h
at 25 °C. The cells were harvested at 5000 x g for 15 min and the resulting pellet was
resuspended in a lysis buffer (300 mM KCl, 50 mM Tris pH 8.0) and included protease
inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) and sonicated.
Soluble protein was obtained by centrifugation for 20 minutes at 30,000 x g, 4 °C.
Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA resin. Protein
was purified by rinsing with lysis buffer followed by washing with wash buffer (300 mM
KCl, 50 mM Tris pH 8.0, and 15 mM imidazole). Protein was eluted with 4 x 1 mL
Elution Buffer A (300 mM KCl, 50 mM Tris pH 8.0, and 50 mM imidazole) followed by
4 x 1 mL Elution Buffer B (300 mM KCl, 50 mM Tris pH 8.0, and 250 mM imidazole).
SDS-PAGE analysis was performed to analyze the purity of elution fractions. Collected
protein fractions were dialyzed against storage buffer (50 mM Tris pH 7.5 in 50 %
glycerol) at 4 °C. Protein was stored in 0.5 mL aliquots at -80 °C.

3.3.6 – Chemoenzymatic LysAlaAcm Ligation Assay
Each ligation reaction, 125 µL total volume, contained the following reagents:
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2). The reaction mixtures were incubated at
37 °C for four hours. At the second, third, and fourth hour of the reaction, an additional 1
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mM dose of aminoacyl adenosine donor was added to the reaction mixture. The reaction
was quenched with 1 % acetic acid at 4 h. One reaction material modification was made
for Hcm analog only, in which we prepared AaT in transferase buffer without the
presence of β-mercaptoethanol (50 mM Tris, 30 % glycerol, 120 mM (NH4)2SO4). The
proteins were extracted from the reactions via acetone precipitation. The reactions were
precipitated using 4X reaction volume of acetone and cooled at - 20 °C for 1 hour. Next,
the reactions were centrifuged at 13,200 rpm at 4 °C for 20 min to separate the reaction
from precipitated protein. The supernatant was transferred to fresh 1.5 mL centrifuge
tubes and allowed for acetone evaporation overnight at room temperature for all nondisulfide analogs.

For all disulfide analogs, the reactions were rotary evaporated

immediately to remove acetone in order to minimize disulfide reduction due to air
exposure. After acetone evaporation, the supernatant was dried in a Speedvac (Savant,
Thermo Scientific, Fisher Inc.) for 30 min to remove residual acetone. The resulting
reaction volume was dissolved up to 1.2 mL using MilliQ water and analyzed by HPLC
(Gradient 6) to determine ligation yield by integration of separated peak intensities
monitored at 325 nm. Collected HPLC fractions were characterized through MALDI MS
analysis. Reactions were performed with 3 trials on at least two protein preparations for
all successful reactions.

3.3.7 – Fully Enzymatic LysAlaAcm Ligation Assay
Each ligation reaction, 125 µL total volume, contained the following reagents:
amino acid (1 mM), ATP (2.5 mM), total E. coli tRNA (2 µg/µL), recombinant Histagged E. coli MetRS or Met*RS, recombinant His10-tagged E. coli aminoacyl transferase
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(2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM HEPES pH
8.0, 150 mM KCl, 10 mM MgCl2). The reaction mixtures were incubated at 37 °C for 30
minutes and quenched with 1 % acetic acid. Acetone precipitation and subsequent
analysis were performed as described for the Chemoenzymatic LysAlaAcm Ligation
Assay.

3.3.8 – AaT Ligation Reaction Analysis by HPLC
All HPLC analyses of LysAlaAcm ligations were monitored using a Waters
Symmetry Shield C18 reversed phase column (Gradient 6). Peptide retention times
monitored at 325 nm (Acm absorption) are in Table 3-3 and MALDI MS analyses,
confirming peptide identity, are in Table 3-2.
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Table 3-2. Calculated and Observed Peptide and Protein Masses
Peptide
a

MetLysAlaAcm
a
CsmLysAlaAcm
a
CbzLysAlaAcm
a
CspLysAlaAcm
a
CsbLysAlaAcm
a
CsfLysAlaAcm
a
CsTfLysAlaAcm
a*
HcsLysAlaAcm
a
HcmLysAlaAcm (14)
a
HcpLysAlaAcm
a
HcbLysAlaAcm
a
HcfLysAlaAcm
a
HcTfLysAlaAcm
a
Ac-MetAspValPhe-SR (11)
a
Ac-MetAspValPheHcsLys (S8)
a
Ac-MetAspValPheMetLys (S9)
a
Ac-McmMetAspValPhe-SR (S10)
a
Ac-MetAspValPheHcsLysAlaAcm (15)
a
Ac-MetAspValPheMetLysAlaAcm (16)
b
αS6-140 (18)
b
Hcm-αS6-140 (19)
b
AcMcm-αS-Hcs5 (20a)
b
AcMcm-αS (21a)
b
Ac-αS-Hcs5 (20b)
b
Ac-αS (21b)
•
•

a

Calculated
+
(M+H)
506.243
524.200
568.259
552.231
566.247
586.215
592.187
492.611
538.215
566.247
580.262
600.231
606.203
655.247
798.352
812.368
900.31
1026.44
1040.46
13, 837.3
14, 000.6
14, 733.4
14, 747.4
14, 489.2
14, 503.2

b

Observed
+
(M+H)
506.114
523.892
--552.436
566.400
------538.162
566.393
579.923
------798.600
812.449
--1026.59
1040.24
13, 837.7
14, 001.0
14, 735.1
14, 748.4
14, 490.0
14, 502.7

Calculated
+
(M+Na)
528.225
546.182
590.241
574.213
588.229
608.198
614.169
514.209
560.197
588.228
602.224
622.213
628.185
677.229
820.334
834.350
922.31
1048.42
1062.44
13, 859.3
14, 022.6
14, 755.4
14, 769.4
14, 511.2
14, 525.2

Observed
+
(M+Na)
528.1
545.893
------------560.167
588.357
601.924
----677.302
820.591
834.437
922.25
1048.56
---------------

Exact mass, Molecular weight
HcsLysAlaAcm observed as a byproduct of transfer of 5a, 5b, or 5c in the presence of
BME.
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Table 3-3. HPLC Analysis of LysAlaAcm Transfer Reactions
Peptide
LysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
PheLysAlaAcm
MetLysAlaAcm
MetLysAlaAcm
MetLysAlaAcm
MetLysAlaAcm
MetLysAlaAcm
CbzLysAlaAcm
CsmLysAlaAcm
CspLysAlaAcm
CsbLysAlaAcm
CsfLysAlaAcm
CsTfLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcmLysAlaAcm
HcpLysAlaAcm
HcbLysAlaAcm
HcfLysAlaAcm
HcTfLysAlaAcm

Time (min)
11.3
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.1
12.1
12.1
12.1
12.1
NA
12.3
13.0
13.3
NA
NA
12.7
12.7
12.7
12.7
12.7
12.7
12.7
12.7
12.7
12.7
13.5
13.7
NA
NA

Conditions
S1
S1, 0.05 M Gdn•HCl
S1, 0.10 M Gdn•HCl
S1, 0.20 M Gdn•HCl
S1, 0.30 M Gdn•HCl
S1, 0.40 M Gdn•HCl
S1, 0.50 M Gdn•HCl
S1, 1.00 M Gdn•HCl
S1, 1.50 M Gdn•HCl
S1, 2.00 M Gdn•HCl
S1, 0.1 % Triton
S1, 0.5 % Triton
S1, 1.0 % Triton
S1, 2.0 % Triton
S1, 5.0 % Triton
S4a
Met, MetRS
Met, 1 mg/mL Met*RS, 0.20 M Gdn•HCl
Met, 1 mg/mL Met*RS, 0.50 M Gdn•HCl
Met, 1mg/mL Met*RS, 5.0 % Triton
S4b
5*a
5*b
5*c
5*d
5*e
5a
5a, 0 mM BME
5a, 1 mg/mL MetRS
5a, 0.1mg/mL MetRS, 30 min
5a, 1 mg/mL Met*RS
5a, 0.1mg/mL Met*RS, 30 min
5a, 0.1mg/mL Met*RS
5a, 1 mg/mL Met*RS, 5.0 % Triton
5a, 1 mg/mL Met*RS, 0.20 M Gdn•HCl
5a, 1 mg/mL Met*RS, 0.50 M Gdn•HCl
5b
5c
5d
5e
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% Yield
NA
99.5 ± 0.1
96.0 ± 0.1
93.4 ± 0.1
79.2 ± 5.0
71.2 ± 4.0
62.0 ± 3.8
54.5 ± 0.4
25.4 ± 2.4
10.6 ± 0.4
3.0 ± 0.2
95.0 ± 3.8
97.8 ± 0.1
96.5 ± 2.4
97.4 ± 1.5
98.4 ± 0.5
74.6 ± 1.3
99.9 ± 0.1
74.2 ± 8.7
30.1 ± 1.3
92.0 ± 9.6
0
20.9 ± 0.5
68.4± 0.2
41.3 ± 0.7
0
0
21.2 ± 0.7
36.5 ± 0.1
99.9 ± 0.1
48.8 ± 4.8
99.9 ± 0.1
63.8 ± 3.1
99.9 ± 0.1
99.4 ± 0.1
76.7 ± 8.1
15.3 ± 8.3
14.6 ± 0.3
2.7 ± 0.2
0
0

3.3.9 – Ligation of Ac-MetAspValPhe-SR (11) and HcmLysAlaAcm (14)
Ligation buffer was prepared as follows: 200 mM sodium phosphate dibasic, 40
mM TCEP, 1 % v/v thiophenol and 1 % v/v benzylmercaptan, pH 7.2. Ligation buffer
was prepared fresh and sparged with argon for 10 – 20 minutes. 50 uL of the ligation
buffer was added to 50 uL of a 2 mM stock of HcmLysAlaAcm. The solution was then
added to 0.33 µmol of Ac-MetAspValPhe-SR and the reaction mixture was sparged for
an additional 15 minutes. The reaction was mixed overnight using a micro-stir bar. The
reaction was quenched the following day with a 10-fold amount of 0.1 % trifluoroacetic
acid and analyzed by HPLC (Gradient 7). Peptide retention times were monitored at 215
nm (peptide bond absorption) and MALDI MS analyses, confirming peptide identity, are
in Table 3-2.

3.3.10 – Construction of Recombinant αS6-140 Expression Plasmid
We have previously described the cloning of the αS gene from a pT7-7 vector into
the pET-16b prokaryotic expression vector, which contains an N-terminal His tag
followed by a Factor Xa recognition site (IEGR) (Figure 3-28 Ia).2

QuikChange®

mutagenesis was used to delete residues H-1 and M1 (Figure 3-28 Ib) followed by a D2K
mutation (Figure 3-28 Ic) to yield the αS2-140K2 plasmid. Residues K2-M5 were deleted
(Figure 3-28 Id) from the αS2-140K2 plasmid using QuickChange® mutagenesis to give
the αS6-140 plasmid. All mutagenesis steps were confirmed by DNA sequencing using the
T7 promoter primer. Plasmid constructed by John Warner.
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I. Construction of αS6-140 Plasmid DNA

II. DNA Oligomers Used for QuickChange® Mutagenesis

Figure 3-28. Construction of αS6-140 Plasmid

3.3.11 – Cloning of Calmodulin Expression Constructs
Quikchange ® mutagenesis was used to generate the following mutant plasmids:
pET15b-H10-CaM77-149 (C-terminal domain) and pTXB1-CaM1-72 (N-terminal domain).
All mutagenesis steps were confirmed by DNA sequencing using the T7 promoter
primer.
The C-terminal domain of calmodulin (CaM) was cloned from a plasmid
containing a gene encoding full-length wild-type calmodulin from the chicken genus.
This plasmid was provided by the Wand Laboratory of the University of Pennsylvania
School of Medicine. The CaM gene had been cloned into the pET15b vector (Novagen,
Gibbstown, NJ) at the NcoI and XhoI restriction enzyme cut sites. An NdeI site was
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introduced at K76 of the CaM gene using QuikChange® mutagenesis. The plasmid was
digested with PacI/NdeI. The CaM digested insert was ligated into a pEG6 vector50,
which contains an N-terminal H10 tag with a factor Xa cleavage site, at cut sites, Nde1
and XhoI with T4 DNA ligase. The pEG6 plasmid was a gift from the Muir Lab at
Princeton University.

To complete the plasmid, an N-terminal lysine was exposed

through the deletion of HM at the inserted NdeI site resulting in the plasmid pEG6-H10FactorXa-(Lys)CaM78-149 (Figure 3-29).
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Figure 3-29. Construction of WT CaM78-149 His-Tagged Expression Plasmid
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XhoI

The N-terminal domain of calmodulin (CaM) was cloned from a plasmid
containing a gene encoding wild-type calmodulinS17C, 1-116. This plasmid was provided by
the Linse Laboratory of the Department of Biochemistry and Structural Biology at Lund
University. The plasmid contained the pTXB1 vector, which encodes a mini-intein GyrA
from the Mycobacterium xenopi followed by a chitin-binding domain (CBD). A PacI site
was introduced at M72 and L117 of the CaM gene using QuikChange® mutagenesis. With
the PacI sites encoded, the plasmid was digested with PacI and then the resulting sticky
ends were ligated using T4 DNA ligase resulting in a pTXB1-CaM1-72-PacI plasmid.
Next, the PacI site at 72 was mutated back to wild type M72. To bring the CaM gene
back to wild-type CaM1-72, the S17C mutation was mutated back to wild type C17S
(Figure 3-30).
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Figure 3-30. Construction of WT CaM1-72 Intein Expression Plasmid with C-Terminal ChitinBinding Domain

3.3.12 – Expression and Purification of αS6-140
The plasmid containing the αS gene was used to transform Escherichia coli
BL21(DE3) cells. Transformed cells were selected on the basis of ampicillin resistance.
Single colonies were used to inoculate 5 mL of LB media supplemented with ampicillin
(100 µg/mL). The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm
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for 5 hours. 500 mL of LB media supplemented with ampicillin was inoculated with 1
mL of the primary culture. The 500 mL culture was incubated at 37 °C with shaking at
250 rpm until an OD600 of 0.6 was reached. Expression was induced with the addition of
1.0 mM isopropyl β-D-thiogalactoside and cells were incubated at 25 °C for 16 hours.
The cells were harvested at 5000 x g for 15 min and the resulting pellet was resuspended
in a Factor Xa cleavage buffer (100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2) and
included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II)
and sonicated. Following sonication, the cell lysate was boiled for 20 minutes prior to
centrifugation for 20 minutes at 30,000 x g, 4 °C. Collected soluble protein was gently
shaken for 1 h on ice with Ni-NTA resin. Protein was purified by rinsing with Factor Xa
cleavage buffer followed by washing with Factor Xa wash buffer (100 mM NaCl, 50 mM
Tris pH 8.0, 5 mM CaCl2, and 50 mM imidazole). Protein was eluted with Factor Xa
elution buffer 100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2¸and 250 mM imidazole).
SDS-PAGE analysis was performed to analyze the purity of αS elution fractions.
Collected protein fractions were dialyzed against Factor Xa cleavage buffer at 4 °C. The
His10 purification tag was removed by incubation of purified αS (0.5 mg/mL) with Factor
Xa, Restriction Grade, Bovine Plasma (Novagen) (20 Units) overnight at 37 °C. Factor
Xa was removed by boiling for 20 minutes and centrifugation for 20 minutes at 30,000 x
g, 4 °C. Soluble protein was purified from N-terminal peptide and uncleaved protein by
1 h incubation with Ni-NTA resin. Protein concentration was determined by BCA assay
(Pierce) and adjusted to 1.0 mg/mL, purity was confirmed by SDS-PAGE and MALDI
mass spectrometry. Protein was stored at – 80 °C until further use.
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3.3.13 – Expression and Purification of CaM78-149
The plasmid containing the CaM78-149 gene was used to transform Escherichia
coli BL21(DE3) cells.

Transformed cells were selected on the basis of ampicillin

resistance. Single colonies were used to inoculate 5 mL of LB media supplemented with
ampicillin (100 µg/mL). The primary 5 mL culture was incubated at 37 °C with shaking
at 250 rpm for ~ 3 hours, until log phase was reached.

One liter of LB media

supplemented with ampicillin was inoculated with 1 mL of the primary culture. The 1
liter culture was incubated at 37 °C with shaking at 250 rpm until an OD600 of 0.6 was
reached.

Expression was induced with the addition of 1.0 mM isopropyl β-D-

thiogalactoside and cells were incubated at 25 °C for 16 hours. The cells were harvested
at 5000 x g for 15 min and the resulting pellet was resuspended in binding buffer (50 mM
Tris pH 8) and included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL
DNAse1–Grade II) and sonicated. Following resuspension, the cell lysate was sonicated
for 1 min, 6 times, with a one minute rest between each sonication. Collected soluble
protein was gently shaken for 1 h on ice with Ni-NTA resin. Protein was purified by
rinsing with Factor Xa cleavage buffer followed by washing with wash buffer (50 mM
Tris pH 8 and increasing imidazole from 10 mM – 50 mM). Protein was eluted with
elution buffer (50 mM Tris pH 8 and 250 mM imidazole). SDS-PAGE analysis was
performed to analyze the purity of CaM78-149 elution fractions.

Collected protein

fractions were dialyzed against Factor Xa cleavage buffer (50 mM Tris, 100 mM NaCl, 5
mM CaCl2 pH 8) at 4 °C. The His10 purification tag was removed by incubation of
purified CaM77-149 with Factor Xa, Restriction Grade, Bovine Plasma (Novagen) (20
Units) overnight at 37 °C (or until reaction is complete, which can take up to 2 days if
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high concentration of protein is used). Factor Xa cleavage was halted by addition of 1
mM PMSF, and solution was kept at room temperature for 1 h to ensure PMSF
degradation. Protein concentration was determined by BCA assay (Pierce) and adjusted
to 1.0 mg/mL, purity was confirmed by SDS-PAGE and MALDI mass spectrometry.
Protein was stored at – 80 °C until further use.

3.3.14 – Expression and Purification of CaM1-72
The plasmid containing the CaM1-72 gene was used to transform Escherichia coli
BL21(DE3) cells. Transformed cells were selected on the basis of ampicillin resistance.
Single colonies were used to inoculate 5 mL of LB media supplemented with ampicillin
(100 µg/mL). The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm
for ~ 3 hours, until log phase was reached. One liter of LB media supplemented with
ampicillin was inoculated with 1 mL of the primary culture. The 1 liter culture was
incubated at 37 °C with shaking at 250 rpm until an OD600 of 0.6 was reached.
Expression was induced with the addition of 1.0 mM isopropyl β -D-thiogalactoside and
cells were incubated at 25 °C for 16 hours. The cells were harvested at 5000 x g for 15
min and the resulting pellet was resuspended in binding buffer (20 mM Tris, 0.5 M NaCl
pH 7.5) and included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL
DNAse1–Grade II) and sonicated. Following resuspension, the cell lysate was sonicated
for 1 min, 6 times, with a one-minute rest between each sonication. Collected soluble
protein was incubated with Chitin Beads (pre-equilibrated with binding buffer) and
gently rotated at 4 °C for 1 - 4 hours (longer incubation enhanced chitin binding to
protein). Post incubation, the flow through was collected and the column was washed
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with 3 x 10 mL binding buffer. 2.5 mL of chitin cleavage buffer was added to the beads
(20 mM Tris, 0.5 M NaCl, 200 mM MESNA pH 7.5) and incubated at 4 °C with rotation.
Protein was eluted with elution buffer by collecting incubated flow through and beads
were washed with 3 x 2 mL chitin cleavage buffer. SDS-PAGE analysis was performed
to analyze the purity of CaM1-72 elution fractions. Collected protein fractions were
dialyzed against water overnight at 4 °C. Protein concentration was determined by BCA
assay (Pierce) and adjusted to 1.0 mg/mL, purity was confirmed by SDS-PAGE and
MALDI mass spectrometry. Protein was stored at – 80 °C until further use.

3.3.15 – Full Enzymatic Transfer to αS6-140 and CaM78-149
For a typical reaction, 4.25 mg αS6-140 in AaT Ligation Buffer pH 8.0 was
modified with Hcm (1 mM) containing 20 mg E. coli total tRNA, 2.5 mM ATP, 1.0 - 0.1
mg E. coli Met*RS, and 0.1 mg E. coli AaT. The reaction was carried out at 37 °C for 4
h and arrested by boiling for 30 min. The supernatant was cleared by centrifuging for 20
min at 30,000 x g. Hcm-αS6-140 (19) was further purified on the with a HiTrap Q HP
column (GE Healthcare). Protein was buffer exchanged into Milli-Q water and stored at
-80 °C. The same procedure was used for CaM78-149 except that post-reaction the sample
was not boiled and instead the reaction was halted by dialysis against 20 mM Tris pH8
overnight at 4 °C. FPLC purification and purified protein storage remained the same for
CaM as with αS.
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3.3.16 – Ligation of Ac-MetAspValPhe-SR (11) and Ac-McmMetAspValPhe-SR (S10)
to Hcs-αS6-140 (19)
Ligation buffer was prepared fresh as follows: 100 mM sodium phosphate dibasic,
20 mM TCEP, 6 M guanidine hydrochloride and 2 % v/v thiophenol at pH 7.2. The
buffer was sparged twice with argon: 20 minutes for a 100 mM sodium phosphate dibasic
and 6 M guanidine hydrochloride solution and then for an additional 10 min post addition
of TCEP, thiophenol, and pH adjustment to 7.2. Sparged ligation buffer (100 uL) was
added to 0.0404 µmol (1 equivalent) of dried Hcm-αS6-140 protein. The mixture was
briefly vortexed and allowed to reduce for 10 min. Next, the protein solution was added
to 0.1212 µmol (3 equivalents) of Ac-MetAspValPhe-SR (11). The reaction was mixed
overnight at 250 RPM at 37°C. The reaction was quenched the following day with a 3
mL addition of MilliQ water and buffer exchanged solvent with six water washes using a
3 kDa protein concentrator microfuge tube and analyzed by HPLC (Gradient 7). Protein
retention times were monitored at 215 nm (and 325 nm for S13). MALDI MS analyses
are in Table 3-2. Example HPLC traces are shown in Figure 3-8.

3.3.17 – Ellman’s Reagent Analysis
0.8 nmoles of αS-Mcm-Hcs5 (20a) were methylated with 1000 equivalents of
methyl iodide in 0.1 M sodium bicarbonate pH 8.6 for 5 min at room temperature.
Following methylation, the reaction was incubated with 150 µM 5,5’-dithiobis-(2nitrobenzoic acid (DTNB) for 5 min at room temperature. UV/Vis measurements were
taken using a Tecan M1000 plate reader. Excitation slit width was 5 nm, integration time
0.02 s, data interval 2.0 nm, flash frequency 400 Hz, 25 flashes, gain set to 100, and z170

height 20 mm (Figure 3-7). Section 3.3.17 was performed by John Warner.

3.3.18 - aS-Mcm Fluorescence Readings
Fluorescence spectra were collected with a Varian Cary Eclipse fluorescence
spectrophotometer fitted with a Peltier multicell holder. Fluorescence spectra were
collected using quartz cells with 1 cm path lengths. Excitation and emission slit widths
were 5 nm, scan rate 120 nm/min, averaging time 0.5 s, and data interval 1.0 nm. Section
3.3.18 was performed by John Warner.

3.3.19 – Trypsin Digest and MALDI MS Analysis
Ac-αS 21b (5.4 µg) was buffer-exchanged into 100 µL of freshly prepared 25 mM
NH4HCO3 (pH 7.6), and digested with 2 µL of sequencing-grade modified trypsin (0.1
µg/µL). The digestion was allowed to proceed at 37 °C for 3 h. An aliquot (1.0 µL) of
the digest was taken and analyzed by MALDI MS in CHCA matrix (Figure 3-31, Table
3-4). MALDI MS data shown in Figure 3-32 confirm that no methylation of His50 took
place. To determine the sensitivity of our method for identifying the extent of Hcs
methylation, we synthesized authentic Ac-MetAspValPheHcsLys (S8) and AcMetAspValPheMetLys (S9). We mixed them in ratios varying from 1:1 to 1:100 S8/S9
and spotted these mixtures in CHCA matrix in a manner identical to the analysis of
trypsinized 21b. We found that the ionization of Hcs-containing S8 was proportional to
its ratio in the mixture.

Therefore we feel confident that ratios of Ac-

MetAspValPheHcsLys to Ac-MetAspValPheMetLys observed in the MALDI MS data of
trypsinized 21b are reflective of the degree of conversion of Hcs5 to Met5. The 5:95 and
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1:99 S8/S9 MALDI MS data are shown in Figure 3-31.

Figure 3-31. MALDI MS Data for Mixtures of Ac-MetAspValPheHcsLys (S8) and AcMetAspValPheMetLys (S9)

Table 3-4. Trypsin Digest Ac-αS (13b) Sequence Coverage
m/z

Start

End

Missed

Peptide

798.42

1

6

0

Ac-MDVFXK

812.37

1

6

0

Ac-MDVFMK

830.44

24

32

0

QGVAEAAGK

873.47

13

21

0

EGVVAAAEK

951.51

35

43

0

EGVLYVGSK

1295.70

46

58

0

EGVVHGVATVAEK

1478.78

81

96

0

TVEGAGSIAAATGFVK

2157.19

59

80

1

TKEQVTNVGGAVVTGVTAVAQK

4286.73

103

140

0

NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

Underline indicates observed fragment. Ligation site fragment shown in bold. X = Homocysteine
(Hcs).
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Figure 3-32. αS Full-Length Sequence and MALDI MS Data for Trypsin Digested Ac-αS6-140
The fragment corresponds to EGVVHGVATVAEK and the asterisk indicates mass of peptide with
methylated His50.

3.3.20 – Ligation Motif Prevalence Analysis
The frequency of XaaMetArg and XaaMetLys motifs (Xaa = any amino acid) in
protein sequences of the Protein Data Bank (PDB) was assessed using PHI-BLAST.174
Briefly, a four-letter query, “X1MRX2” or “X1MKX2” (where X1 and X2 were varied to
cover all 20 natural amino acids), was aligned to the database under the constraints of a
“X1MR/K” pattern and the PAM30 substitution matrix. The results were then pooled in a
spreadsheet, inspected for false hits, and categorized (Table 3-5, 3-6 and 3-7) by Jerri
Wang.

173

Table 3-5. Summary of Unique PDB Entries Containing One or More MR or MK Ligation
Site(s)
Ligation
Sites per
Entry
1

# of
Entries

# of
Entries

Ligation Sites per
Entry

# of
Entries

13,550

Ligation
Sites per
Entry
5

142

9

5

2

4,842

6

44

11

1

3

1,554 7

14

14

1

1

4

543

8

4

17

1

of unique entries with MetArg or MetLys Ligation site(s)

20,701

# of unique entries with N-Terminal (≤ 40 aa) MetArg or MetLys Ligation site(s)

5,156

# of entries in the PDB Database (as of Oct 14, 2012)

60,325

Table 3-6. Selected Examples of Potential Ligation Targets
Protein

Taxonomy

Length Alignment

PDB ID

Human Prion Protein

H. sapien

142 19 NMK 21

2LSB

Ribonuclease S

H. sapien

127 6 MMK 8

2K11

Caspase 2, Chain B

H. sapien

105 29 AMR 31

1PYO

CTerminal Src Kinase

H. sapien

278 19 NMK 21

1BYG

Annexin

H. sapien

319 26 AMK 28

2ZOC

Anti HIV1 Protease Fab, Chain H

M. musculus

226 29 FMR 31

1MF2

Cytochrome P450

B. megaterium

471 29 LMK 31

1FAH

Myosin

P. magellanicus

840 20 MMK 22

2OS8

BetaAlanine Synthase

S. kluyveri

474 34 GMR 36

2VL1

30S Ribosomal Protein S2

E. coli

241 26 KMK 28

1VS5
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Table 3-7. Distribution of Ligation Sites by Thioester Residues and Relative Positions

Thioester
Residue

# of Distinct
Ligation Sites
MR

MK

Relative Positions
N-Terminal
(≤ 40 aa)
MR

Middle

C-Terminal
(≤ 40 aa)

MK

MR

MK

MR

MK

202
354
234
169
106
74

644
961
945
242
375
401

815
1,177
1,183
268
455
427

100
124
181
97
89
67

141
277
274
87
93
89

Very Suitable for Native Chemical Ligation
G
A
L
M
F
Y

846
1,224
1,261
411
542
506

Sub-total

1,158
1,808
1,691
524
654
590

102
139
135
72
78
38

11,215

1,703

7,893

1,619

Suitable for Native Chemical Ligation
K
R
N
Q
S
C
W
Sub-total

729
828
529
528
932
202
189

1,109
898
619
692
1,054
224
197

138
125
83
115
266
28
23

8,730

170
181
122
105
327
30
18

481
589
389
354
579
129
139

1,731

754
579
410
509
551
156
166

110
114
57
59
87
45
27

5,785

185
138
87
78
176
38
13
1,214

Mutations Needed to Promote Native Chemical Ligation
V
I
T
H
D
E
P

1,029
702
784
371
636
907
396

1,155
941
950
761
905
1,391
386

164
80
124
211
59
131
52

141
147
150
348
104
195
65

706
488
516
137
442
601
278

831
684
647
329
663
952
257

159
134
144
23
135
175
66

183
110
153
84
138
244
64

Sub-total

11,314

1,971

7,531

1,812

Total

31,259

5,405

21,209

4,645
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CHAPTER 4

EXPANSION OF AMINOACYL TRANSFERASE SUBSTRATE SCOPE
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Section 4.1 - Introduction
An enzyme’s active site is the location in which a chemical reaction occurs, and
the amino acid residues within the active site convey binding to appropriate substrates.
Many factors dictate whether a compound will be an enzyme substrate, including
substrate/enzyme complementarity, active site flexibility, steric matching, and
noncovalent forces arising from hydrophobicity and charge.131 Some active sites have
stringent substrate restrictions, which have evolved to make the enzyme highly specific to
one substrate. Alternatively, an enzyme can have less specificity, which would allow it
to accept a variety of substrates; E. coli leucyl/phenylalanyl aminoacyl transferase (AaT)
falls into this second class. AaT is an enzyme that can naturally transfer three amino
acids, leucine, phenylalanine and – to a lesser extent – methionine, from their respective
aminoacyl tRNAs, to the α-amino group of proteins with an N-terminal lysine or
arginine.126 The active site of AaT is very hydrophobic and also selective against βbranched amino acids, such as valine.56

The enzyme delicately balances moderate

selectivity for its amino acid substrate with high specificity binding for the protein Nterminus.
Using X-ray crystallography, MALDI-TOF MS, amino acid mutagenesis, and
enzyme kinetics, two groups have proposed mechanisms for the AaT amide bondforming reaction. Suto et al. solved a crystal structure of AaT bound to an aminoacyltRNA analog, puromycin, to help elucidate the key residues that recognize the
aminoacyl-tRNA substrate. They performed site-directed mutagenesis at residues within
close proximity to puromycin bound in the enzyme active site.
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A hydrophobic pocket

containing, M144, F153, L170, F173, and I185, was found to hold the p-methoxybenzyl moiety
of puromycin, which represented the phenylalanine/leucine portion of the natural
aminoacyl substrate (Figure 4-1).56 Upon mutation of those residues to alanine, they
found enzymatic activity to be substantially reduced, indicating the importance of the
specific size of the hydrophobic amino acids in the active site to correctly fit the Phe/Leu
aminoacyl tRNA substrates. Additionally, the hydrophobic residues are well conserved
within transferases from other eubacteria, giving further proof of their importance in the
AaT amide bond-forming reaction.56 Additional residues that were proposed to be linked
to AaT activity included Glu156 and Gln188, which could interact with the positivelycharged N-terminal arginine/lysine of the protein substrate by positioning it for favorable
reactivity.43

Figure 4-1. Recognition of Puromycin in AaT
From X-ray crystal structure by Suto et al. Hydrophobic pocket: Met144, Phe153, Leu170, Phe173,
56
Ile185.
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The same group proposed a specific AaT reaction mechanism in a following
paper in 2007 when they obtained two crystal structures of AaT, one with phenylalanyl
adenosine, the 3' end of the phenylalanine aminoacyl tRNA natural substrate, and one
with the product Phe-ligated peptide (PheArgTyrLeuGly).43 Watanabe et al. proposed
that the AaT ligation reaction of phenylalanine from Phe-tRNA to the N-terminus of an
Arg/Lys-peptide had a catalytic mechanism similar to the reverse reaction of a serine
protease (Figure 4-2).43 They determined that nucleophilic attack of the backbone αamino group of the N-terminal arginine/lysine on the carbonyl carbon of the 3' ester bond
of the aminoacyl tRNA is facilitated by several amino acid residues within the active site.
They proposed that Gln188 acts as a general base, while Asp186 helps place Gln188 in the
correct reaction orientation, and Asn191 stabilizes the formation of the oxyanion hole that
is produced in the formation of the tetrahedral intermediate.

When comparing the

product-bound peptide structure to the starting material Phe-A bound state, they found
substantial amino acid movement had occurred within the active site, where tryptophan
residues W49 and W111 rotated and flipped, respectively, to accommodate the product. As
they had found before, in addition to the hydrophobic pocket that holds the phenylalanine
portion of the aminoacyl-tRNA substrate, the specific size of the negatively charged site
that holds the arginine in place is directly connected to AaT activity, with alanine or
aspartate mutations abolishing or reducing activity, respectively.

Their research

determined that the AaT reaction does not act like the peptidyl transfer site of the
ribosome, which positions residues for substrate-assisted catalysis (below), and instead
mimics a reverse acylation reaction seen in proteases and esterases.
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Figure 4-2. First Proposed AaT Ligation Mechanism
43
Adapted from Watanabe et al. 2007.

The mechanism proposed by Watanabe et al. was challenged by Fung et al. in
2011.59 They reevaluated the catalytic mechanism using a quantitative MALDI-TOF
MS-based assay with radioisotope-enriched peptide standards. Fung et al. stated that it
was unconventional for glutamine (Q188) to act as general base and therefore re-analyzed
the alanine mutations with their MALDI method to determine if the residue mutants were
indeed catalytically deleterious.59 Using their highly sensitive technique, they determined
that the previously-determined catalytic residues, D186 and Q188, were not directly
involved with catalysis, but instead critical for correct orientation of the aminoacyl tRNA
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and acceptor protein, which react to form a peptide bond without the direct aid of the
enzyme. This is similar to the established mechanism of peptide bond formation on the
ribosome (Figure 4-3).59 An additional argument that they make for a ribosome-like
active site behavior is the slow reaction rate of AaT, kcat/KM = 8.02 x 103 M-1s-1.43, 59 The
substrate-assisted catalysis mechanism is still a proposal, however, and the exact
influence of AaT on peptide bond catalysis is currently unconfirmed. While the two
proposed mechanisms suggest differing means of enzyme catalysis, both include
nucleophilic attack on the aminoacyl tRNA carbonyl by the α-amino group arginine.
NH2
N
N
tRNA

O

N
N

O
HOH

O

O

O
H

H2N

R1

H

HN

Arg-peptide

R2
O

Figure 4-3. Second Proposed AaT Ligation Mechanism
Adapted from Fung et al. 2011. The reaction takes place via the 2'-hydroxyl in “substrateassisted catalysis.” The AaT-bound aminoacyl tRNA acts similarly to the P-site in the ribosome,
59
and the Arg-peptide is analogous to the A-site.

The AaT crystal structures with bound substrate Phe-A and product Phe-peptide,
give evidence that the AaT active site has flexibility upon substrate binding; however, we
had determined that the WT AaT, while accommodating a variety of unnatural amino
acid residues, has a steric limit. In the aforementioned discussion of the AaT catalysis
mechanism, mutagenesis was used to help determine key residues involved in substrate
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recognition and influence in enzyme activity.

For our purposes, we used alanine

mutagenesis to expose space within the AaT active site to accommodate larger amino
acid residues. We synthesized several aminoacyl adenosine analogs with residues that
could not transfer to the N-terminus of our model peptide, LysAlaAcm, using WT AaT
(Figure 4-4). We determined that we would need space within the active site to allow for
extension in areas that around the aminoacyl adenosine α-amino group and sidechain Rgroup. By inspection of the crystal structures, we chose several amino acids that could
“open up” the active site to accommodate the larger unnatural amino acids: M144A,
M158A, L170A, F173A, F177A, I185A, C187A. We made individual and double amino acid
substitution combinations but had difficulty with expressed protein stability.

We

obtained several expression-stable single alanine mutants, M144A, L170A, I185A, and
C187A, which we assayed for enzymatic activity with a natural aminoacyl substrate
mimic, Phe-A, and corresponding donors with the unnatural amino acids, Mef, Azf, Nap,
Nbd, Mcm, 1, 8-naphthalimide (Npt1,8), and 2, 3-Naphthalenedicarboximide (Npt2,3)
(Figure 4-4). Phe-A and Nap-A had lower peptide bond-forming efficiency than WT and
none of the unnatural residues larger than napthylalanine were compatible with our
mutant enzymes.
We next established a collaboration with the Saven group to attempt to find an
AaT mutant that, through predictions from computer-aided protein design, would be
more active for one particular type of unnatural aminoacyl adenosine substrate,
homocysteine or cysteine disulfide-protected analogs. An improved enzyme for these
specific substrates would enhance our efficiency in forming native chemical ligation182

ready precursor proteins. Along with our studies of the AaT active site, we explored the
possibility of utilizing another aminoacyl transferase, Bpt from V. vulnificus, by
examining its ability to accept a minimized substrate, leucyl adenosine, similarly to AaT.
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Figure 4-4. Amino Acids Not Utilized by WT AaT

Section 4.2 - Results and Discussion
In our previous work, we determined that WT AaT could use a variety of
substrates with bulky sidechain R-groups such as naphthylalanine, and reactive handles
residues such as p-azido-phenylalanine. However, we determined that the active site has
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polar and steric restrictions; therefore, a phase of this project has been to create active site
mutations to open space for more bulky and/or more polar R-groups in order to expand
substrate scope. We chose a several amino acids that could “open up” the active site to
accommodate the larger unnatural amino acids: M144A, M158A, L170A, F173A, F177A,
I185A, C187A (Figure 4-5). We were careful not to choose amino acids that were directly
involved with substrate binding in an attempt to avoid issues of enzyme catalysis
inactivation. We made individual amino acid substitutions and additionally made all the
respective combinations of double mutants of the listed residues, resulting in a total of 27
mutants. All of the residues chosen for alanine mutagenesis are located around the
aminoacyl R-group recognition site. Phe173 and Phe177 are the farthest from the substrate
phenylalanyl moiety, seen in Figure 4-5, but could possibly open a “slot” to fit planar
fluorescent molecules such as Npt1,8 and Npt2,3.

Figure 4-5. AaT Residues Selected for Mutagenesis
Residues to be mutagenized (green spheres) and Phe-A (grey spheres) bound to active site.
43
PDB ID: 2Z3K
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Of the mutants, few could be expressed successfully. Most of the mutants had
problems of folding stability, and while could be expressed, would fall out of solution
upon cellular extraction mixed with the cellular debris and likely stuck in inclusion
bodies (Figures 4-6 and 4-7). Additionally, with the mutants that expressed poorly, we
tended to see an increase in a higher molecular weight band, which approximately
corresponded to dimerization of AaT (Figure 4-7, beige arrow).

Of the 27 mutant

enzymes, enzymes that expressed to a degree comparable to wild type included both
double mutants and single mutants. One double mutant in particular, L170A M158A, had
the best expression of the mutants (Figures 4-8 and 4-9). However, even with this case, a
substantial amount of protein precipitated from solution during lysis and removal of
cellular debris through centrifugation to obtain the soluble protein in the supernatant.

Figure 4-6. SDS PAGE Gel Production Analysis of F177A AaT
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Figure 4-7. SDS PAGE Gel Expression Analysis of F177A AaT

Figure 4-8. SDS PAGE Gel Production Analysis of L170A/M158A AaT
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Figure 4-9. SDS PAGE Gel Expression Analysis of Double Mutant L170A/M158A AaT

We attempted to keep the protein more soluble by altering lysis buffer conditions
through changing the salt composition (Figure 4-10). We had noticed that we lost some
protein into the insoluble fraction during overexpression; therefore, due to the expression
variability of each mutant we did this lysis analysis on WT AaT.

The standard

resuspension lysis buffer conditions consist of 50 mM Tris, 10 mM imidazole, 300 mM
potassium chloride, and 5 mM β-mercaptoethanol. For each altered condition, DNAse,
PMSF, and His-Tag protease inhibitor concentrations were kept the same as for standard
WT AaT overexpression. The conditions varied with salt concentration ranging from 300
– 600 mM of ammonium sulfate or potassium chloride. Additionally, one condition
maintained standard lysis buffer conditions with the addition of 10 % glycerol. None of
these changes increased the percentage of soluble AaT retained in the supernatant.
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Figure 4-10. Soluble Fraction Analysis of Salt Concentration Lysis Conditions for WT AaT
L = lysis, S = Supernatant. Conditions (1) 50 mM Tris, 10 mM imidazole, 300 mM ammonium
sulfate, 5 mM β-mercaptoethanol, (2) 50 mM Tris, 10 mM imidazole, 600 mM ammonium sulfate,
5 mM β mercaptoethanol, (3) 50 mM Tris, 10 mM imidazole, 600 mM potassium chloride, 5 mM
β-mercaptoethanol, (4) 50 mM Tris, 10 mM imidazole, 300 mM potassium chloride, 300 mM
ammonium sulfate, 5 mM β-mercaptoethanol, (5) 50 mM Tris, 10 mM imidazole, 300 mM
potassium chloride, 5 mM β-mercaptoethanol, 10 % glycerol, (6) Standard resuspension lysis
buffer conditions: 50 mM Tris, 10 mM imidazole, 300 mM potassium chloride, 5 mM βmercaptoethanol.

After the first trial of lysis buffers, we changed other possible variables that could
affect AaT solubility, including the duration and type of cell lysis, higher percentages of
glycerol in the lysis buffer, and different buffer compositions used in published AaT
overexpression protocols. We tested seven different conditions for cell lysis (Figure 411). The trials that yielded the greater soluble protein over wild type conditions included
increased waiting time between 1 min sonications, addition of 30 % glycerol to the
standard lysis buffer, or use of lysozyme instead of sonication to break open the cells.
However, it is important to note that in all of the higher yielding AaT protein
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supernatants, a substantial amount of AaT was still lost between the lysis and supernatant
removal steps.

Figure 4-11. Soluble Fraction Analysis of Alternate AaT Lysis Conditions
Lysis buffer conditions are as follows: (1) decreased sonication to three iterations of 1 min
sonication at 30 %, (2) Increased waiting time between standard six sonications from 1 min to 2
min, (3) included 20 % glycerol in lysis buffer, (4) included 30 % glycerol in lysis buffer, (5) new
130
lysis buffer = 50 mM Tris, 1 mM imidazole, 100 mM KCl (6) new lysis buffer = 20 mM Tris, 500
175
mM NaCl (7) used lysozyme for cell lysis instead of sonication. Unless otherwise specified, all
resuspended cells were lysed by sonication as described in 4.3 materials and methods section for
WT AaT.

Given that the aforementioned buffer and lysis conditions did not substantially
decrease the amount of AaT lost into the cell debris pellet, we decided to take another
approach, and completely change the cell overexpression conditions. The overexpression
protocol was adapted from Graciet et al.50 The major changes of this protocol were a one
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hour pre-IPTG cell growth stage at 42 °C and a post IPTG-induced cell growth phase for
a shortened period, 5 h instead of 16 h (Figures 4-12 and 4-13). We found that our new
overexpression protocol had better retention of soluble protein compared to previous
mutant protein expressions. However, again, much of the overexpressed AaT was lost in
the cell pellet again during cell debris removal. Therefore, despite our best efforts, we
decided to continue our analysis of larger unnatural aminoacyl adenosine analogs
substrates with AaT mutants that had previously expressed to a high enough
concentration to be tested by our LysAlaAcm peptide bond formation analysis assay (see
4.3 Materials and Methods).

Figure 4-12. SDS PAGE Gel Overexpression Conditions of I185A AaT
Protein was overexpressed and purified from E. coli using IPTG overexpression and Nickel Bead
50
purification. Protocol adapted from Graciet et al.
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Figure 4-13. SDS PAGE Gel Expression Analysis of Mutant I185A Elution Fractions

Several expression-stable mutants (M144A, L170A, I185A, and C187A) were assayed
for enzymatic activity with Phe-A and LysAlaAcm to determine a standard of peptide
bond-formation activity compared to wild type. For additional comparison, we tested
other unnatural aminoacyl adenosine analogs that could be transferred by WT AaT with
varying degree: Nap, Azf, and Mef. To complete our assay, we analyzed several of our
unnatural amino acids that could not be transferred with WT AaT (Nbd, Mcm, Npt1,8,
and Npt2,3) to determine if the mutants could use them as substrates with the “space”
made from the amino acid replacements with alanine. Unfortunately, we found that none
of the mutants were more active than the WT enzyme toward the substrates that could
already be transferred by wild-type, and none could utilize substrates with an R-group
larger than napthylalanine (Figure 4-14, Table 4-1).
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Figure 4-14. Transfer Efficiencies of Phenylalanine by AaT Mutants
Phenylalanine adenosine was ligated onto peptidyl substrate LysAlaAcm via AaT and percent
ligation was determined by HPLC analysis of peak integration. All reactions were standardized
according to the Materials and Methods. The ligation reactions were monitored at 325 nm, the
absorption maximum of Acm (aminomethylcoumarin).
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Table 4-1. Percent LysAlaAcm Ligation of Analogs Using Mutant AaT
Enzyme

Analog R-Group

% AA-LysAlaAcm

WT AaT

None

0

L170A

Phe

58.6

M158A

Phe

68.0

M144A

Phe

6.2

C187A

Phe

36.4

WT AaT

Phe

98.0

L170A

Nap

74.6

M158A

Nap
Nap

32.7

M144A
C187A

Nap

L170A

AzF

3.6
41.3

M158A

35.2

M144A

AzF
AzF

C187A

AzF

4.7

L170A

Nbd

0

M158A

0

M144A

Nbd
Nbd

C187A

Nbd

0

WT AaT

Nbd

0

L170A, buffer pH 6

Nbd

0

M158A, buffer pH 6

Nbd

0

WT AaT, buffer pH 6

Nbd

L170A
M158A

Mef
Mef

0
0

M144A

Mef

0

C187A

Mef

0

L170A

Mcm

0

M158A

Mcm

0

WT AaT

Mcm

0

L170A

Npt1,8

0

b

M158A

Npt1,8

0

b

WT AaT

Npt1,8

0

b

L170A

0

M158A

Npt2,3
Npt2,3

M144A

Npt2,3

10.3

a

27.7

18.4

0

0

0
b

Npt2,3
C187A
0
AA corresponds to the amino acid transferred to the LysAlaAcm peptide N-terminus.
b
Additional peaks appear in the HPLC spectra but none correspond to product formation.
a
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Additionally, we had some problems in resolving the signal from the fluorescent
analogs from the LysAlaAcm product peptide on the HPLC chromatogram (Figure 4-15).
Nbd, Npt1,8, Npt2,3, and Mcm all absorb in 325 nm, the wavelength used to monitor
Acm. For Nbd, we observed a peak in the HPLC analysis of the LysAlalAcm reaction at
10.9 min, corresponding to the analog.

Npt2,3 had the greatest “bleed-through”

absorption at 325 nm with a total of three visible peaks. The co-absorptions at 325 nm
made for difficult analysis via HPLC, but product formation could generally be resolved
by MALDI MS analysis of HPLC fractions.

Figure 4-15. Co-absorption of Analogs at 325 nm for LysAlaAcm Ligation HPLCs

We concluded that despite our attempts, the mutants were not as enzymatically
efficient or structurally stable as the respective WT AaT. Therefore, we collaborated
with the Saven group to design an AaT mutant that, through predictions from computeraided protein design, would be mutated to become more specific for an unnatural
aminoacyl adenosine substrate.

Enhanced substrate specificity for a cysteine or
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homocysteine disulfide analog would be advantageous because currently our best analog
is only at 68 % product formation for S-isopropyl cysteine (Csp). Structural changes and
amino acid interactions must take place for the accommodation of the disulfide analogs,
which have increased polarity and length compared to the natural residue substrates of
AaT, phenylalanine and leucine (Figure 4-16). To help understand the unnatural amino
acid fit into the AaT active site, the Saven group determined which locations and residue
mutations would favorably interact with the respective aminoacyl adenosine analog of
interest (Table 4-2). Currently, we have focused our efforts on making a more specific
and stable AaT for a variety of substrates, in particular, cysteine disulfides. We have
designed primers for the following mutants: L67M, F173L, T194A, and T194I. With the help
of Haviva Garrett, we have successfully made the following mutants, L67M and T194A,
and have also overexpressed the T194I mutant. Our efforts are ongoing to make a better
mutant AaT that can maintain solubility.

Csp-A

NH2
N
N

HO
O

N
N

O
O

OH

H2N
S

S

Figure 4-16. Csp-A Docking in WT AaT Active Site
Image was produced using Spartan and the AaT crystal structure (PDB ID: 2Z3K), which had
43
Phe-A docked in the active site.
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Table 4-2. Mutagenesis Determined by Computational Modeling
WT E. coli
AaT*

L67

L72

M144

M158

L170

F173

I185

C187

T194

L197

Leu

L67M

L72

M144

M158

L170

F173L

I185

C187

T194A

L197

Met

L67M

L72

M144

M158

L170

F173L

I185

C187

T194I

L197

Csm

L67M

L72

M144

M158

L170

F173L

I185

C187

T194I

L197

Csp

L67M

L72

M144

M158L

L170V

F173M

I185

C187

T194I

L197

Csb

L67M

L72

M144

M158L

L170V

F173M

I185

C187

T194I

L197

Trp

L67M

L72

M144L

M158

L170

F173L

I185M

C187

T194I

L197

•
•

Modeling completed by L. Lu.
*This sequence is for WT AaT E. coli active site amino acids. The following rows are
mutations predicted to aid in the specificity of binding to a particular aminoacyl adenosine

In addition to our studies of the AaT active site, we also investigated the
possibility of using an alternate transferase, Bpt from V. vulnificus. This transferase has a
different N-terminal specificity than AaT. Bpt ligates leucine onto proteins with an Nterminal aspartate or glutamate (Scheme 4-1).50 We found that Bpt is not as efficient an
enzyme as AaT, and even with Leu-tRNA and a leucyl tRNA synthetase, the highest
yielding product formation of LeuAspAlaAcm was only 44.5 % compared to WT AaT
and Phe-tRNA/PheRS going to completion after 4 h (Figure 4-17). We also investigated
the use of a Leu-A analog with Bpt and found that its product yield was even worse, 1.6
% LeuAspAlaAcm. Both ligations, enzymatic or chemoenzymatic, had lower percent
ligation when used with an N-terminal glutamate peptide, GluAlaAcm. We hypothesized
that Bpt might need a molecular chaperone to enhance its enzymatic activity. We have
not rigorously tested this hypothesis, but because we noted that AaT and Bpt are
expressed in a gene cluster in V. vulnificus, we have carried out Bpt reactions in the
presence of AaT. No enhancement of Bpt activity was observed.
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ATP
tRNALeu
LRS
Bpt
H2N

A
D/E

+

O

H2N

H
N

H2N

OH

O
N
H

O

L-Leu

B

O

O
N
H

O

(Asp/Glu)AlaAcm

D/E

H
N

O
N
H

O

O

O

O

O

Leu(Asp/Glu)AlaAcm

NH2
N

HO
O

N

N
N
D/E

+

OH O

H
N

H2N
O

O

Bpt

O
N
H

O

O

O
H2N

D/E
N
H

O

H
N

O
N
H

NH2

Leu-A

(Asp/Glu)AlaAcm

Leu(Asp/Glu)AlaAcm

Scheme 4-1. Peptide Analysis of Bpt Reaction
(A) fully enzymatic and (B) chemoenzymatic with methylcoumarin reporter peptides.
Asp/GluAlaAcm peptides were synthesized by I. Medina.

The

Figure 4-17. HPLC Analysis of Bpt Reaction
Bpt was tested as fully enzymatic (non-analog based) and chemoenzymatic (Leu-A analog used)
with two methylcoumarin reporter peptides, AspAlaAcm and GluAlaAcm, monitored at 325 nm.
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Through our analysis of AaT, we have concluded that active site mutagenesis is a
delicate task. Even one amino acid mutation can make the enzyme insoluble. Therefore,
we are hopeful that with the aid of L. Lu of the Saven group that we can rationally-design
a more efficient and stable transferase. It is also possible that we will additionally
investigate Bpt with in silico design to help understand its low degree of enzymatic
catalysis in vitro.

We are continuing our efforts to better understand the mode of

enzymatic catalysis and importance of active site residues in AaT.
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Section 4.3 – Materials and Methods
4.3.1 – Materials
General Information. Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA), 5′O-(4,4′-Dimethoxytrityl)

adenosine

((DMT)-A),

4-Chloro-7-nitrobenzofurazan,

tetrabutylammonium acetate (TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane
(TIPSH) were purchased from Sigma-Aldrich (St. Louis, MO). (DMT)-A production
was discontinued by Sigma-Aldrich, after which it was purchased as a custom order from
ChemGenes Corporation (Wilmington, MA) and was additionally synthesized in-house
following the protocol outlined by Ogilvie et al.139 Lysylalanyl-aminomethylcoumarin
(LysAlaAcm) was purchased from Bachem (Torrance, CA). N-Boc-L-phenylalanine
(Boc-Phe-OH), 1, 8-naphthalic anhydride and all solvents were purchased from Fisher
Scientific (Pittsburgh, PA). 2, 3-naphthalic anhydride was purchased from TCI America
(Portland, OR).

All deuterated solvents were purchased from Cambridge Isotopes

Laboratories, Inc. (Andover, MA).

E. coli BL21(DE3) cells were purchased from

Stratagene (La Jolla, CA). The pEG6 plasmid, containing His10-tagged E. coli AaT, was
a gift from Alexander Varshavsky (California Institute of Technology).

All other

reagents were purchased from Fisher Scientific (Pittsburgh, PA). N-Boc-L-leucine (BocLeu-OH),

N-Boc-L-p-azidophenylalanine

(Boc-Nap-OH),

N-Me-L-phenylalanine

(Boc-Azf-OH),

N-Boc-L-naphthylalanine

(Boc-Mef-OH),

and

N-Fmoc-

methoxycoumarinylalanine (Fmoc-Mcm-OH) were purchased from Bachem (Torrence,
CA).

All solvents were purchased from Fisher Scientific (Pittsburgh, PA).

QuikChange® site-directed mutagenesis kits were purchased from Stratagene (La Jolla,
CA).

DNA oligomers were purchased from Integrated DNA Technologies, Inc
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(Coralville, IA).

Bradford reagent assay kits and protease inhibitor cocktail was

purchased from Sigma-Aldrich (St. Louis, MO). All other reagents were purchased from
Fisher Scientific (Pittsburgh, PA). Milli-Q filtered (18 MΩ) water was used for all
aqueous solutions (Millipore; Billerica, MA). Matrix-assisted laser desorption ionization
(MALDI) mass spectra were collected using a Bruker Ultraflex III MALDI-TOF-TOF
mass spectrometer (Billerica, MA).

UV absorbance spectra were obtained with a

Hewlett-Packard 8452A diode array spectrophotometer (currently Agilent Technologies;
Santa Clara, CA). Donor molecule purification was conducted on a BioCad Sprint FPLC
(GMI Inc.; Ramsey, MN; originally from Perseptive Biosystems) and Varian HPLC with
a Waters Sunfire Prep C18-prep OBD column, 5 µm, 17 - 150 mm (Milford, MA).
Analytical HPLC assays were performed on an Agilent 1100 HPLC using a Waters
Symmetry Shield C18 column. NMR spectra, 1H and 13C, were collected with a Bruker
DRX 500 MHz instrument. “Low resolution” electrospray ionization (ESI) mass spectra
(LRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single
quadrupole detector (SQD) mass spectrometer. DNA sequencing was performed at the
University of Pennsylvania DNA sequencing facility.

4.3.2 – Aminoacyl adenosine cyanomethyl ester precursors
The respective aminoacyl adenosine cyanomethyl ester precursors, 2A-D, were
synthesized and characterized by Mark Fegley (Scheme 4-2). Information describing
their synthesis and characterization can be found in his Master’s degree thesis, M. Fegley,
University of Pennsylvania 2007.
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Scheme 4-2. Synthesis of Xaa-A Analogs from Cyanomethylester Precursors

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propanoate
(Boc-Nbd-(DMT)-A, 3A).
Tetrahydrofuran (5 mL) was added to Boc-Nbd-OCH2CN (288.6 mg, 0.710
mmol), (DMT)-A (99.8 mg, 0.175 mmol), and NBu4Ac (13 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and silica chromatography (100 %
ethyl acetate, 2.5 % - 10 % methanol in ethyl acetate), afforded 23.3 mg of an orange
solid in 14.5 % yield. Rf 0.5 in 5 % methanol in ethyl acetate; 1H and 13C NMR shown
below in Figure 4-18; LRMS (ESI) m/z calculated for C45H47N10O12 (M + H)+ 919.3,
found 919.5.
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-((7-nitrobenzo[c][1,2,5]oxadiazol4-yl)amino)propanoate (Nbd-A, 4A).
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (16.1 mg, 0.021
mL, 0.101 mmol) were added to 3A (23.3 mg, 0.0254 mmol). The reaction mixture was
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane
layer. The water-soluble layer containing 4A was then HPLC-purified on a C18-prep
column using Gradient 1 (Table 4-3).

HPLC/MALDI analysis m/z calculated

C19H21N10O8 (M + H)+ 517.2; product was found in four separate peaks (17.5 min, 18.3
min, 18.5 min, and 19.3 min), and in all four peaks found 517.1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate

(Boc-

Mcm-(DMT)-A, 3B).
Tetrahydrofuran (5 mL) was added to Boc-Mcm-OCH2CN (26 mg, 0.0646
mmol), (DMT)-A (35.5 mg, 0.0623 mmol), and NBu4Ac (4.8 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin-layer
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform),
afforded 26.5 mg of a white solid in 44.8 % yield. Rf 0.3 in 5 % methanol in ethyl
acetate; 1H and

13

C NMR shown below in Figure 4-19; LRMS (ESI) m/z calculated for
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C49H51N6O12 (M + H)+ 915.4, found 915.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(7-methoxy-2-oxo-2H-chromen-4yl)propanoate (Mcm-A, 4B).
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (18.3 mg, 0.024
mL, 0.116 mmol) were added to 3B (26.5 mg, 0.0290 mmol). The reaction mixture was
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane
layer. The water-soluble layer containing 4B was then HPLC-purified on a C18-prep
column using Gradient 1 (Table 4-3).

HPLC/MALDI analysis m/z calculated

C23H25N6O8 (M + H)+ 513.2; retention time 19.9 min, found 513.1; retention time 21 min,
found 513.1.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-(1,3-dioxo-1H-benzo[f]isoindol-2(3H)-yl)propanoate (BocNpt2,3-(DMT)-A, 3C).
Tetrahydrofuran (5 mL) was added to Boc-Npt2,3-OCH2CN (350.4 mg, 0.828
mmol), (DMT)-A (118.9 mg, 0.207 mmol), and NBu4Ac (20.9 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and silica chromatography (100 %
ethyl acetate, 2.5 % - 10 % methanol in ethyl acetate), afforded 31 mg of an orange solid
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in 16 % yield. Rf 0.75 in 5 % methanol in ethyl acetate; 1H and 13C NMR shown below
in Figure 4-20; LRMS (ESI) m/z calculated for C51H50N7O11 (M + H)+ 936.4, found
936.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-(1,3-dioxo-1H-benzo[f]isoindol-

2(3H)-yl)propanoate (Npt2,3-A, 4C).
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) were added to 3C (31 mg,
0.0331 mmol). The reaction mixture was reduced to dryness by rotary evaporation and
extracted using 1 mL dichloromethane and 1 mL water twice with a final 1 mL water
back-extraction against the dichloromethane layer. The water-soluble layer containing
4C was then HPLC-purified on a C18-prep column using Gradient 1 (Table 4-3).
HPLC/MALDI analysis m/z calculated C25H23N7O7 (M + H)+ 534.2; retention time 23.7
min, found 534.2; retention time 25 min, found 534.3.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl

2-((tert-

butoxycarbonyl)amino)-3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate
(Boc-Npt1,8-(DMT)-A, 3D).
Tetrahydrofuran (5 mL) was added to Boc-Npt1,8-OCH2CN (26.5 mg, 0.0283
mmol), (DMT)-A (15.6 mg, 0.0274 mmol), and NBu4Ac (2.1 mg,) and stirred for 24 h.
The solvent was removed under reduced pressure and preparative thin-layer
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chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in
dichloromethane), afforded 17.2 mg of a white solid in 67.2 % yield. Rf 0.5 in 100 %
ethyl acetate; 1H and 13C NMR shown below in Figure 4-21; LRMS (ESI) m/z calculated
for C51H50N7O11 (M + H)+ 936.4, found 936.5.

(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5(hydroxymethyl)tetrahydrofuran-3-yl

2-amino-3-(1,3-dioxo-1H-

benzo[de]isoquinolin-2(3H)-yl)propanoate (Npt2,3-A, 4D).
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (11.7 mg, 0.015
mL, 0.074 mmol) were added to 3D (17.2 mg, 0.0184 mmol). The reaction mixture was
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane
layer. The water-soluble layer containing 4D was then HPLC-purified on a C18-prep
column using Gradient 1 (Table 4-3).

HPLC/MALDI analysis m/z calculated

C25H24N7O7 (M + H)+ 534.2; retention time 20.5 min, found 534.2; retention time 22 min,
found 534.2.

205

1

Figure 4-18. H and

13

C NMR Characterization of Boc-Nbd-(DMT)-A (3A)
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1

Figure 4-19. H and

13

C NMR Characterization of Boc-Mcm-(DMT)-A (3B)
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1

Figure 4-20. H and

13

C NMR Characterization of Boc-Npt2,3-(DMT)-A (3C)
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1

Figure 4-21. H and

13

C NMR Characterization of Boc-Npt1,8-(DMT)-A (3D)
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Table 4-3. Gradients Used for HPLC Purification of Small Molecules and Peptides
Gradient #
1
15 mL/min

Time (min)
0:00
10:00
40:00
45:00
50:00
55:00
60:00

Buffer A (%)
99
99
65
0
0
99
99

Gradient #
2
1 mL/min

Time (min)
0:00
5:00
10:00
15:00
20:00
25:00
27:00
30:00

Buffer A (%)
99
99
70
60
0
0
99
99

4.3.3 – Aminoacyl Transferase Expression and Purification
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3)
cells using a procedure adapted from Graciet et al.50 E. coli were grown in a primary
culture of 5 mL LB at 37 °C to OD600 of 0.5 and then were rediluted into a secondary
culture of 500 mL LB and grown to OD600 of 0.6. AaT expression was induced using 0.1
mM isopropyl β-D-thiogalactoside and cells were grown at 25 °C for ~16 h. Cells were
pelleted at 6, 000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge. Cell pellets were
resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 mM imidazole, 300 mM
KCl, and 5 mM β-mercaptoethanol, pH 8.0) and included protease inhibitor cocktail, 1
mM PMSF, and 10 units/mL DNAse1–Grade II. Following resuspension, the cells were
lysed using sonication. Soluble proteins were collected via centrifugation at 13,200 RPM
for 15 min. Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA
resin. The resin was prepared by rinsing with Ni-NTA binding buffer and then washed
with four volumes of Ni-NTA wash buffer (50 mM Tris, 50 mM imidazole, 300 mM
KCl, and 5 mM β-mercaptoethanol, pH 8.0). The proteins were eluted with elution buffer
(50 mM Tris, 250 mM imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0).
Pure elution fractions of E. coli AaT were dialyzed overnight in transferase buffer (50
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mM Tris, 30 % glycerol, 120 mM (NH4)2SO4, 5 mM β-mercaptoethanol, pH 8.0). The
dialyzed enzymes were stored at – 80 °C. Protein concentrations were determined using
the Bradford assay and a bovine serum albumin standard curve according to the
manufacturer’s instructions (Figure 4-22). (Sigma Aldrich; St. Louis, MO)

Figure 4-22. SDS PAGE Gel Analysis of AaT Expression and Purification
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2)
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) NiNTA column flow-through; 7) Column wash 1; 8) Column wash 3; 9) Elution fraction 1; 10)
Combined elution fractions 3-5 after overnight dialysis. Figure reprinted with permission from
(Anne M. Wagner, Mark W. Fegley, John B. Warner, Christina L. J. Grindley, Nicholas P. Marotta,
and E. James Petersson. J. Am. Chem. Soc. 2011, 133, 15139–15147.). Copyright (2011)
American Chemical Society.

4.3.4 – Bpt Transferase Expression and Purification
V. vulnificus Bpt, 29.7 kDa, was expressed from the pEG6 plasmid in E. coli
BL21-Gold (DE3) cells using the same procedure as discussed above for AaT, which was
adapted from Graciet et al.50 The enzyme preparation only differed from AaT in the
dialysis buffer. Pure elution fractions of V. vulnificus Bpt were dialyzed overnight in 1X
Bpt buffer (50 mM Tris, 300 mM potassium chloride, 10 % glycerol, and 15 mM βmercaptoethanol, pH 8.0). Overexpression of Bpt can be found in Figure 4-23.
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Figure 4-23. SDS PAGE Gel Analysis of Bpt Expression and Purification
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2)
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) NiNTA column binding wash flow-through; 7) Column wash 1; 8) Column wash 2; 9) Column wash
3; 10) Combined elution fractions after overnight dialysis.

4.3.5 – Chemoenzymatic LysAlaAcm Ligation Assay
Each ligation reaction, 125 µL total volume, contained the following reagents:
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2). The reaction mixtures were incubated at
37 °C for four hours. At the second, third, and fourth hour of the reaction, an additional 1
mM dose of aminoacyl adenosine donor was added to the reaction mixture. The reaction
was quenched with 1 % acetic acid at 4 h. One reaction material modification was made
for Hcm analog only, in which we prepared AaT in transferase buffer without the
presence of β-mercaptoethanol (50 mM Tris, 30 % glycerol, 120 mM (NH4)2SO4). The
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proteins were extracted from the reactions via acetone precipitation. The reactions were
precipitated using 4X reaction volume of acetone and cooled at – 20 °C for 1 h. Next, the
reactions were centrifuged at 13,200 rpm at 4 °C for 20 min to separate the reaction from
precipitated protein. The supernatant was transferred to fresh 1.5 mL centrifuge tubes
and allowed for acetone evaporation overnight at room temperature for all non-disulfide
analogs. For all disulfide analogs, the reactions were rotary evaporated immediately to
remove acetone in order to minimize disulfide reduction due to air exposure. After
acetone evaporation, the supernatant was dried in a Speedvac (Savant, Thermo Scientific,
Fisher Inc.) for 30 min to remove residual acetone. The resulting reaction volume was
dissolved up to 1.2 mL using MilliQ water and analyzed by HPLC (gradient 1) to
determine ligation yield by integration of separated peak intensities monitored at 325 nm
(Table 4-4). Collected HPLC fractions were characterized through MALDI MS analysis.

4.3.6 – Fully Enzymatic LysAlaAcm Ligation Assay
Each ligation reaction, 125 µL total volume, contained the following reagents:
amino acid (1 mM), ATP (2.5 mM), total E. coli tRNA (2 µg/µL), recombinant Histagged E. coli LeuRS, recombinant His10-tagged E. coli aminoacyl transferase (2.26 µM),
and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM HEPES pH 8.0, 150 mM
KCl, 10 mM MgCl2). The reaction mixtures were incubated at 37 °C for 4 h and
quenched with 1 % acetic acid. Acetone precipitation and subsequent analysis were
performed as described for the Chemoenzymatic LysAlaAcm Ligation Assay.
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4.3.7 – AaT Ligation Reaction Analysis by HPLC
All HPLC analyses of LysAlaAcm ligations were monitored on an Agilent HPLC
using a Waters C18 column (Milford, MA). The solvents used for peptide purification
were the following: 0.1 % trifluoroacetic acid in water (Solvent A) and 0.1 %
trifluoroacetic acid in acetonitrile (Solvent B). The HPLC method had the following
solvent gradient 1 (Table 4-4). Peptides were monitored at two absorption wavelengths
during HPLC analysis, 215 nm for peptide absorption, and 325 nm for Acm absorption.
MALDI MS analyses confirmed identity N-terminally modified peptide products (Table
4-5).
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Table 4-4. Calculated and Observed masses for LysAlaAcm assay Using Mutant AaT
Product Peptide

Enzyme

PheLysAlaAcm
PheLysAlaAcm

M+H

M+Na

+

Calc’d

Obs.

Calc’d

L170A

522.271

522.083

M158A

522.271

522.098

544.254
544.254

PheLysAlaAcm

M144A

522.271

522.290

544.254

---

PheLysAlaAcm

C187A

522.271

522.328

544.254

544.299

Obs.
544.048
544.063

PheLysAlaAcm

WT AaT

522.271

522.096

544.254

544.062

NapLysAlaAcm

L170A

572.287

572.110

594.065

NapLysAlaAcm

M158A

572.287

572.135

594.269
594.269

NapLysAlaAcm

M144A

572.287

572.302

594.269

594.302

NapLysAlaAcm

C187A

572.287

572.270

594.269

---

AzfLysAlaAcm

L170A

563.272

563.062

585.255
585.255

---

a

594.079

AzfLysAlaAcm

M158A

563.272

537.089

AzfLysAlaAcm

M144A

563.272

563.307

585.255

---

AzfLysAlaAcm

C187A

563.272

563.288

585.255

---

NbdLysAlaAcm

L170A

624.252

---

M158A

624.252

---

646.235
646.235

---

NbdLysAlaAcm
NbdLysAlaAcm

M144A

624.252

---

646.235

---

NbdLysAlaAcm

C187A

624.252

---

646.235

---

NbdLysAlaAcm

---

WT AaT

624.252

---

646.235

-----

---

NbdLysAlaAcm

L170A, pH6

624.252

---

646.235

NbdLysAlaAcm

M158A, pH 6

624.252

---

646.235

---

NbdLysAlaAcm

WT AaT, pH 6

624.252

646.235

---

MefLysAlaAcm

L170A

536.287

-----

558.269

---

MefLysAlaAcm

M158A

536.287

---

558.269

---

---

558.269

-----

MefLysAlaAcm

M144A

536.287

MefLysAlaAcm

C187A

536.287

---

558.269

McmLysAlaAcm

L170A

620.271

---

---

McmLysAlaAcm

M158A

620.271

---

642.254
642.254

---

McmLysAlaAcm

---

WT AaT

620.271

---

642.254

Npt1,8LysAlaAcm

L170A

641.272

---

M158A

641.272

---

663.254
663.254

---

Npt1,8LysAlaAcm
Npt1,8LysAlaAcm

WT AaT

641.272

---

663.254

Npt2,3LysAlaAcm

L170A

641.272

---

663.254

-----

Npt2,3LysAlaAcm

M158A

641.272

---

663.254

---

Npt2,3LysAlaAcm

M144A

641.272

641.283

663.254

---

Npt2,3LysAlaAcm

a

+

---

663.254
--C187A
641.272
--Loss of N2 in MALDI analysis. This has been seen in many Azf-peptide samples.
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Table 4-5. Elution Times for LysAlaAcm Ligation Reactions

WT AaT

Analog
R-Group
None

L170A

Phe

11.92

13.13

M158A

Phe

11.92

13.13

M144A

Phe

12.06

13.28

C187A

Phe

12.06

13.28

WT AaT

Phe

11.93

13.14

L170A

Nap

11.93

14.22

M158A

Nap
Nap

11.91

14.20

M144A

11.90

14.19

C187A

Nap

11.90

14.20

L170A

AzF

11.91

13.76

M158A

AzF
AzF

11.90

13.75

M144A

11.89

13.76

C187A

AzF

11.88

13.76

L170A

Nbd

11.91

M158A

11.92

M144A

Nbd
Nbd

-----

12.06

---

C187A

Nbd

12.06

---

WT AaT

Nbd

11.92

---

L170A, buffer pH 6

Nbd

11.91

---

M158A, buffer pH 6

Nbd

11.90

---

WT AaT, buffer pH 6

Nbd

11.91

---

L170A

11.90

---

M158A

Mef
Mef

11.90

---

M144A

Mef

11.91

---

C187A

Mef

11.91

---

L170A

Mcm

11.97

---

M158A

Mcm

11.96

---

WT AaT

Mcm

11.95

---

L170A

Npt1,8

11.90

---

Enzyme

KACm (min)

Product (min)

11.03

---

M158A

Npt1,8

11.90

---

WT AaT

Npt1,8

11.91

---

L170A

11.88

M158A

Npt2,3
Npt2,3

11.88

-----

M144A

Npt2,3

11.90

12.95*

Npt2,3
--C187A
11.89
* See co-absorption of analog at this time point, but there is also a small MALDI hit for product.
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4.3.8 – Design of an AaT Mutant Library
Quikchange ® mutagenesis was used to generate the following alanine mutations.
E. coli AaTH10, from the pEG6 plasmid, was mutated at specific residues listed in Tables
4-6 and 4-7. For the double alanine mutants, if the residues were close, we opted to make
a double mutant primer, Table 4-7.

For all other double mutant combinations, we

performed two Quikchange ® mutagenesis steps. The primers used for the collaboration
with the Saven group can be found in Table 4-8. All mutagenesis steps were confirmed
by DNA sequencing using the T7 promoter primer.

Table 4-6. Single Codon Reassignment Primers for AaT Alanine Mutations
(A) M144A

M144A
Forward 5' – GCTTGTCGGCGGTGCGTACGGCGTGGCC – 3'
Reverse 5' – GGCCACGCCGTACGCACCGCCGACAAGC – 3'

(B) M158A

M158A
Forward 5' – GTGGCGAGTCCGCGTTCAGCCGGATGGAAAATG – 3'
Reverse 5' – CATTTTCCATCCGGCTGAACGCGGACTCGCCAC – 3'

(C) L170A

L170A
Forward 5' – GAAAATGCGTCTAAAACGGCGGCGCTGGTATTCTGTGAGG – 3'
Reverse 5' – CCTCACAGAATACCAGCGCCGCCGTTTTAGACGCATTTTC – 3'

(D) L173A

F173A
Forward 5' – GCTTCTGGTAGCGTGTGAGGAATTTATCGGTCATGG – 3'
Reverse 5' – CCATGACCGATAAATTCCTCACACGCTACCAGAAGC – 3'

(E) L177A

F177A
Forward 5' – CTGGTATTCTGTGAGGAAGCGATCGGTCATGGCGGTAAG – 3'
Reverse 5' – CTTACCGCCATGACCGATCGCTTCCTCACAGAATACCAG – 3'

(F) I185A

I185A
Forward 5' – CATGGCGGTAAGCTTGCGGACTGCCAGGTCCTTAAC – 3'
Reverse 5' – GTTAAGGACCTGGCAGTCCGCAAGCTTACCGCCATG – 3'

(G) C187A

C187A
Forward 5' – GCGGTAAGCTTATCGACGCGCAGGTCCTTAACGATCACAC – 3'
Reverse 5' – GTGTGATCGTTAAGGACCTGCGCGTCGATAAGCTTACCGC – 3'
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Table 4-7. Double Codon Reassignment Primers for AaT Alanine Mutations

(A) L170A F173A

L170A
F173A
Forward 5' – GCGTCTAAAACGGCGGCGCTGGTAGCGTGTGAGGAATTTATCGG – 3'
Reverse 5' – CCGATAAATTCCTCACACGCTACCAGCGCCGCCGTTTTAGACGC – 3'

(B) L170A F177A

L170A
F177A
Forward 5' – CGTCTAAAACGGCGGCGCTGGTATTCTGTGAGGAAGCGATCGGTCATGGC – 3'
Reverse 5' – GCCATGACCGATCGCTTCCTCACAGAATACCAGCGCCGCCGTTTTAGACG – 3'

(C) F173A F177A

F173A
F177A
Forward 5' – GCGCTTCTGGTAGCGTGTGAGGAAGCGATCGGTCATGGCGGTAAGC – 3'
Reverse 5' – GCTTACCGCCATGACCGATCGCTTCCTCACACGCTACCAGAAGCGC – 3'

(D) I185A C187A

I185A
C187A
Forward 5' – CGGTCATGGCGGTAAGCTTGCGGACGCGCAGGTCCTTAACGATCAC – 3'
Reverse 5' – GTGATCGTTAAGGACCTGCGCGTCCGCAAGCTTACCGCCATGACCG – 3'

Table 4-8. Codon Reassignment Primers for AaT Mutations for Saven Collaboration

(A) L67M

L67M
Forward 5' – GATCCCCGCGCGGTGATGTGGCCAGAATCACTG – 3'
Reverse 5' – CTAGGGGCGCGCCACTACACCGGTCTTAGTGAC – 3'

(B) F173L

F173L
Forward 5' – CTAAAACGGCGCTTCTGGTACTGTGTGAGGAATTTATCGGT – 3'
Reverse 5' – GATTTTGCCGCGAAGACCATGACACACTCCTTAAATAGCCA – 3'

(C) T194A

T194A
Forward 5' – GGTCCTTAACGATCACGCAGCATCGCTTGGTGC – 3'
Reverse 5' – CCAGGAATTGCTAGTGCGTCGTAGCGAACCACG – 3'

(D) T194I

T194I
Forward 5' – CTGCCAGGTCCTTAACGATCACATTGCATCGCTTGGT – 3'
Reverse 5' – CCATGACCGATAAATTCCTCACACGCTACCAGAAGC – 3'
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CHAPTER 5

ATTEMPTED APPLICATIONS OF LEUCYL/PHENYLALANYL AMINOACYL
TRANSFERASE
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Section 5.1 – Introduction
Alternate routes for the utilization of AaT were attempted over the course of our
research in the Petersson Laboratory. We have developed two collaborations with the
Bode Laboratory in the Laboratorium für Organische Chemie at the Eidgenössische
Technische Hochschule (ETH) in Zürich, Switzerland and the Kashina Laboratory in the
University of Pennsylvania Veterinary Medicine School.

In both areas, we made

progress in the usage at AaT in different ligation reactions and peptide substrates.
With the Bode group, we investigated the possibility of AaT utilization of Nhydroxylamine-phenylalanyl adenosine (HONH-Phe-A). Bode et al. determined that an
α-hydroxylamine can act as a reactive moiety in the amide bond-forming ligation with an
α-ketoacid, called the KAHA ligation.30 If AaT could transfer an amino acid bearing an
α-hydroxylamine, it could be possible to bring this ligation from peptides to the protein
domain ligation scale. We envisioned using the hydroxylamine as an orthogonal reactive
handle in a three-piece protein ligation strategy that could be prepared in a one-pot
synthesis (Figure 5-1). Generation of semi-synthetic proteins would take place in a onepot, chemically-specific dual ligation reaction allowing insertion of synthetic fragments
into proteins while taking maximal advantage of cellular biosynthesis.
O

OH +

R1
O

O
HO

N
H

R2 - H2O, -CO2
DMF, 40 C

R1

N
H

R2

0.2 -0.01 M

Figure 5-1. KAHA Ligation of a Hydroxylamine and keto-Acid
This reaction, developed by Bode et al., can be done in aqueous conditions with and without
30
substitution at the hydroxylamine oxygen.
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Native Chemical Ligation
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O
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SH

N
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SH
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Dual Ligation Method
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H2N
SR

SH

O

N
H
O

R
OH +
O
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SH

O
N
H

R

O
N
H

LEGEND
= N-terminal protein fragment
= C-terminal protein fragment
= Synthetic unnatural peptidyl insert

Figure 5-2. KAHA Ligation and NCL Ligation in a One-Pot Protein Dual Ligation Strategy
The reactive handles of each ligation, NCL and KAHA, will only react with their respective partner.
The orthogonality and high specificity of these ligations will allow for the reactions to take place in
one pot without cross-reactivity between handles.

The Kashina Laboratory is interested in Ate1, a mammalian arginyl transferase.
Ate1 is an enzyme that arginylates proteins and is essential for cardiovascular
development, actin development and the mammalian N-end protein degradation
pathway.176 The destabilizing residue signals are different for the mammalian pathway,
but Ate1 essentially serves the same function as AaT, it ligates a primary destabilizing
residue (Arg) onto a secondary destabilizing residue (Asp/Glu) (Figures 5-3, 5-4). One
difference from AaT, according to Wang et al, is MALDI evidence that Ate1 can also
ligate an arginine residue onto aspartates and glutamates that are located internally in
addition to the N-terminus.177 The N-end pathway is only a portion of Ate1 function and
the biological function of arginylation is still being elucidated. One way in which the
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Kashina lab has learned more about Ate1 arginylation is through a global analysis of
mammalian protein substrates that become arginylated using 2D gels and MALDI
analysis of Ate1-/- and Ate1+/+ knockout and wild type mouse strains.178 In conjunction
with our research in the Petersson laboratory, we aimed to explore the possibility of using
AaT to tag Ate1-arginylated proteins. The goal was to tag N-terminally arginylated
proteins with p-azidophenylalanine via AaT, and then use a click reaction-mediated pull
down assay to determine the identity of the arginylated proteins. AaT could possibly
identify arginylated proteins that were not found through previous methods.

E. coli N-End Rule
A

B

C

AaT

ClpS

ClpA/P, ATP

C

D

K/R

D

K/R
L/F

Mammalian N-End Rule
A

B
Ate1

N/Q/C

D/E/C*

D/E/C*
R

E2, E3
26S
Ub. Proteosome

Figure 5-3. Ate1 and AaT Involvement in N-Degradation of Proteins
In the E. coli N-End rule a secondary residue, Lys/Arg, is exposed via peptidase or exogenous
activities (A). In B, AaT transfers a primary residue, Leu/Phe, to the protein N-terminus. ClpS is
a molecular chaperone that recognizes the destabilizing residues (C) and brings the protein to the
ATP-mediated protein degradation machinery, ClpA/P (D). In the mammalian N-End rule, a
tertiary destabilizing residues is converted to a secondary destabilizing residue, Asp/Glu/Oxidized
Cys, is exposed (A). In B, Ate1 transfers a primary destabilizing residue, Arg, to the protein Nterminus. E2 and E3 recognize the N-terminal sequence and poly-ubiquitin is transferred to the
39
protein N-terminus (C), which signals the protein to be degraded by the 26S proteosome (D).
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O

O
NH2 +

O

Ate1

+

H2N

R

R

H
N

H2N
O

O
N
D/E H

N
D/E H

PROTEIN
D/E

PROTEIN
D/E
R

Figure 5-4. Ate1 Reaction Specificity
Ate1 uses arginyl-tRNA as a substrate and transfers arginine onto Asp/Glu at the N-terminus and
177
has been implicated as possibly arginylating at internal Asp/Glu residues.

In this chapter, I will discuss the progress we have made with the Bode and
Kashina laboratory collaborations. With the Bode group, our greatest difficulty was the
instability of the hydroxylamine, even in its protected form as the phenylnitrone. We
thought that we observed transfer of an α-hydroxylamine to the N-terminus of a model
peptide, LysAlaAcm, using the analog, N-hydroxylamine-phenylalanyl adenosine
(HONH-Phe-A); however, we found that we had substantial loss of the hydroxylamine on
the product peptide to the α-amine.

The instability of the hydroxylamine and the

concurrent inability to demonstrate the KAHA ligation on the protein scale (data not
shown, determined by I. Medina of the Bode Lab) caused us to abandon this project. For
the Kashina laboratory collaboration, the efforts are ongoing, but we have determined
that AaT can utilize Ate1-arginylated peptides as substrates. We believe that it will be
feasible to bring this multi-enzyme reactivity into cell lysates and possibly to fixed cells.
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Section 5.2 – Results and Discussion
For the KAHA ligation, we synthesized two possible substrates for AaT ligation
of a hydroxylamine onto the N-terminus of peptides, N-hydroxylamine-leucine (HONHLeu) and HONH-Phe-A (Figure 5-5). We planned to use the HONH-Leu as a free amino
substrate that we could use with total synthetase and AaT in a solely enzymatic reaction.
The HONH-Phe-A was going to be used as an adenylate small-molecule substrate to be
used with AaT without any synthetases present in the reaction.

One of the major

obstacles of using the HONH-Leu was its insolubility in water requiring it to be dissolved
in dimethylsulfoxide. When using this HONH-Leu in a LysAlaAcm transferase reaction,
the best product formation was about 52 %; however, according to MALDI, only leucine
was transferred to the peptide N-terminus, not leucyl hydroxylamine. Additionally, we
attempted to reduce hydroxylamine instability by lowing the pH of the AaT reaction to
pH 6.5 and reducing the β-meracaptoethanol concentration in the AaT storage buffer to 5
mM. However, with both changes, again only leucine was ligated to the peptide. We
changed our approach to use an adenosyl analog to transfer the α-amino hydroxylamine
to avoid the use of a synthetase that could be preferentially selecting the leucine amino
acid degraded from the hydroxylamine substrate. One of the issues that we found with
the HONH-Phe-A analog again stemmed from hydroxylamine instability again but in the
form of its protected precursor N-phenylnitrone-Phe-A (See section 5.3, Scheme 2, 10).
The N-phenylnitrone-Phe-A degraded while being purified on the HPLC to the
hydroxylamine and oxime forms. This degradation effectively negated the last step of the
synthesis, deprotection of the hydroxylamine.
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We used the HPLC purified

hydroxylamine-Phe-A in AaT reactions. Again, we found the same problem observed
with the HONH-Leu substrate. The HONH-Phe that was ligated onto the peptide also
contained a substantial portion of PheLysAlaAcm peptide, which could not be used as a
substrate in the KAHA ligation (Figure 5-6).

The 53.1 % product yield was a

combination of PheLysAlaAcm peptide with and without the hydroxyl at the α-amine.
At the time, the Bode group was unable to perform KAHA ligations under suitable
aqueous conditions for subsequent elongation of the transferred HONH-Phe; therefore we
decided to halt our research until a more stable hydroxylamine precursor could be
synthesized.
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Figure 5-5. AaT Ligation of Hydroxylamine Substrates Onto LysAlaAcm Model Peptide
A. Structures of HONH-Leu and HONH-Phe-A. B. Reactions of hydroxylamine analogs with
LysAlaAcm. HONH-Leu could not be used as a substrate for AaT and E. coli synthetases.
HONH-Phe-A analog could not be transferred without degradation product formation.
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Absorbance at 325 nm!

HONH-PheLysAlaAcm,!
PheLysAlaAcm!

LysAlaAcm!

Time/min!

Figure 5-6. HPLC Analysis of AaT ligation of HONH-Phe-A Onto LysAlaAcm Peptide
LysAlaAcm elutes at 12.6 min and HONH-PheLysAlaAcm/PheLysAlaAcm co-elutes at 13.8 min.
MALDI confirmation of all HPLC peaks. Co-product percent yield = 53.1 %.

For the Kashina collaboration, we started on the peptide level, and Junling Wang
from the Kashina laboratory argninylated two model peptides, AspAlaAcm and
GluAlaAcm, synthesized by I. Medina. We found that AaT can use Ate1-arginylated
peptides as substrates (Figure 5-7). Using HPLC analysis, we found that the Ate1
reaction produced 63 % ligated product (Figure 5-8). The AaT reaction produced 75 %
phenylalanine ligated to the ArgGluAlaAcm peptide. Additionally, we attempted to
determine whether Ate1, like AaT, could use minimalist substrates in order to bypass the
use of synthetases and arginyl-tRNA substrates. However, Ate1 could not use Arg-A as a
substrate. More investigation into minimalist substrates will be required. This research
is ongoing and we are investigating the possibility of using this tagging method with pazidophenylalanine in cell lysates.
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Figure 5-7. Ate1 and AaT Ligation of Peptides
A. Two step N-terminal ligation strategy using Ate1 and AaT. Ligation 1. (Asp/Glu)AlaAcm
peptides are ligated via Ate1 (including synthetase, arginyl tRNA, and ATP) with arginine.
Ligation 2.
Phe-A and arginylated peptides are used as substrates by AaT to form
PheArg(Asp/Glu)AlaAcm peptides. B. Arg-A was synthesized but could not be used as a
substrate by Ate1.
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AaT can use ATE1-arginylated peptides as
substrates!
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PheArgGluAlaAcm
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Figure 5-8. HPLC Analysis of Ate1 and AaT Ligation Onto Model Peptides
GluAlaAcm elutes at 24.4 min, ArgGluAlaAcm elutes at 23.5 min, and PheArgGluAlaAcm elutes
at 28.8 min.
The percent yield of ArgGluAlaAcm was 61 %.
The percent yield of
PheArgGluAlaAcm was 75 %.

Section 5.3 – Materials and Methods
5.3.1 – Materials
General Information.
5′-O-(4,4′-Dimethoxytrityl)

Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA),
adenosine

((DMT)-A),

tetrabutylammonium

acetate

(TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane (TIPSH) were purchased
from Sigma-Aldrich (St. Louis, MO). Note: (DMT)-A production was discontinued by
Sigma-Aldrich, after which it was purchased as a custom order from ChemGenes
Corporation (Wilmington, MA) and was additionally synthesized in-house following the
protocol outlined by Ogilvie et al.139 Lysylalanylaminomethylcoumarin (LysAlaAcm)
and N-Boc-p-azidophenylalanine (Boc-Azf-OH) were purchased from Bachem
(Torrance, CA). All solvents were purchased from Fisher Scientific (Pittsburgh, PA).
All deuterated solvents were purchased from Cambridge Isotopes Laboratories, Inc.
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(Andover, MA). E. coli BL21(DE3) cells were purchased from Stratagene (La Jolla,
CA). The pEG6 plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander
Varshavsky (California Institute of Technology). All other reagents were purchased from
Fisher Scientific (Pittsburgh, PA). Bradford reagent assay kits were purchased from
BioRAD (Hercules, CA). Protease inhibitor cocktail was purchased from Sigma-Aldrich
(St. Louis, MO). All other reagents were purchased from Fisher Scientific (Pittsburgh,
PA). Milli-Q filtered (18 MΩ) water was used for all aqueous solutions (Millipore;
Billerica, MA). Matrix-assisted laser desorption/ionization (MALDI) mass spectra were
collected with a Bruker Ultraflex III MALDI-TOFTOF mass spectrometer (Billerica,
MA). Electrospray ionization (ESI) mass spectra were collected with a Waters LCT
Premier XE liquid chromatograph/mass spectrometer (Milford, MA).

UV/Vis

absorbance spectra were obtained with a Hewlett-Packard 8452A diode array
spectrophotometer (Agilent Technologies, Santa Clara, CA).

5.3.2 – Leucyl hydroxylamine (Lha) (6) Synthesis
The synthesis of hydroxylamine donor 6 is given as a general procedure, starting
from commercially available Leu-OH (Scheme 1). The carboxy-terminus of the amino
acid was first protected with a t-butyl group to form 2. Next, the amino group was
activated as a cyanomethyl ester using chloroacetonitrile or bromoacetonitrile to give 3.
Then, the amino group was oxidized using meta-Chloroperoxybenzoic acid (mCPBA),
forming 4.

Then the nitrone hydroxylamine precursor, 4, was converted to the

hydroxylamine, 5, using hydroxylamine hydrochloride.

The carboxyl group was

deprotected with trifluoroacetic acid to form the final leucyl hydroxylamine product, 6.
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Scheme 5-1. Hydroxylamine HONH-Leu Synthesis
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2-amino-4-methylpentanoate (Leu-OtBu, 2).

Leu-OH (13.12 g, 0.1 mol) was dissolved in 200 mL dioxane in a three-arm round
bottom flask. 3.7 equivalents of sulfuric acid (20 mL, 0.37 mol) were added to the
reaction dropwise. After dissolution of materials, the round bottom flask was placed in
an ice bath with stirring. The reaction was kept under nitrogen and a cold finger and gas
condenser were attached to keep the isobutylene cold and liquefied. The gas condenser
was filled with 100 mL of isobutylene and released into the round bottom flask; this step
was repeated a second time to add a total of 21.4 equivalents (200 mL, 2.14 mols).
Reaction was mixed overnight on ice. The reaction was worked up by first neutralizing
the acidic conditions with NaOH and then was extracted with ether. The combined
organic layers were dried with sodium sulfate (anhydrous). The extract was crystallized
as the hydrochloride salt using dry hydrochloric acid (11.6 equiv., 10 mL, 1.6 moles) and
afforded 9.96 g, 44.3 %. Product was characterized using NMR: 1H NMR (500 MHz,
MeOD) δ 3.91 – 3.88 (m, 1H), 1.82 – 1.76 (m, 2H), 1.68 – 1.62 (m, 1H), 1.54 (s, 9H),
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1.04 –1.01 (m, 6H);

13

C NMR (125 MHz, CDCl3) δ 167.3, 82.2, 50.3, 38.1, 25.5, 23.0,

19.8. Product does not ionize well on ESI-MS.

(S)-tert-butyl 2-((cyanomethyl)amino)-4-methylpentanoate (N-CH2CN-Leu-OtBu, 3).
Leu-OtBu, 2, (1 g, 4.45 mmol) was dissolved in 9 mL of dry acetonitrile in an
oven-dried 25 mL round bottom flask. 1.1 equivalents of bromoacetonitrile (0.34 mL,
4.9 mmol) and 2 equivalents of diisopropylethylamine (DIPEA) (1.55 mL, 8.9 mmol)
were added to the reaction mixture under nitrogen via syringe. The reaction was mixed at
room temperature overnight. After evaporation of solvent, the product was purified on
silica gel (gradient solvent system: 10 – 20 % ethyl acetate in hexanes to give 0.5 g (49.4
%). Rf 0.5 in 20 % EtOAc in hexanes. 1H NMR (500 MHz, CDCl3) δ 3.72 – 3.58 (m,
2H), 3.28 – 3.23 (m, 1H), 1.80 – 1.75 (m, 2H), 1.50 (s, 9H), 0.94 (t, J = 6.25, 6 H); 13C
NMR (125 MHz, CDCl3) δ 173.9, 117.8, 82.0, 59.6, 42.5, 36.1, 28.2, 24.9, 22.9, 22.2.
Product does not ionize well on ESI-MS.

(S,Z)-1-(tert-butoxy)-N-(cyanomethylene)-4-methyl-1-oxopentan-2-amine oxide (NCH2CN-nitrone-Leu-OtBu, 4).
N-CH2CN-Leu-OtBu, 3, (0.5 g, 2.2 mmol) was dissolved in 5.5 mL of
dichloromethane under nitrogen in an ice bath. Two equivalents of mCPBA (759 mg, 4.4
mmol) were added in small scoops over 30 minutes. After addition of mCPBA, the
reaction was mixed for 30 min at room temperature. The reaction was monitored via
TLC and worked up upon reaction completion, Rf product = 0.5 in 20 % ethyl acetate in
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hexanes. To quench the reaction, 5 mL saturated aqueous sodium thiosulfate and 15 mL
saturated sodium bicarbonate were added. Slurry was mixed for 15 minutes until all
white solid dissolved.

Product was extracted with dichloromethane and dried with

anhydrous sodium sulfate. The product was characterized using NMR: 1H NMR (500
MHz, CDCl3) δ 6.81 (s, 1H), 4.61 – 4.58 (m, 1H), 2.11 – 2.05 (m, 1H), 1.85 – 1.79 (m,
2H), 1.48 (s, 18.3H), 0.98 – 0.92 (m, 9H).

Product was assumed to go to 100%

completion and taken directly to the next synthetic step to form the hydroxylamine.

(S)-tert-butyl 2-(hydroxyamino)-4-methylpentanoate (Lha-OtBu, 5).
N-CH2CN-nitrone-Leu-OtBu, 4, (0.53 g, 2.2 mmol) was dissolved in 5.5 mL of
methanol. Five equivalents of hydroxylamine hydrochloride (0.76 g, 11 mmol) were
added and the reaction was mixed overnight at 60 ºC. Rf = 0.4 in 20 % ethyl acetate in
hexanes. Unreacted hydroxylamine hydrochloride was precipitated from the reaction
using excess dichloromethane. Aqueous sodium bicarbonate was added and the product
was extracted using dichloromethane.

Collected organic layers were dried with

anhydrous sodium sulfate. 2 equivalents of oxalic acid (0.4 g, 4.4 mmol) dissolved in 2
mL methanol were added to dried extract product. The product was crashed out as a salt
using excess ether. No further purification was needed. 1H NMR (500 MHz, DMSO) δ
3.71 (s, 2 H), 3.49 (s, 1 H), 1.42 (s, 9 H), 0.87 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ
162.3, 64.3, 37.9, 28.3, 25.2, 23.1, 22.7. NMR had poor resolution. MALDI MS calcd
m/z for C10H22NO3 (M + H)+ 204.16, found 203.8.
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(S)-2-(hydroxyamino)-4-methylpentanoic acid (Lha, 6).
Lha-OtBu, 5, was deprotected with the addition of 1 mL 50 % trifluoroacetic acid
and 50 % dichloromethane. 0.5 mL acetonitrile was added to the reaction to help
solubilize Lha-OtBu. The reaction was monitored via TLC every 30 min until complete
in 1.5 hr. Rf = baseline in 50% ethyl acetate in hexanes. No further purification was
needed. ESI MS calcd m/z for C6H13NO3 (M + H)+ 148.1, found 148.6. NMR had poor
resolution and not all peaks were accounted for, but there is a loss of t-butyl peak.

1

H

NMR (500 MHz, DMSO) δ 2.52 – 2.49 (m, 3), 1.73 – 1.46 (m, 6), 0.92 – 0.87 (m, 6 H).

5.3.3 – Phenylalanyl hydroxylamine adenosine (HONH-Phe-A) (11) Synthesis
The synthesis of Phenylalanyl hydroxylamine adenosine 11 is given as a general
procedure, starting from the phenyl nitrone cyanomethyl ester synthesized by I. Medina
according to Bode et al. (Scheme 2).30 The protected amino acid was attached to one of
the available hydroxyls (2′ OH or 3′ OH) of (DMT)-A, which is commercially available,
without preference using a catalytic amount of TBAC. The resulting protected adenylate
(9) was deprotected using a 50/50 mixture of TFA and THF with TIPSH present as a
scavenger, producing 10. The final product 11 containing the N-hydroxylamine, HONHPhe-A, was formed by addition of hydroxylamine hydrochloride.
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Scheme 5-2. Hydroxylamine HONH-Phe-A Analog Synthesis
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(S,Z)-1-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-((bis(4methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl)oxy)-Nbenzylidene-1-oxo-3-phenylpropan-2-amine oxide (N-phenylnitrone-Phe-(DMT)-A,
9).
(DMT)-A (26.2 mg, 0.0460 mmol) was dissolved in 5 mL of tetrahydrofuran
(dried with 4 Å molecular sieves) in an oven-dried 4 dram reaction vessel. Twenty
equivalents of 7 (267.7 mg, 0.878 mmol) were added to the reaction mixture. TBAAc
(27.6 mg, 92 µmol), the catalyst, was added last to the reaction mixture. The reaction
was stirred under argon overnight at room temperature overnight. After evaporation of
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solvent, the product was purified on silica gel (gradient solvent system: 20 – 0 %
petroleum ether in EtOAc, 5 % methanol in EtOAc) to give 24.4 mg (65 %) after
evaporation. Rf 0.5 in 5 % methanol in EtOAc. LRMS (ESI) calcd m/z for
C47H45N6O8 (M + H)+ 821.3, C47H44N6O8Na (M + Na)+ 843.3, found 821.3, 843.3.
(S,Z)-1-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-N-benzylidene-1-oxo-3-phenylpropan-2amine oxide (N-phenylnitrone-Phe-A, 10).
9 (12.2 mg) was dissolved in 1 mL of THF and 1 mL trifluoroacetic acid (TFA)
and 2.3 mg oxalic acid and reacted for 30 min. The reaction mixture was reduced to
dryness by rotary evaporation and extracted using 1 mL dichloromethane and 1 mL water
twice with a 1 mL water final back-extraction against the dichloromethane layer. The
water-soluble layer containing 10 was then HPLC-purified on a C18-prep column using
an increasing acetonitrile gradient (gradient 1 used for Phe-A discussed in Chapter 2
section 2.3). NMR analysis of 10 can be found in Figure 5-9. HPLC/MALDI analysis
m/z calcd C26H27N6O6 (M + H)+ 519.2; retention time 23 - 25 min, found 519.3; retention
time 38.1-38.5 min, found 519.3. During the process of HPLC purification, additional
side products were found, (1) loss of phenyl nitrone producing hydroxylamine at
retention time 21.5 – 25 min ((M + H)+ m/z = 431.2) and (2) formation of oxime at 40.6
min ((M + H)+ m/z = 429.1). Over time in water, product 10 converted into 11.
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(S)-(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2(hydroxymethyl)tetrahydrofuran-3-yl 2-(hydroxyamino)-3-phenylpropanoate
(HONH-Phe-A, 11).
10 (11 mg) was dissolved in to a 0.2 M concentration in methanol (104 µL). 5
equivalents of hydroxylamine hydrochloride was added (7.9 mg, 0.114 mmol) and
reacted for 4 h at 60 ºC, monitoring via MALDI. At the end of the reaction, mixture was
diluted with water and lyophilized to remove solvents. MALDI analysis m/z calcd
C19H23N6O6 (M + H)+ 431.2, found 430.9.
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1

Figure 5-9. H and

13

C NMR Characterization N-phenylnitrone-Phe-A (10)
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5.3.4 – Ate1 and AaT Expression and Purification
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3)
cells using a procedure adapted from Graciet et al and explained in detail in section 2.3.6
of Chapter 2.50 Ate1 was overexpressed and purified by the Kashina Laboratory.

5.3.5 – Model Peptide Assays for AaT and Ate1
For the AaT peptide ligations, they were performed the same as previously
described in Ch. 2 section 2.3.7. All of the AaT ligation reactions using hydroxylamine
substrates were purified by HPLC using the same method as described in Chapter 2
section 2.3.10. Ate1 arginylation reactions of peptides Asp/GluAlaAcm were performed
by the Kashina laboratory according to standard published procedures.177 All HPLCs for
Asp/GluAlaAcm peptides and ligations were purified using the method outlined in Table
5-1. Collected HPLC fractions were characterized through MALDI MS analysis (Table
5-2).

Table 5-1. Gradient Used for HPLC Purification of Asp/GluAlaAcm Peptides and Ligations
Gradient #
1 mL/min

Time (min)
0:00
5:00
30:00
35:00
40:00
45:00
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Buffer A (%)
99
99
74
0
0
99

Table 5-2. HPLC Analysis of (Asp/Glu)AlaAcm Transfer Reactions
M+H

+

M+Na

+

Product Peptide

Retention
Time (min)

Calc’d

Obs.

Calc’d

540.418

Obs.
---

AspAlaAcm

24.0

362.135

362.395

ArgAspAlaAcm

22.9

518.236

518.462

384.117
540.218

PheArgAspAlaAcm

**

665.305

665.515

687.287

687.495

GluAlaAcm

24.4

376.151

376.429

398.398

ArgGluAlaAcm

23.5

532.252

532.487

398.133
554.234

679.482

701.302

701.458

PheArgGluAlaAcm

28.8
**This reaction was not HPLC purified.

679.320
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554.480

CHAPTER 6

CONCLUSIONS
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Current research has shown that there are a variety of ways to modify proteins,
depending on your reaction restrictions.

We have found a new and versatile

chemoenzymatic way to modify proteins that fulfills a wide variety of constraints: sitespecificity, amide bond formation at the ligation site, amino acid substrate variety for
both peptide and small molecule substrates, aqueous conditions, near physiological pH,
high salt concentrations, in the presence of denaturants, and with high reproducibility.
The AaT amide bond forming reaction is slow, but the native N-terminal specificity
outweighs its unfavorable kinetics. We have manipulated a natural enzyme to accept and
ligate a variety of small molecule substrates that range from p-azido-phenylalanine to
protected disulfides without the need for mutagenesis. We hope through the aid of in
silico studies with the Saven group, we will be able to target an aminoacyl adenosine
substrate and enhance ligation efficiency for our lower yielding substrates.
Ligation of synthetic molecules has proven very useful in the study of protein
function, localization, and folding. We plan on using the AaT ligation technique to
access protein folding studies that have yet to be achieved without significant peptide
synthesis. For example, through the demonstrations of model proteins α-synuclein and
calmodulin, we have shown that it is possible to incorporate a small synthetic moiety
while maximizing the use of expressed protein fragments. AaT N-terminal modifications
allow for the accessibility of click reactions at sidechain R-groups and NCL reactions at
new residue locations, arginine and lysine, instead of cysteine. Additionally, AaT-ligated
homocysteine can be masked, under mild conditions, again allowing for an even greater
number of possible ligation sites within proteins.
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With the increased number of

allowable ligation sites for AaT, small synthetic moieties to study protein structure and
function can be inserted into the structure using AaT, with minimal perturbation since the
ligation site results in a natural amide bond.

The AaT ligation will expand the

accessibility of protein structure and folding analysis by incorporating small FRET–based
probes such as a thioamide and p-cyanophenylalanine pair.

The AaT ligation has

expanded the opportunities for scientists as a new tool for studying proteins and
designing new proteins through protein engineering.
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